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FAisting anti-rejection drug regimes are inadequate since patients receive drugs- 
despite serious side effects and poor response. New drugs are being developed 
which ultimately may allow fier prescribing of rational, patient-specific 
immunosuppressive drug protocols. During this thesis the investigation cat' 
lymphocyte responses lrom renal transplant recipients to the itnt11unosuplpressarnnt 
drugs Cyclosporin A (Cy A), FK50 and SI)! RAD were explored toi understand 
the variation in sensitivity oflymphocytes to Cy A and FK506, the development of 
drug resistance, including resistance mechanisms, and the interactions between 
FK506 and SI)l. RAI). 
Cy A and FK506 are substrates fm 11-glycoprotcin (I'-gp), the product of the 
multidrug-resistance (M[)R1) gene in man. A hypothesis established during this 
thesis was that P-gp dependent mechanisms explain variations in lymphocyte 
sensitivities to Cy A and FK50 . 
Lymphocytes from renal transplant recipients were assessed for their sensitivity to 
Cy A and FK506 and subsequently for P-gp expression and functional activity by 
flow cytontry. In further lymphocyte cultures the of feet of the specific P-9p 
inhibitor, PSC 833 on sensitivity was investigated. Finally, the e fects of the 
combination of' FK506 and SDI, RAI) in lymphocyte cultures were analysed. 
Results demonstrate a wide range in lymphocyte sensitivity toi both Cy A and 
FK506, with the development of selective resistance to the drug used fier 
treatment. All patients demonstrated P-gp functional activity but P-gp expression 
was not demonstrable. P-gp function did not account for the variation in 
lymphocyte sensitivity. There was 110 evidence of antagonism of' eficct of SD/ 
RAD in combination with FK5OO. 
In conclusion, these results suggest that non-P-gp mechanisms account loor 
variations in lymphocyte sensitivity to Cy A and FK506. Combination therapy 
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nlloogralt recipicrlts have tu take fýcýýtiýýrf u) drugs tu r11IIlIIlHHSC reiccllOI1 OI' the grölt. 
In clinical transplantation there is a dclicate balance oI anti-refection drllp! el'1icac 
Mnct seriOus side et't. "cts including hypertension, nephrotomcity, increased risk OI 
cancer and infections. New drugs are being dev, eluped and introduced 11110 clitticail 
practice and until means of inducing allugraft tolerance Is introduced into tiºe 
clinic the treatment goals remain to Use these drug coýmhiflati ),, s to Improve 
ef'f ic: ar`y 1tnd reduce side effects. For example soli hirning drug" it I(mer- thorn the 
normal therapeutic levels may lead toi a degree o f'synergy w ith u proývedl e I't icacy 
and less side eff'ects. Existing drug reptiles are inadequate since patiL mints mll 
continue to receive drugs despite marked side el'I'ects and poor response. I Illti 
balance may he improved by tailoring I11111111I1tºtiUhlll'ýtitilýý tl1Cra11)\ protocols to 
individual patients. 
II'hc idea behind the work described in this thesis was to de' chop a nicaiis of 
studying in Oiro patient lymphocyte responses to i1 mural)suppressive drugs in 
order to understand their mode of action, mechhanisi s OI, resistaºkce. and 
interac; ticýns between them. This may allow 1Or Huture prescribing of rational, 
ppaltiellt-sppe'ciflc 1I111111IIlllsuIIIII-essive drug protocols. 
1.1 Renal transplantation 
1.1.1 Introduction 
Transplantation is the process of' taking cells, tissues, or organs, Called a grölt. 
from one individual and placing them into a different individual. A graft 
transplanted between two genetically diIierent 
Individuals is Called an allogra11. 
This thesis is concerned with kidney transplantation in the form of whole organ 
kidney (renal) allogralts. 
1.1.2 Historical perspective 
This historical overview of' transplantation is derived from twos texts (Kuss and 
Bourget, 1992 and Brent, 1996). The earliest recorded attempts It organ 
transplantation date hack thousands of years. Ilowe; ver, it weis in 1902 that 
Illmann perli)rmed a successful renal autotransplant (a graft transplanted lr()rll 
one individual to the same individual) in a dog. Carrel, in 1912, showed that renal 
ý luncticºn. autogralts survived indelinitcly, but that renal allugral s rapidly cease to 
In the 1940s experiments by Medawar into liiiling skin gralts described an 
inflammatory reaction called rejectioonn, which was shown to he a form of specific 
immunity. Clinical transplantation did not become a reality until 
1954. Murray 
and colleagues perlormed the first successful kidncý transplantation hetween 
monozygotic twins in Boston, I SA. The success of this pioneering work was 
t 
based can a number ofearlicr observations from animal and human lxperiments. 
They quote ... 
"several experimental observations which made success between 
identical twins seem likely and justified the removal ofa normal kidney iron a 
healthy donor. 
(1) Immunological and genetic similarity apparently accounts fier the permanent 
survival ofskin homografts between identical twins. 
(? ) When skin or kidney homografts are carried out between antigenically 
dissimilar individuals the early function and the histological picture of " rcjectio n Of 
each appear similar. (3) Skin and kidney homogralts possess a common antigen 
that can sensitisc a recipient to a subsequent hunmogralt of either tissue fironi the 
same donor. This further suggests that skin and kidney grans might behave 
similarly" 
In 1959, I)amcshek and Schwartz used 6-mercaptopurine (6-MI') in place of 
irradiation to precondition patients liar hone marrow transplantation. This work 
was developed by Calne with the introduction of' a safer derivative ()1'6-M f' called 
azathioprine (AZA) into renal transplantation. By 1963, maintenance non and r 
corticosteroids became the standard regimen fier renal transplantation. Allograf1 
survival with these treatment protocols was ýlpproximatch 4O"') at 12 months. In 
the late 1970s to early 1980s C'yelosporin A (('y A) was introduced and has been 
the mainstay of' immunosuppressive regimes in combination Nxvith A/-i1 and 
corticosteroids. Cy A based protocols led toi fewer episodes of' ýicutc n1cctio l 
episodes and improved allogra1t survival at 12 months toi K(l-oI)° ,. FK'06 
('Facrolimus) has been introduced during the I 990s and other experimental drugs. 
including rapamycin (Sirolimus, RAI'A), are hcing developed. Concurrcntly there 
4 
has been marked progress on the development of Ilse of biological agents to 
suppress the immune response to an alloograft in human transplant recipients. All 
these advancements have led to increases in allogratt and patient survival with 
one-year graft survival of approximately ý)0% hcing the rule raltlheF than the 
exception (Gjertson, 1994). By contrast, long-term graft survival remains a major 
problem. This has served to locus attention to the longer-term ()utcOOnle in an 
attempt to manage patients to obtain optimal long-term graft survival while 
minimising, patient morbidity. The search continues, thereiiOre, i'Or the ideal 
immunosuppressive agent, namely one that selectively inhibits alloantigen 
immune responses, prevents chronic allogralt rejection, and is free UI major side 
effects. 
1 
1.1.3 Current perspective 
Renal transplantation is the treatment of choice for patients with endl-stage renal 
tailurc (FSRF). The supply ot'doýnor organs, which averages 30/million population 
per year in the I Jnitcd Kingdom, is greatly Outstripped by demand, lkll1Cil is a1 
minimum cif' 48/million population per year. The number ofpatients can the active 
list for renal transplantation in the l lK has increased Iru in 3800 in 199) 1 toi 4908 in 
2000 (UK Transplant, 2001). Only 28% of' patients with FSRF were on the 
waiting list in 1998 (The UK Renal Registry 2000). 
Not all patients receiving dialysis are suitable for transplantation. In the t )nited 
Kingdom formal acceptance criteria unto a transplant waiting list have not been 
established, although patients with diabetes, severe vascular disease' and a history 
of' malignancy have a lower likelihood of' receiving a transplant since their 
reduced life span would lead to death with a functioning graft. Indeed, despite 
these criteria death with a functioning graft remains the most common cause of 
graft loss (Prommool el a!., 2000). The situation is further complicated by the 
observation that a number of the patients in these high-rill: groups would in tact 
have an improved life expectancy with a transplant compared toi dialysis treatment 
(fort ei a!., 1993). 
Since 1975,1 year graft survival rates for primary cadaveric renal transplants in 
the USA have risen from 50 to almost 90% (haled on data coilc: ctecl by l 1nive'rsity 
of California at Los Angeles (I VIA) and united Network f'or Organ Sharing 
6 
(UNOS) Kidney Transplant Registries (Gjertson, 1994)]. Much of this 
improvement has been attributed to the introduction of Cy A into treatment 
protocols. However, survival curves indicated that the long term loss rate of 
transplanted kidneys remained fairly stable until the early 1990s with the time 
taken for half the grafts to fail (half-life, tu 2)) remaining between 8.5 to 9 years 
(See Figure 1.1). 
Figure 1.1 Results of kidney transplantation. The graph shows the increase in allograft 
one-year survival from 40% during 1975 to 80% in 1990. There was little impact upon 
allograft half-life during this period (Figure taken from The Atlas of Transplantation, 
Roche. Based on original data from Gjertson, 1991). 
Thus, the initial advantage of Cy A treatment diminished beyond l year. The half- 
life for allografts has improved, both for Cy A treated patients and those patients 
treated with FK506, with data from UNOS suggesting a half-life of 11-12 years 
during the mid-1990s (Hariharan et al., 1996). More recently the projected half- 
7 
Iifc fier grafts from living donors has increased steadily from 12.7 to 21.0 wars, 
and that 1or cadaveric grafts has increased lrmii 7. '-) toi 13.8 years (I lariharan (, / cal., 
2000). Aller censoring cif' data for patients who died with functioning gratis, the 
projected half-life ftor grafts 1ýrom living donors has Increased 1rooiu 16-9 bears to 
35.9 years, and that I' Or cadaveric grafts has increased from 11 to 19.5 years 
(Ilariharan ei al., 2000). It' death with a 
functioning graft is removed 1'roni the 
analysis then the predominant cause of'graft dysfunction and ultimate graft loss is 
chronic rejection (Jindal and I lariharan, 1999). 
1.1.4 Chronic Allograft Nephropathy 
The mechanisms of chronic rejection are being clarified and since multiple 
immune and non-immune factors play a part in chronic rejection, the more 
inclusive term `chronic allograft nephropathy" (CAN) has been introduced 
(Halloran et a!., 1999a). This condition is maniI sted clinically by a gradual 
decrease in renal function accompanied by hypertension and low-grade 
proteinuria. An understanding of' the causative factors of CAN iti of paramount 
importance to the transplant community, since there is currently ZR) specific 
treatment. I lowever, it is difficult to establish the relative importance of Putative 
causative factors due to the heterogeneity of medical practice between transplant 
centres both in the [1K and throughout the world. For example, there is marked 
I1 atch1ing. variation in donor management. surgical tCCIIIIigque, tissue-typpC 
recipient selection and drug protocols. Notwithstanding, univariate and 
multivariate analyses have been perll)rmed on donor and recipient variables on 
data from I JNOS (Cecka et ul., 1992, (ijertsoýn, 1994 and I lariharan eel cal, 2000). 
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The conclusions from these studies are that the causes cat' ('AN are multi-factorial 
and can be broadly divided into two groups, namely, immunological and non- 
immunological. The major immunological factor co ntrihtiting to CAN is one or 
r»urc episodes of acute rejection within the first 12 i»ooiiths lotiuwi»tº 
transplantation. Among patients who had an episode cif Clinical acute rejection, the 
projected half=life ol'cadaveric transplants was 7 years in 198 and 8.9 years in 
1995, an increase of' 25%. In contrast, the projected halt-life for cadaveric 
transplants in patients who did not have an episode ul' acute rcjccti()n i» the first 
12 months following transplantation was 8.8 years in 1988 and 17.9 years in 1995 
(I lariharan el a!., 2000). Risk factors t'or development ofacute rejection episodes 
and subsequent CAN include 111, A-DR mismatches and highly sensitised 
individuals manifested by a high percentage of panel-reactive antibodies in their 
serum (Gjertson, 1994 and Connolly ei al., 1996). Further discussion of 1II ,A 
follows in section 1.2.2.1. Apart from clinical acute rejection, patients may have 
sub-clinical rejection that causes ongoing immunological injury (Rush 
1995). 
Yhere are a number of' non-immunological factors that contribute to CAN. For 
example, a prolonged cold ischaeniia time (the time the donor organ remains on 
ice ex vivo) ofI greater than 30 hours is associated with peri-transpiantational injury 
and delayed graft function (Cijertscýn. 1994. and reviewed by 1'aseua11 cci cal., 2OO-'). 
Analyses of the relative importance cif' quality of donor kidney, increasing donor 
age, mode l)1'donor death, racial and sl)ciu-eC()1l()Ililc factors, and CXp-)()SurC to 
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cytomegalovirus infection can he finnnd in a number of' studies (( i. 
jertSOºn, 1994, 
Morris, 1994 and Cole cl al., 1995). Specifically, in the I )SA, the projected hall- 
fite of a kidney in a black recipient is 6 years compared to an Asian recipient of 17 
years (G_jcrtson, 1994). This disparity colallograft survival raises the 1lOS. Sihility' ()i- 
genetic influences on allograft survival as well as those relating to socio- 
economics and compliance. "I'hc studies also report the use Of organs 1'ro11m older 
cadaveric donors. Kidneys from such donors have a lower survival rate than those 
From younger cadaveric donors ((; jertson, 1994). 1)uß" to limited availability, the 
proportion of grafts from older cadaveric donors increased from 10.4 to 18.2 
percent from 198 8 to 1996 (1 l ari haran el al., 2000). 
1.1.5 Impact of immunosuppressive drugs in clinical transplantation 
As discussed in section 1.1.2 the mainstay of anti-rejection regimens have 
included corticosteroids, in the form of' prednisolone, and aiathioprine. These 
drugs in combination with either Cy A or FK 0ß are the predominant reginies 
comprising `triple therapy' in use in UK transplant centres. Treatment with 
prednisolone in high dose or prolonged treatment is associated with a number of 
non-immune side effects such as development cif 
diabetes mellitus, costeopoýrosis. 
thinning of the skin and truncal obesity (British National Formulary. 2001 ). Borne 
marrow suppression is the major dose limiting side ei'llect ol' treatment with 
azathioprine (British National Formulary, September 2001). 
The rationale for the introduction ofnew compounds into clinical tranSplantý1tiun 
is to increase the efficacy ofthe drug regimes and reduce dr119 toxicity'. 
Some side 
effects (infections and malignancy) reflect lack of adequate immune IIunction and 
are inherent in suppressing the host Illlllltllle FC5C)OOn5C. 'I'Ihese side e l'l eis incIIIde 
infections, such as pneumocystis pneumonia, cytcýnnegaluvirus, and certain 
malignancies, SLIC}l as skin cancer and 
lymphoma. A retrospective q tiestioýnimiie 
study from Leeds, UK investigated 918 patients transplanted from 1967-1991 
(London c'1 al., 1995). 7'hc study demonstrated 80 dilicrent tumours in 70 patients: 
42 in skin, 12 of urogenital origin, 5 11 cell lymphomas plus a number of 
miscellancOuS tumours. In an age and sex-matched Hormel population after 20 
years, a 6% prevalence of cancer was observed, compared with a prevalence of 
13.4% at 10 years and 40% at 20 years in the transplant population (I . ýýný1un ci cul., 
1995). Recent data has shown that the prevalence of'nein-melancýtic; skin cancer in 
transplant recipients at 10 years is almost 30% in the UK and 9W/0 in Queensland. 
Australia (Ramsay et ul., 2001). These data suggest that patients receiving 
immunosuppressive drugs require lifelong surveillance fier malignancy. 
1.1.5.1 Cyclosporin A 
Following the introduction of C'yclosporin A (Cy A) in the l9KOs there was a 
dramatic increase in 1-year allograft survival due to a reduction in the number of 
acute rejection episodes (Merion cl al., 1984). 11owever, a number Of in1hOrtant 
side effects have been observed. Nephrotoxicity was soon apparent it, the early 
clinical trials (Caine et al., 1978). This required limiting the drug to those patients 
who were passing adequate volume cal' urine (('alne e/ al., 1979 and 1979). It is 
now practice to use much lower doses of' Cy A ill lillllluil()tiuppressioll drug 
protocols in an effort to avoid acute toxicity. i lcowcvcr, chronic ('y A 
nephrotoxicity remains a major clinical problem (Griffiths el ti1., 19%). I he 
accompanying decreased glomerular filtration rate ((IFR) and raised serum 
crcatinine levels can lead to diagnostic confusion with acute sind chronic rejection. 
'l'iiere are no diagnostic morphological features can blOI)sy in acute toxicity, hilt 
lesions of' chronic ncphrotoxicity consist of' the vascular changes of arteriolar 
hyalinisation and glomcrular ischacniia leading to gIoineRukir occlusioln, and 
tubulointerstitial changes producing interstitial fihrosis and tubular atrophy 
(Grilliths cat a!., 1996, I3cnigni e1 a!., 1999). '('he actiology OI' ('y A induced 
nephrotoxicity is unclear. It has been postulated that sustained glonierular 
arteriolar vasoconstriction eventually promotes structural alteration and occlusion 
of' glomerular vessels (Myers ei al., 1988). Although renal hyp perl isic>n, its 
demonstrated by low renal blood flow has been clenionstrated following 
administration cif' Cy A, the tuhulointerstitial injury may he a separate entity that 
develops independently of the vasoactive effects of the drug (Renlgnl CI eil., 
1999). Renal biopsy material obtained from patients with histologicail fat tires of 
nephrotoxicity revealed frequent tuhulointerstitial lesions and le" glomerular 
lesions. Intense staining of tubular epithelial cells 1'()r the vasoactivc and 
chemotactic mediators, cndothclin-l, IZAN"l'FS and nionocyte c: hcmoattractunt 
protein-I mRNAs, was demonstrated and it is the local production of these 
molecules that may lead to inflammation and fibrosis (Henigni e< al., I99999). 
1.1.5.2 FK506 (Tacrolimus) 
IýK506 is indicated lor use as primary immunosuppressioýn iii liver and kidney 
allograft recipients and liver and kidney allcogralt rejection resistant to 
i-) 
conventional immunosuppressive reginmes. I Iowever, the role o1' !K 06 in clinical 
organ transplantation continues to evolve. Much of tlhe early promise with 1' K 00 
has been reported in liver transplantation with a clear benefit over ('y A in the 
prevention cif acute and chronic allograft rejection (The kurc)l can and I IS, FK506 
Multicenter Liver Study Groups, 1994). Preliminary clinical experience following 
renal transplantation suggests that primary prophylaxis with FK50> results in grail 
and patient survival rates that are equivalent to those achieved with conventional 
Cy A based therapy with an overall graft survival cif' 85-90'%º at one year and onc- 
year patient survival of 94% (Schleihner ei a!., 1995). The incidence of acute 
rejection episodes was 48% (Shapiro et al., 1995). Studies directly comparing the 
effects of' FK506 with Cy A have been reported (Pirsch e/ al., 1997 and Mayer cl 
al., 1997). The American study reported by Pirsch assessed over 400 patients that 
were randomised to receive either FK506 cif' ('y A aller cadaveric renal 
transplantation. Again one year patient survival rates were comparable. There was 
a slight improvement in one year graft survival rates with FK5O6 compared to Cy 
A [91.2% and 87.9% (p=0.289)], and a significant reduction in the incidence of 
biopsy proven acute rejection episodes in the 1ý K50 group (30.7°/)) c cýnýýýirecl 
with the Cy A treated group (46.4%). Similar results were obtained in the 
l; uropean Tacrolimus Multicenter Renal Study (Troup where 448 renal transplant 
patients were recruited and assigned to receive triple-drug therapy consisting cat 
FK506 or Cy A with AZA and low dose corticosteroids (Mayer o cal.. 1997). 
Preliminary data also suggest that long-term survival as estimated from ti, 2 niLiy he 
improved with FK506 haled re gmes ((ijertson ei al., 1995). Ihý"Sc stud iý"S have 
confirmed that there are a number of serious side etfec: ts associated with I' K SO6. 
Nephrotoxicity is common with FK506 treatment with incidence at One year 
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reported between 45-57.6% (Pirsch el al., 1997 and Vin«enti cl a/., 
P)96). 'I'lie 
incidence of' hypertension was similar to that with ('y A and tremor was more 
often seen with FK50 (Pirsch el al., 1997.1lirsutikm, gingivitis and gum 
hyperplasia were negligible compared to that obtained with ('y A (Mayer ei al., 
1997). The overall infection rates were comparable between treatment groups. is 
was the incidence of' opportunistic infections (Mayer c1 a!., 
1997). 
Ilyperlipidaemia was lower in the FK50 treated group compared to the ('y A 
treated group (Mayer et a!., 1997). Of particular Concern, Ihowo"er, is the 
development oide novo insulin dependent diabetes mellitus (II)UM) in the FK506 
Groups. The initial incidence of' post transplant diabetes mellitus, which was 
defined as the use of insulin liar 30 days or longer in patients who had no history 
cif' 1I)I)M or non-insulin dependent diabetes mellitus was 19. ý)% in I" 1500 treated 
patients and 4% in Cy A treated patients (Pirsch ei al., 1997). At 12 months, 
however, the proportion of' FK50(ß treated patients receiving Insulin was 5.51i%º and 
withdrawal of treatment with FK506 due to diabetes mellitus occurred in 1.5`%º cif' 
patients (Mayer ei al., 1997). 
In addition to the evolving value of FK506 as a primary immunosuppreSsant in 
treatment schedules the use of FK506 in salvaging allogrufts has been investigated 
(Jordan et ul., 1994 and 1997, I; herhard el al., 1996). Resistant acute aallogralt 
rejection under Cy A based immunosuppression remains a COflsiderlrhIC prOhielU 
despite the use cif anti-lymphocyte preparations. In 1994, . 
Jordan reported a series 
of' 77 patients with refractory acute rejection on baseline ('y A therapy that were 
converted to FK506 and graft salvage was achieved in 74% of cases (Jordan e/ al., 
1994). The 1997 report included a further 92 patients with similar results (Jordall 
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ei a!., 1997). "I'hc indications for conversion toi VK 506 were Ongoing, biopsy 
confirmed rejection in all patients. The median interval to conversion vtia s two) 
months after transplantation and all patients had received treatment with high close 
corticosteroids and 85%, of' the patients also receiving a Course Ot' an anti- 
lymphocyte preparation in an effort to ameliorate the rejection episode. 
Indeed, the initial stimulus to this present work was the observation that FK 5U(ß 
could he effective in treating patients in whom ('y A had failed. It was surmised 
that sensitivity to the drugs was i) independent and ii) that resistance to these 
drugs could develop. 
1.1.5.3 Rapamycin (Sirolimus/RADA) 
Rapamycin has recently been introduced into clinical transplantation. Rapanlycln 
is a powerful immunosuppressant that is 10-100 fold n»ore potent than ('_y A in 
preventing rejection of' vascularised grafts in animal models anal is also cltýciive. ý 
in alleviating ongoing rejection cat' kidney, pancreas and heart allogralts ill the rat 
(Stepkowski ei al., 1991, Granger et al., 1995). The main clinical data conic from 
three major studies. In 11 European centres, first c adiLvCriC renal <<11ýýýºrýltt 
recipients were randomised to receive either ('y A or rapamycin as part ut ýý triple 
regime with corticosteroids and AlA (Oroýth o al., 1999). At 12 moonths, graft 
survival was excellent in both groups (98% and 90(%O respectively) as w, 'iS piltiCnt 
survival (100% and 99%) and incidence o1' acute rcjection (41'! ý) and 8%). 
Rapamycin did not cause nephrotoxicity, gingival hypcrplasia or tremor in 
contrast to Cy A. Opportunistic inl cticýn rates were ccýr»parahle' although there 
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was a higher incidence 01'pneu111onia. Patients treated with rapui»yciii developed it 
higher incidence of thro)mbocylOpenia and hyperlihiclacnml ((iru(Ih cl I/1., 
fhc Rapainunc tiS , 'turfy Group reported a large prospective, mullicentrv, 
randomised trial comparing rapaniycin to azathio prine in ('y A and prcclnimoIonc 
based regimes (Kahan el al., 2OOO). The results show that the severity and 
incidence of acute rejection episodes up toi six months 111lowing renal 
transplantation were significantly lower in the rapamycin based regimes compared 
to azathioprine-based treatment (acute rejection rates fier rapamycin at low dose of 
16.9%; rapamycin at higher dose, 12.0%, and aiathio prine, 29.8%: p 0.00 1 ). 
Patient and graft survival across the three groups were similar and all greater than 
90% at 12 months. Adverse events in the rapamycin treated patients were divided 
into those associated with an exacerbation of ('y A-related toxic cf'l cts such as 
hypercholesterolaemia, hypertension, headache, hirsutisni, hyperkalaemia and 
acne, and those related specifically to raparnyc; in, such as hyhertriglyceridlaemiaa, 
thromhocytopenia and iymphococle formation. 
Finally, the Rapamune Global Study Group performed a placeho-control ledi trial 
of rapamycin when added to a regimen containing ('y A and prcelnisoýlt)ne 
(Mac[)onald el al., 2001). The study confirms the efficacy of rapali'IyCin at 
reducing acute rejection in renal transplant recipients. 
IZaparnycirl is non-ncphrotoxic ((ýruth o al., 19o)9, Kahan cl erl.. OOO and 
Macdonald ei ul., 2001). 1 lowcver, the data from the IZapa1I1111I1c [ IS Study Group 
reveal that mean scrum creatinine concentrations are higher at 12 months in the 
rapamycin treated patients compared to the azathioprine group. This may have 
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been brought about by increased exposure to ('y A by a phauin1ac0 kinetic 
interaction ol'('y A with rapamycin (Kahan el at., 2000). 
1.1.5.4 SI)Z RAI) (Everolimus\ RAI) \Certican) 
SI)Z RAI) is a rapamycin analogue that has recently been introduced into clinical 
trials and is being evaluated I or its potential synergistic activity with ('y A 
(Schuurman el a!., 1997). To date outcome data with SD! RAI) is limited. A 
phase I study of SDZ RAI) in renal transplant recipients has recently been 
reported (Kahan ef al, 1999). This randomised, blinded, placebo-controlled study 
assessed the safety profile and pharmacokinetics of a 4-week course ol'once daily, 
sequential increasing doses of SDZ RAI). The pharmacokinetic parameters of 
SDZ RAD showed dose proportionality, a good correlation with trough level and 
area under the curve (AUC), and shorter half=life than rapamycin with the 
attainment of steady state levels by day 4. Studies in de novo liver transplant 
recipients and de novo renal transplant recipients followed fier 12 months revealed 
no differential effects on Cy A pharmacokinctics or dosing (Levy e/ al., 2001 and 
Kovarik ei al., 2001). However, a preliminary report to the American Society of 
Transplantation (AST) 2001 suggests that co-administration ofSI)! RAI) with ('y 
A increases the bioavailability of' SD/ RAI) (Kaihag ei cal., 2001 ). Phase III trials 
from the RAI) 251 Study Group and the RAI) International Liver Study Group are 
ongoing. 
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1.1.6 Developing future anti-rejection protocols 
In summary, the side effects cif' FK506 and Cy A, particularly nephrotoxicity, are a 
limitation to the greater use of these drugs. Rapamycin is being introduced into 
clinical transplantation since it is both efficacious and non-nephrotu xic. The 
combination of rapamycin or SI)! RAD with ('y A is being explored for evidence 
cat' synergy. 
One of the interests of the current study has been the investigation of the 
raparnycin analogue, ShZ RAI) and the interaction of this drug with FK50 in in 
vitro systems of lymphocyte proliferation. There are a number ofreasons for this 
to be a useful area of study. Very briefly, in i'ilm work on murinc cells suggested 
that the two drugs were mutually antagonistic (Dumont el ul., 1990a). 'I'bis 
observation suggests that both drugs share the same intracellular binding site. 
However, further studies in experimental animal models suggested no antaigonism, 
but additive or even synergistic effects (Vu et (il., 1997). It is therefore ofinterest 
to examine this polarisation of effect in lymphocytes from renal transplant 
recipients. 
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1.2 'The immune response to an allograft 
1.2.1 Introduction 
The immune system has developed to lorni a highly specialised and tightly 
regulated series of responses that function toi recognise sei f fromu noon-sdI f and too 
respond to tissue injury. T cells arc crucial for the immune response to allýýýraltý. 
This has been demonstrated by the observation that in niurine models that lack "I 
cells cannot reject allogralts (Bolton c1 al., 1989). 'I'hc central rule of the I cell 
and the consequent targeting of' "1' cell activation by the currently available 
immunosuppressant drugs will he discussed. 
1.2.2 The T cell 
1.2.2.1 Antigen presentation 
T cells can respond to processed antigen presented on antigen presenting cells 
(APC) bound in the antigen-binding groove of the major histoýcump tihility 
complex (MIIC) molecules, designated III. A in humans. The M11(' I0ei encode 
polymorphic cell surtäce glycoproteins, referred toi as ('lass I and ('lass 11 
molecules. In humans the MI I(' Class I molecules are expressed on the S111-111 CC OI' 
nucleated cells and consist cri' 1 ll, A-A, -13, -('. ('e: II surface ('lass 11 I11OIec; ules are 
111, A-DR, -DP, -DO, found primarily on APC. Since the alleles at all diese loci 
are highly polymorphic and are co-dominantly expressed there will he multiple 
I () 
III, /\ disparitics in unrelated individuals, Which would lead to `hisst)'-ýýr tissrie- 
incompatibility should an atl0graIt he necessary. 
The immune responSC toi `standard' non-alle)-antigens such as bacteria, toxins, 
viruses and tumour proteins, is seil-M} I(' restricted I. C. I' CCIIs are only activated 
by peptides hound to sei f-M f IC molecules (Zi nkernagc] and Doherty 1974). 
Mature "I' cells are subdivided haled on ex)t-essicorn of either the ('1)4 or ('OK 
glycoproteins. ('I)4-+- cells are MI 1(' class Il-restricted, and ('D81 'I' cells are 
MI 1C 1-restricted in terns cif' antigen rccognition. 
This iiiiplics that recognition ofI 
+ exogenous antigens processed by X11'(' is almost entirely dependent on ('l)4 
cells. The peptide antigell/MI IC' complex can interact with the 
I' cell viii the Tcell 
receptor (TCR) for antigen ((; arhoczi et ul., 1996 and Garcia et ul., 1996). 
1.2.2.2 T cell recognition of allografts 
The principle targets cif the immune response to allografts are the MI ((' molecules 
themselves, and 'I' cell recognition of the allo-MI IC is the primary and central 
event that initiates acute allograft rejection in grafts that are mismatched fier M11(' 
(Krensky Cl cal., 1990). The IlOrlllal T cell repertoire contains il 
I11gh1 Frequency (1- 
I O%) oftotal T cells that are capahle oWresponding to all()-M1 IC I11()Iecules. 
This 
is 1 00-1 000 times as high as a standard response toi a non-seI f aintigen presented 
in 
association with sclf-Ml 1(' (Krensky and ('layhergcr, I )3). Two major models of 
allorecognition have been proposed (reviewed by Purvey and Wood. In the 
direct pathway alloy cognition involves recognition of foreign Ml l(' mclcc; ulcs 
expressed on the surfiiee of donor cells. Since T cells are normally 'self- 
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restricted', in that they only react toi seif=MI I(, I11ACCLIICS, direct recoognnitioon i1 
thought. to OCCUr hecause the aII()- M11(' molecule iiI associatiOIl mth a sell'- 
peptide resembles a self-MI l(' molecule plus fioreign peptide at the lhrce- 
din ciisional level (1, eehler ei ca/., 1990). In Contrast, the indirect hatltwat-ý involves 
recognition ofspecitic fragments offoreign MI 1(' molecules and all other proteins 
shed from the graft that are recognised as antigenic determinants hound in the 
groove of self-MI I(' molecules. This is the same mechanism of presentation gis 
non-allorecognition. Expcriments have Shown that indirect all )recogllltion is 
involved in both acute and chronic allogra11 rejection in murine models (Fluck el 
cal., 1999). These: elegant experiments investigated mouse cardiac transplantation 
in animals that were pre-conditioned to abrogate any direct allorec; o gnitic>n 
response from ('I)4 f cells. The C'I)4 4 cells were restricted tu recognising 
alloantigen only in the context of' recipient MI I(' 11. The study revealed that mice 
that were depleted of'('I)8+ cells alone rejected the grafts slowly with histological 
evidence of acute and chronic rejection, whereas those that were depleted of 
ß'I)4+ cells alone accepted their grafts indefinitely albeit with evidence of heart r 
damage. "Those animals that were depleted of peripheral (1)8 + cells alone were 
found to have C'I)8+ cells infiltrating the graft. This (lid not Occur in the ('1)4 + 
and ('D8-f- depleted animals suggesting a role f'or ('1)41 cells in recruitment of 
('I)8 + cells into the graft. 
Mere is some in vilrO evidence suggesting a role 1i)r indirect allureco gnilion 01 
M1IC-al lopeptides in human renal transplant recipients with chronic grail 
dysfunction (Vella et a!., 1997). Nevertheless, in a recent study ool' aalte skin graft 
rejection greater than 9O% of the anti-donor T cell repertoire was directed against 
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intact donor MI I(' molecules, while less than I 0%º of the response was directed 
against i»cdiº-ectly presented . donor derived peptides ( I3e'iiichutl t'/ c//., 
Rejection of' MI 1('-identical grafts is triggered by products of genetic loci other 
than the MI W, termed 111111tH' histocollipat1hilIt) antigens (rcvlcwked by (iuulillc1, 
1997). 1 videncc fir the involvement ohminor histcýccýmpatihilily antigens (nil lag) 
ill huii al transplantation comes from data from hone marrow transplatltatiotl 
((ioulmcy, 1997). Both cytotoýxic and T-helpcr cells recognise till lag in a classical 
ME IL' fäshion ((looulr»y, ei a!., 1976). The nil lag are naturally pro eSsedi 
fragments of intracellular proteins that associate with MI IC molecules 0 )en Ilain 
el a1.. 1 995). Well defined 1111 lag include the male-spccif is nil lag I 1-Y. The male 
specific antigen I I-Y has been implicated in the rejection of' MI 1('-matched hone 
marrow transplant recipients. For example, Icniale patients that had been 
sensitised to II-Y following multiple blood transfusions developed hone marrow 
graft failure. In vi/ro analysis demonstrated the lrescilce of' Ill . A-A I -restricted 
anti- 11-Y cytotoxic T-lymphocytes ((Goulmy, 1997). 'I'hc significance ofA I-Y in 
recipients that had not been previously sensitised is not 
known. Non-Y-linkcd 
mf ýa for example I IA-1, have been described in recipients of' hone marrow 
transplantation and may play a role in graft füilure Of M11(ß-111Lftc}led recipients 
((ioulmy, 1997). The role of ml lag mismatches in renal transplantation is not 
clear although there was no effect of' I I-Y nil lag in MI W-matched living-donor 
renal transplants (I'llison ('t u1., 1994). 
, Y) 
1.2.2.3 14; ffcctiný; the immune response to an allograft 
Donor cells express MI I(' (111, / in hunmains) molecules on their surlacc. III. A 
class 11 antigens are recognised by ('I)4+ 'helper' t cells while 111A class I 
antigcns are recognised by (1! )8 1 c; ytotoýxic T MIS. 'I'hereiiºrc Illltilllatches 
between donor and recipient in III A ('lass 11 antigens (`1)R' region) will lead to 
activation of (11)4 f CCIIs. T` e host IllllllllllC systems initial Co lltýlCI Willi the 
allograft is %'iu leakage of `passenger Icucocytes' from the graft. 't'hese cells are 
donor haematopoietic cclis that are passively transI rred with the graft (1, echhIcr Cl 
a!., 1982). Aller transplantation, graft-harne APC (cave the allogralt and migrate 
to draining lymph nodes where they mature and acquire potent T cell activatillg 
properties (Larsen et tit., 1990). In the lymph node, passenger leucoc; ytcs provide 
donor MI IC Class I and Class 11 molecules. Both ('1)4 1 and ('I)8 1 "1' cells, which 
recognise donor alloantigen via the direct pathway. become activated. 
Once the I cells have completed their di l cmitiation in the ly mpho11(l tissue they 
home into the graft and find the appropriate target cells bearing their specific 
peptide/MI IC complex. This process is facilitated by the secretion from the graft 
vascular endothelium of chcmo-attractant molecules, called c: hemokinCS, and the 
upregulation of adhesion Ill(liccules on the suriüee 01- the grail vascular- 
endothelium (Fuggle and Koo, 1999). (; raft tissue is destroyed by specific 
cytotoxic T lymphocytes (("IT) and by a delayed hypersensitivity (1)'I l I)-proocess 
in which activated macrophages and cytokincs damage the graft. Allorcactive 
cells, particularly a subcategory of ('I)4 cells reIi. "rred to as 'I'll I cells, activate 
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rn; icruphagcs by the release of* the cylokitie y-interleron and co-siimiilalcºrv 
Signals. Once activated, macrophages release a varlcty t (ICS11-11eiiye medial rs 
inclucliiig nitric oxide, oxygen radicals and prcýteases. 
(1)K+ ('TI. s are able toi destroy cells by two distinct iimccliaiiiSills. Firstly, alter r 
hinding the spccilic peptide/MI I(' Class I complex on to the graft cell, the C TI, 
re-orientates its cy'loskeleton to fUCIIs the release OI' hylie granules towards the 
target cell. ('"I'1, s may also utilize the Fas/Fas liýancý pathway tu induce apuptusiti 
in the target cells (Strohlau ci a!., 1997). "('here ccII-mediated cf'iccts lead Icy the 
clinical picture of'allograft rejection. 
Allo-antibody responses can also contribute to graft rejection. {'reformed 
antibodies directed against MI IC or blood group antigens (ABO) can induce hyper 
acute rejection, a complement-dependent reaction in which endothelial destruction 
results in loss of' the graft through ischacmia. Serological 111,1 crossmatch 
procedures identify donor-specific J ILA or other a11oantihodies in the recipient's 
sera that cause such early graft loss. A positive crossmatch would contra-indicate 
the transplant. 
Rejection is therel'orc a complex process with a vast array of'c: ellular and Chemical 
interactions that ultimately lead to tissue and organ destruction and (j\slu nctio ll 
that is seen in clinical transplantation. I low can we extrapolate this haSic: 
knowledge to develop drugs that prevent this process occurring? It is clear lroº» 
the above discussion that the primary target of immuno suppresivc drugs is the T 
cell. 
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1.3 1 ffect of immunosuppressive drugs on the immune response 
1.3.1 Introduction 
Both ('y /A and FK506 are calcineurin inhibitors sharing the S ahme common 
path vaiy f(), - their et fl. 'cts on the T -cell response to antigens 
(Sickicrka cl al., 1989, 
I larding er ul., 1989, Johansson and Moller, 1990). Rapamycin and the analogue 
SI)l RAI) act can 'I' cell maturation events downstream from the initial I cell 
activation. 
1.3.2 Mechanism of T cell activation following antigen recognition in relation 
to the Calcineurin Inhibitors 
'I'CR engagement is referred to as Signal one. Ilowever, it has been established 
that the proximal events during T cell activation do not occur in the absence of a 
further signals known as Signal two. The best characterised `co-stimulatory' 
pathway is that mediated by the CD 28 surfacc: receptor, which is present oh XO`%, 
of'human 'F cells (Linsley el al., 1993). Two natural ligands O1'('1)28 have been 
clotned, 137-1 (C'DKU) and 137-2 (CE)86)). Both arc expressed exclusively (111 
activated APC. A second pathway in addition to ('[)2 that provides 
co-stimulation is mediated through the (11)40 molecule on MV, which hinds to 
C'1)40-ligand (('1)4O1, ) on activated "I' cells (Larsen and Pearson, 1997). A 
homologue cof'('I)2 . 
("TI A4 is expressed on activated I cells and tralº1tilluees a 
negative signal to the cell interior and may he important in terminating all immune 
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rCSpcýnSC (W11IUntlti ('1 iil., 1996). Following antigen recuºgnitiuºil, and with tli 
appropriate co-stimulatory signals. the initial step o(' IT cell activatioin, aI sustained 
rise of' intracellular calcium, can occur. I'he high level o[C LICium lutist he present 
1l)r two hours 1'or T cells to he coiiilliittcd to activation (lii)hode n and Weiss, 
1987). Once the extra calcium reaches threshold level it hinds Icy the ubiquitous 
calcium dependent regulatory protein calmodulln. Calclurn-calmodulln complexes 
can activate several enzymes, including protein kinases (leading to addition of 
phosphatc groups to a protcin), and protein phosphai&se, S of f)ihoosfplhiite 
groups) such as calcineurin. ('alcineurin is a three component phosphatase made 
up of an n chain, which is a catalytic subunit, -i 11 challil, which IS ýI cýIIclu(ll 
binding subunit, and finally the calmodulin protein, which IS a calcium binding 
regulatory subunit (Kuhhard and Klee, 1989). 
('alcineurin has a pivotal role in downstream events leading to the transcription of 
is a growth cytokines particularly intcrlcukin-2 (11, -2). The transcription of 11-2 
crucial step in 'I' cell activation since following II, -2 expression further 1' cell 
activation becomes antigen independent (Crabtree, 1989). T cell activation not 
only involves IL-2 secretion but also expression of the IL-2 receptor on the 
surface ol'the cell (Hatekeyanma ei al., )989). The ll. -2 receptor IS uhregulaled 
by 
II, -2 and is a heterotrimeric recognition structure (Smith and ('antrcll, 19X4). The 
ca chain ((11)25), undergoes major changes in expression upon T -cell activation 
whereas the (3- chain and the y-chain are largely constitutively expressed on 
resting lymphocytes (I 1atekeyama cl al., 1989, Takeshita ('1 al., 199-1). 
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The intervening step between calcineurin activation and transcription of IL-2 is 
the translocation of NF-AT (Nuclear Factors of Activated T cells) from the 
cytoplasm to the nucleus. NFAT transcription factors are highly phosphorylated 
proteins (Crabtree, 1999). NFAT proteins are located within the cytoplasm of 
resting cells; upon activation they are dephosphorylated by calcineurin and 
transported into the nucleus. Mass spectrometry studies have shown that NFATI 
is phosphorylated on fourteen conserved phosphoserine residues in its regulatory 
domain, thirteen of which are dephosphorylated upon stimulation (Okamura et al... 
2000). Full dephosphorylation of the thirteen residues appears to be required to 
cause full exposure of an identified nuclear localization signal, mask a nuclear 
export sequence and allow maximal transcriptional activity (Okamura et al., 
2000). A summary of the events of T cell activation is represented in Figure 1.2. 
Figure 1.2 T cell activation. T cell receptor engagement by antigen in the form of MHC- 
peptide complex leads to the cascade of intracellular events and activation of the calcium- 
calmodulin dependent phosphatase, calcineurin. Calcineurin cleaves a phosphate moiety 
from NFATc, which allows the translocation of NFAT from the cytoplasm to the nucleus 
and the transcription of genes for growth cytokines. 
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1.3.3 Mechanism of action of Cy A 
Cy /1 is a naturally occurring cyciic peptide isolated 
from a t'ungus, 
7o/vpocla ilium in/lalams 'ums It hinds toi many cellular targets, including the 
ubiquitous soluble cytosolic protein cyclophilill (I lalldscllulllachcr e! erl., 1984). 
Cyclophilin is identical to peptidyl-prolyl isonicrase, an enzyme that catalyses the 
intcrconversk)n of the eis- and trans-rotamers ofthe peptidlyl-hrolyl amide hond of 
peptide and protein substrates (Fischer ei al., 1989). This rotamase activity is 
potently inhibited by Cy A (Siekierka el al., 1989). ('y A-cyclophilin complCXCS 
can bind to calcincurin (C'N), inhibiting the action cif' ('N (l, iu cri al., 1991). The 
dephosphorylation of' NFA"T does not occur in this situation and therefore NFA I' 
remain in the cytoplasm ('Timmerman ei a!., 1996). This leads to Iailurc of the 
early differentiation events associated with i'-cell activation. 
1.3.4 Mechanism of action of FK506 
FK5O6 is a macrolide antibiotic isolated from Sl"(7)lomvc"c'. s' l. sukU/)acn. Si. S' (tiUýto) cl 
eil., 1987). In vilra experiments confirm that in comparison to ('y A, FK506 is 
40-200 times more potent at inhibiting mitogen stimulated responses and allo- 
mixed lymphocyte reactions of murine splenic lymphocytes in a dose dependent 
manner (Sawada ei al., 1987). 
FK50 binds to a family of' intracellular receptors termed. FKI31's or FK binding 
proteins (Fruman, Burakoll and I3icrer, 1993). The principal cytoplasmic isoýlorm 
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()I* the FKBPs is FKBPl2, a I2-ki) protein and like cyc-l()philin, FKUP has 
rc)tclmaSC activity towards a peptide substrate (Sickierka el cal., 1989,1lardiing el 
ul., 1989). FKI3P and cyclophiiin arc rcicrrcd to as IllllliunOphllllnti. FKý06 
inhibits the rotamasc activity of' I'KIWI', but not of cyclophilin, likewise, ('y A 
does not inhibit the rotamase activity of FKRP (Siekierka ei cal., 1999). The 
immunophilins are abundant cytoplasmic proteins and FKBP12 has been 
estimated to account for 0.3-0.5% cif' cellular proteins (Siekierka el al., 1989). In 
addition, the immunophilin proteins are conserved throughout evoiution; prutCifS 
with homology to these proteins have been fund in all eukaryotic species as well 
as in E. coli and plants (Fruman, Burakoff and I3icrcr, 1994). 'ibis suggests that 
these proteins mediate essential cellular functions such as protein fI lding and 
cellular trafficking (Gething and Sambrook, 1992). As with ('y A/cyclophilin 
complexes the complex of IFK506/FKBP inhibits the action of calcineurin (1, iu et 
al., 1991). Experiments utilising an FK5O6 derived radioactive ligand confirm that 
half maximal T cell suppression occurs following occupancy ofFKBI' 12 of only 
3-5% of the available pool (Dumont el al., 1994). 
1.3.5 Mechanism of action of Rapamycin 
Rapamycin is a macrolidc antibiotic product Of Sireptomvcc's h, h1'groscoI1iiI.,, an 
actinomycete, originally isolated from a soil sample in Raga Nui (Faster Island) in 
1975 (Sehgal ei at., 1975). It has a similar structure to FK50 ß and hinds toi the 
same immunophilin as FK506 (Schreiber, 1991). However, the complex of 
rapamycin/I'KI3P is not able to inhibit the action of' ('N. Instead rapamycin is able 
to abrogate enzymes cif the signal transduction cascade utilised by II, -2 to induce 
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T cell activation (Dumont ei cal., 1990h). Moreover, FK 5O( and rapamycin can 
antagonise each other's II1111 uo suppressivc cIThcts (Dull ont ('l a!., I990a; I; ierer 
CI al., I990), consistent with the idea that the drugs share the same intracellular 
binding sites. 
The phosphorylation of' 40S ribosomal protein So appears to he a prerequisite for 
the activation of' protein synthesis and cell growth ('Thomas c/ al., 1982). This 
event is largely regulated by the mitogen-activated p70 S6 kinase in mammalian 
cells. "I, he complex lormcd between FKß1' 12 and rapamycin abrogates the 
enzymatic activity ofthe p70 , '6 kinase (Chung el al., 1992) preventing cells from 
progressing from Gl to the S phase of the cell cycle. The precise target I'M the 
IFKI3P12-rapamycin complex has been identified as a novel protein named 
mammalian target of rapamycin (mTOR) by Sabers ei al (1995) or FRAP (Brown 
e! al., 1994) or RAFT (Sabatini et al., 1994). 1 low m"I'OR directly affects p70 56 
kinase is not known. 
Since rapamycin does not primarily affect early events after "1' cell activation, it is 
a less effective inhibitor of cytokine synthesis than Cy A or FK50 ß. I Jnl ike the 
CN inhibitors, rapamycin blocks calcium-independent pathways in 'F and B cells 
and also blocks activation pathways following stimulation with I1. -2 and Other 
growth cytokines (Kay el al., 1991). Rapamycin blocks mitogenic stimulation of 
11 cell proliferation (Wu et al., 1991) and inlnlunoglohilin synthesis. Although the 
anti-proliferative effects of' ('y A and FK50 are primarily restricted to T and B 
cells, rapamycin can inhibit growth factor induced cell prolileraticýn ()f fibroblasts, 
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endothelial cells, hepatocytes and smooth muscle cells (Akselhand e/ al., 1991 and 
(1ao cl cal., 1995). 
The fact that rapamycin does not inhibit ('N may account fier the diflcrent toxicity 
profile compared to both Cy A and FK 5U(ß. For example, rapamycin is non- 
nephrotoxic although does cause dose dependent lipid abnormalities with 
hypertriglyccridacmia and hypcrcholesterolaemia reported in approximately 5O° o 
of the patients and thrombocytopenia in 37% cif' patients (Groth et at, 1999). 
There are wide inter-individual variations in the pharmaeokinctic properties 
observed upon oral administration in both animals and humans (Kahan el a1., 
1995a). This has prompted the development of rapamycin analogues with more 
favourable pharmacokinetics, such as SDZ RAI). 
1.3.6SDZRAD 
S[)Z RAI) bears a stable 2-hydroxyethyl chain substitution at position 40 on the 
rapamycin structure and is a rapamycin analogue developed by Nuvartis (Basel, 
Switzerland). SDZ RAI) suppresses "I' cell immune responses, by its ability toi 
inhibit T cell proliferation stimulated by II, -2, as well as T-cell dependent and 
'F-cell independent 11 cell responses. SD!.. RAI) binds with high affinity to 
FKßP l 2, although is about three-told weaker than rahamycin (Schuler 0 a/., 
1997). In general the in vilru activity of' SI)/, RAI) is about two to three times 
lower than rapamycin and this level of'effect is Consistent with the lower affinity 
for FKI3P12 (Schuurman ei (1l., 1997). 
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S[)i kAI) has been shown to he etlcctive in in º'itro and in Ovu models with dose 
dependent anti-prol iterative effects on 2 way mouse mixed lymphocyte reaction 
(MIN) and prolongation cif' orthotopic kidney and cardiac allografting in the 
stringent DA-Lewis rat strain cOmhinatiOf (Schuurman el (!., 1997 and 2000). 
Synergism with Cy A has been demonstrated (Schuurman el cal., 1997). Synergism 
is the enhanced effect of 2 compounds above that expected purely by addition of 
their individual effects. As Cy A and macrolides, such as rapamycin and SI)/ 
RAI), differ in their respective side effect profile, this synergism may provide a 
similar level ofefficacy with fewer side effects. For example, in the rat cardiac 
allograft model low dose SDZ RAD in combination with ('y A yielded long-term 
survival (Schuurman et al., 1997). In the same model the maximum tolerated dose 
o#' each drug was less effective in terms of allograft survival. (Schuurman cl al., 
1997). 
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1.3.7 Summary of the effects of immunosuppressive drugs on the immune 
response 
C'yclosporin A and FK506 are potent inhibitors of 'I' cell activation and the 
immunc respOnsC to an allogralt. Although they have dif'lereint Structures they 
mediate their actions through the phosphatase, calcincurin. They bind toi dillerent 
intracellular receptors called immuilophlliiis. Both rapanlycin and Sl)/ RAI) arc 
powerful immunosuppressant compounds. Binding to FKBP 12 is central to their 
immunoSuppressivc action. Ilowever, unlike FK506, which also hinds toi 
FKE3P12, they exert their effects on growth factor stimulated cell proliferation at 
the ribosomal level. 
ýý 
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1.4. Pharmacukinetics of the calcineurin inhibitors in clinical transplantation 
1.4.1 Introduction 
The application of these powerful compounds in clinical practice is evolving 
continuously. The pharmacokinetics of' the developed drugs has a significant 
effect on how they are utilised in clinical practice. The pharmaccýkinetics cif' Cy A 
and FK506 are discussed below. 
1.4.2 Blood level monitoring of Cy A 
Cy A is insoluble and this has made the preparation of reliable pharmaceutical 
förmulations difficult. Conventional Cy A (or Sandimmun(R)) is an incomplete 
emulsification that produces wide variations in hioavailahility (Kahan el (Il., 
1995h). Recently, the microemulsion tbrmulation of ('y A, Neoral(K), has been 
introduced into clinical use. Cy A has a narrow therapeutic window and in clinical 
transplantation it is important to monitor the blood level frequently (Caine e< al., 
1983). The most widely accepted practice is to monitor the `trough' blood level 
(C-O) just prior to the next dose. Accepted trough blood level ranges for ('y A are 
100-400 ng/ml with higher levels 1ör the induction phase cri' treatment during the 
first 3 months and subsequently lower maintenance levels. At these levels, ('y A 
inhibits about 50% o1' CN activity in in vitro experiments. I ligher levels such as 
800-1000ng/ml will lead to approximately 80% inhibition of (1N but with 
increasing toxicity (1 Jalloran ci al., 1999h). 'l'he pharmacokinctic s of ('y A 
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administration have been extensively investigated. It his been clcnioýnstrated that 
conventional ('y A (Sandimmuni) trough blood levels do not predict clinical 
outcome in terms of acute rejection episodes and one year graft survival ( Kahan eel 
al., 1996). 1lowcver, the report also demonstrated that total drug exposure as 
measured by determining the Area linder the drug Concentration/Time curve 
(1AUC) could he correlated with clinical outcomes. Despite this, it IS not rl)uiine 
clinical practice to perf'orm detailed AUC measurements since these are 
cumbersome and time consuming. The `trough' blood level remains the most 
common vehicle for dose adjustment. 
The new formulation, Neoral(k) is better absorbed and gives more consistent blood 
levels. However, as with `conventional' Cy A (Sandimmun(R)), the trough blood 
levels do not give a truly accurate guide to total drug exposure, since there is a 
wide variation in absorption over the first 2-4 hours following dosing (Johnston cl 
a!., 2000). This is important since most of the pharmacodynamic effects of ('y A 
occur within 2 hours (Ilalloran ei a!., 1999h). Thereibrc, it can he envisaged that 
trough blood levels do not accurately represent drug exposure during the critical 
first few hours post dose. Trough blood levels following dosing with the Neoral(R 
formulation do not rellect clinical outcomes in terms (ii acute reýjccticýn rates 
(Mahalati el al., 1999). The data show that although high trough levels were 
associated with increased ilephlrotoxicity the trough levels did not predict those 
patients in whom acute rejection occurs. A drug level taken at 2 hours following 
ingestion correlates well with the formal At JCS measurements and has been shown 
to be predictive of nephrotoxicity and acute rejection episodes (Makilati Cl at, 
2000). 
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1.4.3 FK506 blood monitoring 
Absorption of FK506 flollowing oral administration is erratic with oral 
hioavailahility varying from 5-67`% (Venkataramanan el (f., 199) 1 ). there is 
marked inter-individual and intra-individual variation in the dose-normalised 
AUC following administration of FK5O6 in renal transplant recipients Ohara ei 
ul., 1995) However, there was good correlation between trough levels and the 
highest drug level reached, Cmax and 't'rough levels offer an 
acceptable practical way to monitor blood levels of FK50O (Ihara c'l cal., 1995). In 
kidney transplant patients the trough level of FKSO6 is well correlated with acute 
rejection episodes and nephrotoxicity (Kershner and Fitzsimmons, 1996). 
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1.5 Developing hypotheses 
1.5.1 Introduction 
Resistant allogralt rejection under ('y A-based immunosuppression remains ai 
considerable problem. As discussed in section 1.1.5.2, Jordan cl at (1994 and 
1997) reported two series of renal transplant recipients receiving ('y A as their 
primary therapy (Jordan cal ul., 1994 and 1997). These patients were rejecting their 
grafts despite apparently adequate trough blood levels and were `salvaged' by 
conversion to FK506 in 74% of cases. "1'he reason for this `salvaging' el'icct cat' 
conversion to FK506 is not wholly defined although one can speculate can possible 
contributory factors. 
1.5.2 Explaining Cy A `failure' 
Could apparent `Cy A failure be attributed to the pharmacokinetics of ('v A and 
the lack of correlation of trough levels and total drug exposure? Conversely, does 
FK506 ouier the advantage that trough blood levels more accurately reflect drug 
exposure than with ('y A in both ofthe formulations, Sandimmun(R) and Neoýral)R) ? 
FK506 has been shown to he more potent than ('y A in both iii rilr"n models of 
allo reactivity and in animal models. Could the salvaging effect he as a result of 
increased potency of Cy A? Alternatively, are there additional pharmacl)dynaniic 
effects that may lead to the development of' resistance to either drug following 
treatment'? 
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Following consideration of all thcsc points a novel approach toi the problem of 
drug failure would be to explore the Possibility cof'selective resistance developing 
to either drug. The hypothesis presented here is that resistance to the drugs either 
develops in lymphocytes following prolonged exposure toi the drugs or may pre- 
exist. The sensitivities of lymphocytes from renal transplant patients to the drugs 
have been examined. 
1.5.3 Drug resistance 
Briefly, these experiments confirm a wide range of lymphocyte sensitivities to 
both Cy A and FK506 and the development of' resistance to the drug used for 
treatment. The potential cause of these observations has been investigated. 'hie 
next part of the thesis (section 1.6) explores the concept of multidrug resistance. 
1.5.4 Drug interactions 
FK506 and rapamycin share the same intracellular binding sites and yet 
have 
different anti-proliferative targets within the cell (reviewed by }3ierer, 1994). 
Studies on rapamycin confirm mutual antagonism with FK-50 and led to the 
theory of' a shared intracellular binding site (Dumont et aal., 1 990a). 1 IOwcvCr, a 
study in a rat cardiac transplantation model did not demonstrate antagonism but an 
enhanced immunosuppressant effect cif' combining rapamycin with FK 506 (Vu l 
erl., 1997). Similarly, the combination of FK50 and rapamycin has been used as 
therapy for 1 xperi ncntal Autoimmune t. lveoretiinitis (UM l) (Ikeda ei cal., 1997). 
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t he combination therapy with FK5O6 and rapamycln achieved I00% inhibition of' 
Clinical EAtJ in a rat model, and 67% suppression o[ histological Fnl 1. Therapy 
with either drug alone achieved only partial clinical suppression (Ikeda eI cal., 
1997). 
Fhese reports contradict the notion that the two drugs are mutual antagonists. 
However, likely explanations 1ým these effects have been offered. Firstly, in 
Dumont's early report the two drugs, FK506 and rapamycin were mutually 
antagonistic when either drug was present in much higher quantities than the other 
(Dumont et ul., 1990a). Secondly, the mutual intracellular binding protein, 
FKBP12, is present within the cell in very high amounts, and this abundance in 
vivo could prevent competition (Siekierka el al., 1989). 'T'hirdly, only a small 
fraction of the cellular pool of FKBP 12 needs to he occupied by the drugs in order 
to achieve high levels of immunosuppression (Dumont et ul., 1994). The 
investigation of the interaction of the two drugs, FK506 and the rapamycin 
analogue, SDZ, RAD, in in vitro lymphocyte cultures from renal transplant 
patients is a worthwhile area of study. This is because USinlg two drugs with 
predictable pharmacokinetic profiles in a synergistic way may lead to safer and 
more efficacious anti rejection protocols. 
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1.6. Multidrug Resistance 
1.6.1 Introduction 
Multidrug-resistance (MICR) is a phenomenon whereby cells that have been 
selected for resistance to one drug develop resistance to a wide variety of 
unrelated drugs (Endicott and ling, 1989). The drugs most often involved in 
MDR are alkaloids, such as vincristine and vinhlastine, or antibiotics of' plant u1' 
Fungal origin. MDR cell lines can he isolated in vitro by selecting cells for 
resistance to a single cytotoxic agent. The cells simultaneously become resistant to 
a number of other compounds. Although the drugs to which these cell lines are 
resistant appear to have no common structural or chemical properties, they tend to 
be large, planar, hydrophobic molecules (Endicott and Ling, 1989). 
1.6.2 P-glycoprotein-170 
One of the gene products mediating MDR was discovered in 1997 and is called 
P-glycoprotein-170 (P-gp). Transtection experiments using human P-gp cl)NA 
sequences show that increased 11-gp expression is able to conicr a complete M[)R 
phenotype on drug sensitive cells (Ueda et al., 1997). i'he human P-gp genes Heir 
to the long arm of chromosome 7 at 7g21-31 ("Trent and Witkowski, 1997). P-gp 
has been shown to he conserved across species. CI)NA analysis has confirmed that 
there is a high degree of homology between different 11-gp gene fämily members 
within a species and across species (Ng cat al., 1999). P-gp is now known to he the 
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170-kD product of the MDRI gene, and is a member of the adenosine 
triphosphate [ATP]ase binding cassette (ABC) superfamily of active transporters 
(Hyde et al., 1990). P-gp is a transmembrane protein that is 1280 amino acids long 
and consists of two homologous halves of 610 amino acids joined by a flexible 
linker region of 60 amino acids. Each half has an N-terminal hydrophobic domain 
containing six transmembrane domains followed by a hydrophilic domain 
containing a nucleotide-binding site. The nucleotide-binding sites can bind ATP 
and its analogues and both sites are essential since inactivation of either site 
inhibits substrate-stimulated ATPase activity. The structure of P-gp has been 
determined to 2.5 nanometre (nm) resolution by electron microscopy and image 
analysis (Rosenberg et al., 1997). This is represented in Figure 1.3. 
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Figure 1.7 Three-dimensional structure of P-gp. `P', aqueous pore open at the 
extracellular face of the membrane. "TMD': transmembrane domains. `NBD', 
Nucleotide-Binding Domains (annotated from Rosenberg ei al., 1997). 
When viewed from above the plasma membrane, P-gp is donut shaped with 6-fold 
symmetry, a diameter of about I Onm and a large central pore of about 5nm in 
diameter. It has a thickness in the plane of the plasma membrane of about 8nm. 
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Since the depth ofthe plasma membrane lipid hilayer is about 4nm, about halt of 
the molecule is Within the Plasma Illembrane. '111C Central pore is closed at the 
inner (cytoplasmic) end, forming an aqueous chamber within the membrane that is 
open to the extracellular medium. There is an opening frei» this chan»her to the 
lipid phase. Two lobes of about 3nm each are exposed at the cytoplasmic end and 
probably correspond to the nucleotide binding domains. The model proposed fier 
this molecule is that it functions as an energy dependent transnmemhrane protein 
using ATP hydrolysis to pump cytotoxic drugs out Of MIS thus reducing their 
intracellular concentration and toxicity ((. iottcsman, 1993). 
1.6.3 Physiological role for P-gp 
P-gp is expressed in normal tissues, particularly on the luminal surllices of 
transporting epithelia, such as the proximal tubules of the kidney, epithelial cells 
of the small intestine and colon, and hiliary hepatocytes of the liver ("I'hiehaut e! 
al., 1987). The tissue distribution cal P-gp is consistent with a membrane transport 
function. By homology to its transport role in MDR cells 11-gp has been proposed 
to protect the organism from harmful natural toxins and xenoýhiutics (FndiCOýtt aný1 
Ling, 1989). 
Monoclonal antibodies provide a method for determining the expression of 1'-9P 
in normal and tumour samples. A number ol'antibodies have been characterised 
that recognise cytoplasmic domains and external cpiicýpcs of'1'- ; fi such as MRK 16 
(I lamada and Tsuruo, 1986). Other tools that have been vital to the investigation 
of' M[)R phenotype have been the fluorescent dyes such as r1hodanline-123 
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(R-123) (Ncylhkh ei al., 1989). 1'hcsc dyes are actively transported from cells and 
indicate drug pumping. The ability Of cells to efflux these dyes ft nr» the 
intracellular compartment to the surrounding medium is a reflection cri' MI)R 
phenotype activity since it can he blocked by known c henmical inhibitors of I'-gpp 
(Feller et al., 1995, Pilarski et al., 1995, Broxterinan el al., 1996, I'elriw, o al., 
1997). 
1.6.4 P-gp expression on human peripheral blood lymphocytes 
It has been demonstrated that some normal Ith)USe spleen cells and human 
peripheral blood mononuclear cells could rapidly efflux R-123 and that such 
efflux was blocked by known chemical inhibitors cif' ll-gp (Ncyfükh, 1988). 'T'hese 
observations have been developed further to quantify the differential activity of 
a!., P-gp in normal blood lymphocyte subsets (Chaudhary et al., 1992, Klimecki cl 
1994, Pilarski ei al., 1995, and Ludeschcr ei a/., 1998). For example, ('haudhary's 
group demonstrated that human peripheral blood lymphocytes express f'-gli, and 
that P-gp expression correlates with the efflux of'fluorescent dyes from cells. The 
efflux was suppressed by chemical inhibitors of' P-gp and also by a P-gp specific 
monoclonal antibody (Chaudhary ei al., 1992). I)uuhle labeling of cells with 
specific antibodies to lymphocyte subsets demonstrated which lyniphoýcyte subsets 
were able to efflux the P-gp specific fluorescent probes. The majority (K(1-`>ýý°ýý) of 
the ("D8 positive cells CHILIxed the dye and stained positive for he s pecilic; 
monoclonal antibody. Some 9O-95% o1' NK cells (('x)56 + cells) were positive. In 
contrast only 40-50% of' Cl)4-+- cells were positive h)F dve efflux 111(1 anti body 
staining. "There was no P gp activity demonstrated can (1)14 º 11111nocytes 
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(Chaudhary e/ al., 1992). Approximately 42% of total adult peripheral blood 
mOnOnuclcar cells exported dye, 58% appeared to have no active eillax pump 
(Filarski el (al., 1995). Similarly, 64% of 11 cells and 52% of T cells expressec) 
surläcc i'-gp as evaluated by staining with the nio no cIOilLil antibody, MRK 16, 
which recognises an external cpitope cif' I'-gp. '('hc proportion cif' positive staining 
cells was lowest among children less than 10 years of age, increased in adllllthood, 
and decreased after 60 years of' age. B cells from blood and spleen included a 
substantial proportion of cells with efficient dye ef'ilux. In contrast, 13 cells from 
thymus and cord blood had only minimal dye efflux (Filarski ei al., 1995). It was 
postulated that since there is developmentally regulated expression of P-gp 
function on lymphocytes that P-gp might have an important function in normal 
immune developnment. It has been shown that T cells with nave phenotype have 
greater expression of P-gp than memory 'I' cells (I. udeschcr el ul., 1999). The 
differential expression of P-gp activity suggests a physiological role fier P-gp in 
lymphocyte function (Pilarski ei al., 1995). For example, I'-gp has a putative role 
as a transporter of cytokines (Drach el al., 1996). t Jpon stimulation, lymphocyte's 
exert their immunological actions in part via production of cytokines. The release 
of 11, -2, I1, -4 and interferon-y from stimulated normal lymphocytes is significantly 
suppressed in the presence of I'-gp inhibitors although there was not sig11il1C, lnt 
down regulation ut' II, -2 mRNA expression (I)rach cq cal., 1996). Simjlarly, 
it has 
been demonstrated in mitogen stimulated lymphocyte cultures treated with 
monoclonal antibodies to P-gp have a significant reduction in II, -2 levels in the 
culture supernatant (Raghu ei al., 1996). 
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1.6.5 P-gp expression on tumours 
Fxpression ofthe MI)R 1 gelle in different types ofsolid tumours and Ieukaci»ias 
has been associated with increased clinical resistance to chemotherapy (( ioýldstein 
el al., 1999). Considerable heterogeneity is seen in P-gp expression in human 
cancers. Retrospective studies on tumour samples taken sequentially from patients 
with neurohlastoma, childhood soll tissue sarcoma and retiiiuhlastoýi»a have 
demonstrated that P-gp expression inversely correlates with tumour 
responsiveness to chemotherapy (Chan el al., 1990 and 1991). 
1.6.6 Cyclosporin A and FK506 are substrates for P-gp 
The role of' MI)R mechanisms in transplantation is Unknown. I IOWCvCr, it his 
been considered a worthwhile area of study since the report that human P-gp 
transports Cy A and FK506 (Saeki o (il., 1993). 11 . C'-1'K I cells 
derived f'run1 
porcine kidney tubular cells were planted can bottom- fi Itered cups. Further cells 
were transfected with human M[)Rl eDNA and a clone established alter selection 
in coichicine. Tritiated Cy A (; I i-cry A) was added to the medium oithe basal side 
or ofthe apical side of the monolayer of'cells. The trans1 cted cells, terinied Ii . ('- 
(; A5-COI, 300, express P-gp specifically on the apical surfäcc. 'I'hß" amount of 
Cy A that passed across the transfected cells' epithelium 11m the basal to the 
apical surface reached 10% in 3 hours, which was higher than the 4.5% which 
passed through the non transf cted cells. The corresponding amount that traversed 
from apical to the basal side was only 3.9%. When the ;I I-('y A content of the 
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cells was measured it was found that only one sixth of the amount was present in 
the transfi: cted cells compared to the non-translec; ted cells when 
tll-('v A was 
added to the apical side. The experiments were repeated with FK506. The 
amounts Of FK506 that passed from the basal toi the apical sidle OI' the I .I . ('-I'K 
I 
epithelium were 27 and 26% respectively, indicating passage by simple diffusion. 
The anR)unt passed across the transiccted cell mo nl)layer i'roi» the basal toi the 
apical side was 40%, and the amount from the apical toi the basal side was only 
10%,, representing the typical pattern oforiented transport by P-gp. Accumulated 
FK506 in the transfected cells decreased to one fourth of' that in the non- 
transfected cells. The conclusions from these experiments were that ('y A and 
F'K506 are substrates lör P-gp mediated transport (Saeki el al., 1993). 
1.6.7 The biological consequences of P-gp mediated Cy A and FK506 
transport 
There are both pharmacokinetic and pharmacodynamic consequences of f'-9P 
mediated Cy A and FK506 transport. Cy A and F; K506 are mctaholiscd primarily 
by cytochrome P45() 3A (CY113A4) in the liver (Kronhach cl a/., 1988 a ndl Sattler 
e! (!., 1992). 1 lowever, small bowel epithelial cells express abundant quantities of 
CYP3A4 (Kolars ei a!., 1992), and metabolism via this pparthway accounts tier 5O°%o 
of oral Cy A metabolism (Kolars et a!., 1991 ). The quantity OI' intestinal 1'-gp 
accounts fror approximately 17`%0 of the variability in oral ('y A pharillacokinctic s 
in a study cif renal transplant patients (l, own el al., 1997). 
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The pharmacodynamic cf accts of' I'-gp mediated transport of' Cy A have been 
investigated (IFaikat, a ei al., 1998). 'Hie hypothesis that iiicreýascci expression of 
P-gp confers protection against Cy A dependent inhibition of ('N phosphýltase 
activity was explored on selected cell lines expressing varying levels of I'-gp 
(Fakata et a!., 1998). The study group utilised the human epkkrmal carcinoma 
cell line KB-V that were grown in media supplemented with varying strengths of 
vinhlastine. Dose response curves were then obtained for ('N phosphatase activity 
against Cy A concentration. Kß-V cells grown in high dose vinbiastine shifted the 
dose response curve to the right some 70-fold compared to the parent K II cells. 
Veraparnil, a 11-gp inhibitor, completely extinguished the protection allorded by P- 
gp expression. There are no reports of similar experiments in the target cells tier 
Cy A, namely, lymphocytes, in renal transplant patients. I lowcvcr, modulating the 
effects of P-gp on lymphocytes has been reported in respect to sensitivity toi 
doxurubiein in the mouse (Pourticr-Manzancdo ei a!., 1993). ('uncaiiavalin A- 
stimulated mouse spleen cells display a doxoruhicin-resistant component. 
I However, by adding inhibitors of P-gp, in this case the ('y A analogue S1)/. 833, 
the Tcell proliferative responses display a much higher doxoruhicin sensitivity. 
1.6.8 Non P-gp mediated MI)R: Role of MRP and I. RI' 
1 . 6.8.1 Introduction 
I'-gp, the phenotype of the M I)R 1 gene 111 111,1111 clOes not account fi)r all MDR that 
has been observed to develop in the treatment of cancer. Studies have confirmed 
that drug selected cell lines have MI)R activity but do not contain P-gp (I aylor 0 
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a/., 1991). One of the most extensively characterised noon-l -gp niultidrug-resistant 
cell Iinc is II69AR, a small cell 
lung Cancer cell Iron which was derived Iron, the 
drug sensitive parental cell line 1169 by step-wise selection in doxcýruhiciti (Mirski 
el al., 1987). The mRNA species that was over expressed in the resistant cells was 
identified and sequencing of'el)NA clones derived from this niRNA revealed that 
it had the potential to encode a 1531 amine acid protein which was named 
multidrug resistance-associated protein (MRP). This protein is a member of the 
same ATI'-dependent transmcmbrane transporter superfhmily as P-gp (('ole cc/ al., 
1992). Transfcction of' MRP cI)NA confers a similar pattern of resistance to 
important cytotoxic drugs such as anthracyclines. Vinca alkaloids, and antibiotics 
(Cole et al., 1992). 
1.6.8.2 Physiological role for MRP 
The physiological relevance of MRP is not cstablishcd although M[ZP has been 
demonstrated to transport cysteinyl leukotriene, LI'('4, and other glutathicýne 
conjugates (Zaman et ul., 1995). MRP mRNA is expressed at low levels 
111 111, Iny 
tissues, including haematopoietic cells. Analysis of the tissue distribution of 
mRNAs for human and murine MRII indicate that the highest levels ofexpression 
are in the testes, skeletal muscle, heart, kidney and lung. I. Ow levels are SCCn 
in 
liver and intestine (Kruh et eil., 1995). Reduced drug accumulaition and enhanced 
drug efflux is usually observed in drug selected cells that over-extpress MRP 
(Zaman el al., 1994). The expression of MRP in normal cells from peripheral 
blood and bone marrow has been examined (I. egrand el cal., 1996). The MRl 
mRNA levels were estimated by reverse transcriptase/polymerase chain reaction 
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(IZ'I'/I'C'IZ) and in , silu hybridization (INI I) assay. MRI' was present in peripheral 
blood and hone marrow cells Isom normal donors, and those in rem ssion aller 
chemotherapy for large cell lymphoma or acute myeloid leukaemia. Individual 
expression levels were variable; however, there was »c) difference b tweein 
untreated normal hone marrow and post chemotherapy hone niarrcýw. MR II 
protein expression was determined by flow cytoýnietry with the 111oiioclonaal 
antibody MRPm6. The CI)4+ lymphocytes exhibited a higher MRI' protein 
expression than the other cell lineages, including ('I)8 1 cells (1. cgrand ci al., 
1996). 
1.6.8.3 Investigating the clinical importance of MRP 
I'he role of MRP in chemotherapy failure remains poorly defined, although 
circumstantial evidence for a role has been reported. Firstly, deletion of the MRI' 
gene can the inverted chromosome 16 of myeiomonocytic leukaemia correlated 
with a better outcome (Kuss ei al., 1994). Secondly, MRP expression ill 
retinohlastoma correlated with failure of chemotherapy despite inhibiting P-gp 
with Cy A (Chan et a!., 1997). 
I'u facilitate studies of MRP several specific monoclonal antibodies have been 
developed which may lead to detection and characterisation in clinical 
tumour 
samples (Hens el al., 1994 and I Iip ner ei ul., 1996). The majority 01 clinical data 
relating to MRI' has been obtained in leukaemic; cells. The studies of MRl in 
clinical specimens are difficult to interpret since the methods used toi characterise 
the expression and functional activity Of MRP are not standardized (I"eticr ei (Il., 
4() 
1995). In a study in 65 heterogeneous Ieukaemic patients only 69/o OI' cases 
expressed MRP in contrast to 53`%0 expressing I'-gp either 1111111 or 
in coll1I1111atiOn 
with MRI' or Lung Resistance Protein (1 RP) (Michieli et (d., 1997). 
1 . 6.8.4 Lung Resistance 
Protein 
Lung-Resistance Protein has been described in non 11-gp MDR. The I ,RP 
is the 
human major vault protein (Scheflcr el cal., 1995). It is aII O-kI) protein that his 
been associated with a poor prognosis in acute myeloid Ieukaemia and ovarian 
carcinoma when over expressed (Izquierdo el al., 1995). It is expressed in all I'-gp 
negative MDR cell lines tested so far. The LRP gene has been localised to the 
short arm of C-16 and this region appears to he critically involved in MDR 
(Scheffer et a!., 1995). A monoclonal antibody, LRP-56, has been used fier the 
specific detection of' LRP in frozen sections by in n, unoh istochcmistry and 
in flow, 
cytometry (Izquierdo el al., 1995 and Michieli ei al., 1997). In flow cyto nictry 
studies the parental cell lines and normal Icucocytes reacted weakly toi all the 
monoclonal antibodies tested and functional assays of' LRI' have not been 
established (Michieli et ul., 1997). Although I. RP does have prognostic 
implications in certain malignancies as an important mediator ofdrug resistance, 
the lack of'detection in normal peripheral blood mononuclear cells (I113M(') made 
the study of this and indeed the study of' MRP in PBMC from renal transplant 
patients unattractive. 
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1.6.9 MI)R inhibitors 
1.6.9.1 Introduction 
A characteristic of MI)R is that it can he reversed by a number of' diverse 
compounds which can act as cheniosensitisers. These agents are not toxic to MDR 
cells at concentrations that reverse the MI)R phenotype. When administered in 
combination with anti-cancer drugs they enhance cellular anti-cancer drug 
accumulation by acting as competitive inhibitors for drug transport. A number eil' 
compounds have been investigated for their ability to reverse the MI)1Z 
Fxamples include verapamil, amiodaronc, phenothiazincs, ncurcýleptics, and ('y A. 
However, many of these compounds produced severe toxic clThcts such as 
blocking ion channels or modulation of' other physiological pathways (F. ndic: ott 
and Ling, 1989). 
1.6.9.2 PSC 833 
I'SC 833 is a cyclosporin analogue that has been extensively studied with respect 
to inhibiting MI)R (Twentyman and Riechen, ]()()I, Boesch eI c1l., 1991 anal 
Broxterman el al., 1996). Resistant cell lines have been utilised toi dleternuiinC the 
human potency and mechanism of' action of' PS(' 933. For example. the MDR 
breast adenocarcinoma cell lines were developed that express increasing lCVeIs of 
P-gp. At doses of I µmolar, PSC 833 restored the sensitivity of'these resistant cells 
to anticancer drugs (Atadja el al., 1999). An investigation into the nat"N 0fthe 
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interaction of' PSC 833 with f'-gp has been pcrl rnied (Archiýil-Mýitthýýiý cýi cý/., 
1995). Plasma membrane-enriched fractions 1imm drug sensitive and resistant cells 
were labelled with photoreactive 
'If-cyclosporin and ; ll-11S(' 833 denvativCS. 
I'-gip was detected only in (1 embranes derived from drug-resistant cells. I Ihis 
photoaflinity labelling was competitively inhibited by excess I'S(' 833 or ('y A, 
demonstrating P-gp as the target molecule of' PS(' 833 and ('y A. I -i i ux 
experiments reveal no efflux of' PSC 933 in drug sensitive or resistant cell Imes, 
probably due to high affinity for I'-gp (Archinal-Mattbeis e1 al., 1995). Further 
evidence for E'-gp as the target of PSC833 comes from experiments on single 
point mutations in P-gp molecules. "I'hcsc mutant proteins when transfCctcd into 
cell lines alter the MDR inhibiting characteristics of ('y A and PS(' 933 
(Watanabe et a!., 1996). 
PSC 833 is being developed as a resistance modifier in cancer chemotherapy 
protocols. For, example, PSC 833 (Valspodar(R)) has completed phase I/II clinical 
trials (Boote et ul., 1996) in combination with etoposidc für treatment of lung 
cancer and in combination with daunoruhicin in acute myeloid leukaemia 
("Tidefclt et al., 2000). 
1.6.10 Clinical significance of MDR 
There are no prospective data examining MI)R mechanisms and outcome. The 
majority of' the clinical studies have involved the treatment of' leukaemia. I here 
were demonstrable increased levels of'Ml)R phenotype expression in relapsed and 
refractory cases cat acute myeloid and 
Iymph1(1hiastic Icukaemias (AMI, and All) 
Si 
(Takeshita ei crl., 1995). 1lcowever, the clinical relevance 
in childhood acute 
Iymphohlastic leukaemia is unknown (Den Boer el al., 
1997). A recent review of 
the published data für AMI, concluded that the effect of 
I'-gp can outcome was 
weak (I lolmeS and West, 1994). Therefore, the relevance of the I'ulidtiOýn OI' 
I'-gl) 
in clinical M[)R will require multicentrc prospective clinical trials (Rroýxterman el 
a!., 1996). 
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1.7 Final hypothesis 
1.7.1 Explaining Cy A `failure' 
As discussed in section 1.5 "Developing hypothesis" the observation of ('v A 
failure and the subsequent Salvaging of renal allografts with another calcincuriii 
inhibitor, namely, FK506 was unexplained. Following consideration of all the 
pharmacokinctic and pharmacodynamic points that have illustrated during this 
introduction a novel approach to the problem cif drug fhilure is an exploration of 
the possibility cif selective resistance developing to either drug. The hypothesis is 
that resistance to the drugs either developed in lymphocytes tiollowing prolonged 
exposure to the drugs or may pre-exist. 
1.7.2 Drug resistance 
The sensitivities to Cy A and FK50 cat 
lymphocytes from renal transplant patients 
were examined. Briefly, these experiments confirm a wide range of' lymphocyte 
sensitivities to both Cy A and 1'K506 and the devcl()p llent ()1 FCSistance to the 
drug used for treatment. The product of the MI)R I gene, I'-gp may explain this 
variation in sensitivity and development ofselective resistance to the drugs. 
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1.7.3 Drug; interactions 
FK506 and SI)Z RAI) share the same intracellular hinding sites and vet have 
different anti-proliferative targets within the cell (see section 1.3). Studies on 
rapamycin confirmed mutual antagonism with FK506 (I )unicoiit cl (I/., P)90). 
I lowever, studies in animal models did not demonstrate antagonism but an 
enhanced immunosuppressant effect of combining rapamvcin with FK 5O6 (Vu ei 
a!., 1997). The interaction of FK506 and the rapamycin analogue SD/ RAI) in in 
vi/ro lymphocyte cultures from renal transplant patients was examined. this is 11 
worthwhile area of study since the potential of using two drugs with predictable 
pharmacokinetic profiles in a synergistic way may lead to sal ff and more 
efficacious anti rejection protocols. 
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CHAPTER 2 
AIMS AND OBJECTIVES 
2 Aims and Objectives 
The primary aim of the work described in this thesis was to assess the 
pharmacodynamic effects of' immunosuppressive drugs on in vitro cultures of 
peripheral blood mononuclear cells (I'IBMC') from renal transplant patients. this 
work can be divided into the following areas of study: 
1. An exploration of the in v lro methods of' I'RMC stimulation toi test tier 
variations in sensitivity oi' PBMC to immunosuppressive drugs. 
2. An examination oftilt development 0i' resistance to these drugs since this may 
predict individuals `tailing' on a particular drug. 
3. The study of' Multidrug-Resistance (MI)R) mechlailiSills and an exploratR) l of 
the relevance of MI)R in I3I3MC from renal transplant patients 
4. Finally, the investigation ()1' the interactions hýýtýýýýý"n }h 5O(ý '111(i the 





3.1 In vitro lymphocyte cultures 
3.1.1 Introduction 
To assess the pharmacodynamic effects of rrllmun(>suppressive drugs on 
peripheral blood mononuclear cells (1113MC) from renal transplant patients the 
cells must first he cultured and then stimulated to proliferate. Stimulation of the 
cultured cells can occur in the presence of mitogen or from taking advantage of 
alloreactivity by co-culturing cells from two different individuals, as in the mixed 
lymphocyte reaction. 
3.1.2 Mitogen stimulation of PBM(' 
C'oncanavalin A, a plant lectin, is aT cell Illltogl'n that has 
been used toi , tlillLll. ltc 
T cells in in vitro cultures ihr many years (Kay and Rcnzic. 1983; Kay el al., 1989 
and Liu el ul., 1992). Additionally, plant 1ec; tins such as ('on A and 
Phytohaemagglutinin (PI (A) have been shown to stimulate cells in a way that is 
sensitive to the effects ('y A, FK506 and rapalnycin (Kay el al., 1989, P)91, \Vu 
et a!., 1991 and hu ei ul., 1992). The ('can A rCS OnSc shows a greater sensitivity 
to inhibition by Cy A than the response to PI IA (Kay and Reivie. 1981). The 
mechanism of action of the plant lectin mitogcns is unclear. they hind to a 
number of "l' cell membrane glyc; oproteins, and it has been suggested that PI IA 
hinds ('1)2, the 20 kI) molecule ofthe ('1)3 complex and "I'(1R (Valentine el al.. 
ý'Iý'ý ation 1985). The responses obtained to Con A and 11 IA are dependent on tllc 
ý lý 
of the cytoplasmic calcium concentration. (Kay and RRenr. ie. 1993 and Kay ei c, /., 
198 9). {'olyclonal II CCII activation Can also he delivered tisi11 1111111111'ý1111ý11 
antibodies directed at the ('I)3/'I'(1R in the presence ofaccessory cells (Vine ci al., 
1988). 'l'hc "1' ccli response in these systems is dramatically e'11lla heed hti including 
antibodies against the co-stimulatory receptor, ('I )? K (Linsley and I , eclhc ttcr, 
1993). Similarly. an enhanced response to PI IA has been demonstrated in It cell" 
co-cultured with the anti-('I)28 monoclonal antibody ((Iniunder cl al, 1984). In 
summary, lectin mitogens and anti-CD3 monoclonal antibodies are hAticlon<<I 
stimulators of 'F cells in the presence of accessory cells. The use of ('on A 
stimulation of' mononuclear cells in in Vilru cultures is ýi valuable toºoºI to 
investigate the anti-proliferative effects of'('y A, FK50 and rapamyc",. 
3.1.3. Mixed lymphocyte reactions 
The mixed lymphocyte reaction (MIA) is an'? in %'! IrO correlate fier rejection 
responses (1layry and I)efendi, 1970). In the MI. R, atIogeneic Stimulation of I, 
cells leads to cytokine production and proliferation. "l'his response is tho tight to 
mimic events occurring during transplant rejection. The MIR is induced hY 
culturing mononuclear lcucocytcs (which include T cells, 11 cells, natural killer 
cells, mononuclear phagocytes, and dcndritic cells) from one individual wwitli eelIs 
derived from another individual. If'there are ditThrcnces in the alleles cif' the major 
histocompatihility complex (MIl(') genes between the two individ" lls, a 
proportion of the cells, approximately 10%, will proýli krate over a period ()1' 4-7 
days (Ilayry and I)c endi, 1970). This prcýlilcrativc response can he nucalsured h` 
incorporation of tritiatcd (3[1)-thymidinc into DNA during cell replicaiti()n. TO 
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simplify the analysis, one of the mononuclear cell populations can he rendered 
incapable of' proliferation, either by gam ma irradiation or by pre-treatinent with 
mitomycin C, an anti-mitotic drug. This sets up a `one way Ml SR'. 
The treated 
cells serve as stimulators and the responder cells prolilerale". In general, the MIR 
depends on differences in the ('lass 11 MIIC antigens between the responder and 
stimulator, although discrepancies at only Class I MI I(' antigens can stimulate a 
response. "1' cells do not express class 11 MI I(' antigens and therefore responses are 
seen in the MIR when 'I cells from the responder interact with 11 cells and 
monocytcs from the stimulator population. 
Despite the convenience and reproducibility of' nlito gen stimulated assays the 
MI. R is the more specific allo-response. The MIR was therefiOre utilised to 
investigate and characterise immunosuppressivc drug interac: tio ns. For these 
studies, surrogate donor cells were used as stimulators with the renal transplant 
recipients' cells being the responding cells. The surrogate donor cells were 
matched for the Class 11 Ml IC antigens present can the cells ofthe original kidney 
donor (see 'fahle 4.2). The original donor cells were not available to use li)r these 
experiments. 
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3.1.4 Previous studies of variation of sensitivity to immunosuppressive drugs 
in in vitro cultures of Pi3MC 
'I'hc pharmacodynamic assessment of' individuals' lymphocyte responses to 
immunosuppressive drugs could he an efficient strategy for tailoring treatment 
protocols. Previous reports have attempted tu predict clinical response toi anti- 
rejection drugs based on an in vitro test of lymphocyte sensitivity. 
(a) Francis (1988) studied MLR in preoperative samples from potential renal 
transplant patients and assessed sensitivities to anti-rejection drugs. The 
resistant group had a higher rate of graft loss from acute rejection, more 
episodes of graft rejection and higher levels of serum creatinine (Irancis cl al., 
1988). 
(b) Transplant recipient lymphocyte sensitivity to mcthylprednisolone strongly 
influenced the survival of MI. C-mismatched kidneys (Langhof el cal., 1996). 
(c) Hirano, 1997 performed drug sensitivity tests with I'RM(' from four subject 
groups: 69 healthy subjects, 100 patients with Chronic renal failure cri- which 40 
had received a renal transplant, 38 patients with nephrosis, and 51 patients with 
psoriasis (llirano et at, 1997). The values for the conmitration oi'('y A that 
produced 50% inhibition of lymphocyte proliferation (11)5()s) were estimated. 
The median IIDSO values in the subject groups were broadly the same. I lowever. 
there were large individual variations in IDs values. A higher incidence of 
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resistance to (1y A was observed in the chronic renal tiriInrc group. hic 
incidence cif' graft loss in those 5 patients in the low SCI1Sitivlly, ggroup compared 
to the highly sensitive group (1) patients) was significantly higher and there was 
an association with higher SCI II1l creatinine in the 1()w sensitivity group. 
(d) (ihobrial (1994) perf()rmed a longitudinal study carried out on 19 recipients of 
cadaveric: renal allogralts, monitoring their anti-donor and anti-third party 
responses in the MLR. The study concluded that in some renal allogralt 
recipients a state oi'donor-specific hyporesponsiveness develops, and this state 
was associated with better graft outcome at 1 year (Ghohrial et ul., 1994). 
These studies attempted to predict clinical response to antirejectiOn drugs based 
on an in vitro test of lymphocyte sensitivity. I lowcver, during the current project 
this effect was not assessed, simply, the in vitro methods of lymphocyte 
stimulation were utilised to test fr variation in lymphocyte sensitivity toi 
immunosuppressive drugs; the development of' resistance to these drugs. and 
finally to explore the potential drug interactions between FK50 and SI)! RAI). 
3.1.5 CD25 expression assays 
Cell proliferation can he measured in different ways. Firstly, by incorporation of 
A 1-thyn idine into DNA during Cell replication and secondly by incorporation Of 
15methionine. Flow cytometric analysis of'I cell activation markers such as (I)25. 
the a, -chain of'the interleukin-2 receptor (II. -2R) can he used as surrogate markers 
of'proliferation. "hhe high affinity It, -2R consists ofthree individual poýIypcptide's, 
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the (t, 11 and y chains. Although the 1ý- and y- chains arc shared by other 
lymphokine receptors, the u-clia 1 (als( called Tar, or p55 proton) is restrict d toi 
the [[, -2R and is strongly induced at the transcriptional level a to Tcell activation 
(I Iatckeyania el cal., 1989). (1)25 does not tRlrlsdtice' al signal but IS resp-)cornsihlc fier 
the rapid association of 11, -2 with the (ý and y chains, which in turn trigger the 
antigen activated T cell to enter mitosis and undergo clonal expansion (Rohh cl 
a!., 1984). Following the development of specific antibodies to (11)25 it is possible 
to measure CI)25 expression by flow cytonmctry. Mitogenic: activation of-I' cells 
leads to upregulation of' ('I)25 expression that is sensitive tee the eti its of' the 
immunosuppressant drugs Cy A, FK50 and rapamycin (Ryllcl ei al., 1995 and 
Woerly et a!., 1996). This effect is dependent on the type of' mito gen chosen. "I' 
cell activation by anti -C'I)3-antibody, tier example, that utilises early calcium r 
dependent pathways in a similar way to ('can A and J)J IA, is fully sensitive to 
inhibition by the immunosuppressants mentioned above. Conversely. P MA- 
induced CD25 expression is drug resistant (Ryllcl el al., 1995). 
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3.1.6 Conclusion: In vitro assays of lymphocyte sensitivity 
Con A stimulation of PBM(' is an established and reproducible Illethod iOf 
investigation of' lymphocyte sensitivity to immuno suppressive drugs, the 
investigation of the development of selective resistance to these drugs and fier 
assessment of interactions between them. The MI, R offers a more physiological 
stimulus, however, the low level of cell stimulation 
in MI I(' ('lass II matched 
donor/recipient pairs renders the investigation of drug effects on the cells difficult. 
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3.2 Investigating Multidrug Resistance 
3.2.1 Introduction 
To be able to characterise expression and "uncticonal activity of Ml)R in clinical 
specimens requires specific probes. Investigators have utilised hoth monoclonal 
antibodies (Mab) and drugs that accumulate in cells unless actively pumped out of 
by MDR phenotypes 0 lamada and 'I'suruo, 1986, I'ilarski el al., 1995, Uroxterman 
ei a/., 1997). Finally, the effects of' MI)R modifiers have been explored in an 
effort to develop a system that is specific for the MI)R phenotype Of interest 
(Feller ei al., 1995, Filarski ei a!., 11)95, Broxterman ei a!., 1996.1'etriz ei a!., 
1997). There is not a universally agreed specific system employed by 
investigators. The experimental systems continue to evolve and are modified tee 
improve specificity and sensitivity. During international workshops discussions 
continue about standardisation of' MI)R detection in clinical samples (Beck el al., 
1996). 
3.2.2 Flow Cytometry 
I'he flaw cytometcr is a versatile tool for the investigation 01 individual cells 
within larger populations. For every cell, numerous light scattering and 
fluorescent properties, each reilccting an underlying structural, hiuc: hemical and 
genetic attribute ofthe cell, can he measured simultaneously. The method requires 
as its raw material a suspension of single MIS car IILICIei, which is usually obtained 
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fron fresh disaggregated biological tissues or cultured cells. During the current 
thesis iiio loclonal antihcýdies toi spec. il e antigens have hcen used tu icleintiIy 
lymphocyte subsets and explore 11-gp expression. After the primary antibody is 
attached to the antigeil in question the next step Is to label the antibody' With a 
microscopically dense marker in order to make it visible. 'there are several Ways 
of' doing this but because of' the reliability arrndl ease of Epet'fllr'rllLrricc we used 
fluorescein isothiocyanate (FIT('-) or phyccýerythrin (I'F, -) label led conjugates. In 
essence, FI'hC- and PF- are tluuresc ent prohes that 0111 he Cojiigaltcdd directly toi 
the primary antibody or conjugated to a secondary antibody raised against the 
primary antibody. Non-immunological attachment of antihcýdies and dense 
markers to the cells can result in non-specific staining. Blocking reagents such as 
bovine serum albumin or goats serum contain proteins that compete with the 
immunological reagents for non-immunological sticky sites can the cells. In corder 
to allow for non-specific binding isotype matched control antibodies are used. The 
isotype refers to the immunoglohulin subclass that the antibody contains. The Clow 
cytomcter is set to discriminate lymphocytes from other nucleated cells by their 
light scatter characteristics. The cells are defined in a two dimensional Plot by 
forward scatter of light and side scatter. Forward Scatter (cell sire) versus Side 
Scatter (cell granularity) identifies the cell population of' interest. 'I'he F[TC- or 
PF, - light emissions are collected From 5000-10000 lymphocytes and stored in list 
mode data files prior to analysis. The flow cytometer can also detect cellular 
accumulation cif' fluorescent dyes such as rhudamitie 123. 
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3.2.3 Detection of P-glycoprotein 170 expression 
Flow cytoietty has been mainly used fier the detection of surlýtc ý" t»ýýt»htýtnýý 
antigens such as those 11-glyc: oprotcin-17O (11-gp) epitopes recognised by 
monoclonal antibodies, MRK16,4}`. 3 and JSB-1 (Filarski ci cal., 1995, Mikhicli c! 
al., 1997, Klimecki cal al., 1994, Rroxtcrman c'/ cal., 1996, I)elvillc el a/., I995). 
The advantage of these antibodies is that they can stain viable cells with intact cell 
membranes. '[here is variation in reporting of 11-gp expression on J UM(' frcýni 
normal volunteers and patients. "There: have been two reports of high levels Of 
expression of' P-gp following binding with the MRK 16 monoclonal antibody 
allowing characterisation cif' lymphocyte subset expression (Klinmecki el ill-, 1994 
and Pilarski el (il., 1995). A further study showed P-gp functional activity but no 
detectable P-gp expression with a further characterised monoclonal antibody to 
P-gp, JSB-l (Delville et al., 1995). Following the recommendations in the 
literature as outlined above the monoclonal antibodies to external epitup-)es of P-911 
4E3 and MRK 16 were used. The MIZK 16 monoclonal antibody is a mouse anti- 
human P-gp. The antibody reacts with P-gp exposed can the cell suriüce, which 
allows labelling of living cells (Ilamada and I'suruo, 1986). Similarly, 41-, 3 is a 
mouse monoclonal antibody of IgG2a class, which specifically rccugnises the 
human MDRI gene product P-gp. 4F3 is generally less reliable than MRK 10 and 
is more hatch dependent (Den Boer el a1., 1997). 
The human breast carcinoma cell line M('F-7 (originally described by Soule ei ul., 
1973) is rendered resistant to chemotherapeutic agents by exposure to, lot' 
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example, dcýxoruhicin or adriamycin (AI)R) in increasing concentrations. 
Such 
selected cell limes I VC been used frequently as models liar the study OI' MDR 
(I)avics el al., 1996) and this cell line served as a positive control tier P-9p 
cxpression and functional activity. 
3.2.4 Functional assays of MI)R 
3.2.4.1 Rhodamine 123 
The development of' fluorescent dyes that behave like chemotherapeutic drugs 
without any deleterious elThcts on cell biology or viýihility serve as valuable 
alternatives to functional studies with the drug itself' (Neyläkh, 1999). Rhodamine 
123 (R-123) is a cationic, lipophilic lluorochromc, which accumulates rapidly in 
cells, preferentially in the mitochondria membranes cifliving cells (. Johnson el (II., 
1980). Cell viability following exposure to R-123 remains very high and has been 
shown to be around 95% (Melville el al., 1995). R-123 is transported out of'CCllS 
by P-gp (Neyfakh et a!.. 1988). Many studies have utilised R-123 retention and 
expulsion from cells to test for MDR and by performing combined experiments 
with specific P-gp Mab have concluded that IZ-123 expulsion is secondary toi P-gp 
efflux mechanisms. In addition the use of'P-gp inhibitors have demonstrated that 
R-123 efflux can he specifically inhibited or modulated (Chaudhary 0 cal., I ()()2, 
Ludescher ei al., 1992 and 1998, Broxterman e1 c'l., 1996, Feller el cii., 1995, 
Pilarski el al., 1995, Petrie el al, 1997). P-gp -mediated transport u1' R-123 
has 
also been established by demonstrating that it is efficiently eliluxed by a P-gp- 
expressing subline of K562 leukaemia cells (derived from retruviral trnnsler of 
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MI)i I gene, without c: ytcýtcýxic: selection) but not by the rarenlal P-grp negative 
1<562 (C'haudhary and Roninso 1,1991 ). R-l 23 accuirrrilation is an insensitive way 
to measure the transport function of non-P-gp MI )R in the form of MRP inferring 
selectivity for P-gp (Feller el al., 1995). Other probes tested (i)I' P-gpp ILlIlCtioii al 
activity include the anthracyclinc, daunorubicin (I)NR) and caiccin-acetoxyn, ethyl 
ester (calcein-AM). Ilcowever, both DNR and ('aiccin-AM could also he used to 
detect MRE'-mediated resistance (Feller cal al., 1995). 
3.2.4.2 Inhibition of Rhodamine-123 efflux 
Prolonged inhibition of the efflux of R-123, a P-gp substrata, from drug resistant 
cells was observed following treatment with PSC 833. This compound is the most 
potent MI)R modulator compared to verapamil and ('y A (Petri, el al., 1997). 
Verapamil also has an inhibitory efifec; t on claunoruhicin (I)NR) exclusion via 11011 
P-gp mechanisms (Versantvoort el a!., 1993). In cell line experiments the I'SC 
833/R-1 23 combination was the most sensitive lunctiona l P-gp assay (UUroxterman 
el al., 1996). 
3.2.5 Conclusion: Investigation of MDR 
The PSC 833/R-123 combination is the most sensitive and specific 
functional 
P-gp assay. This functional assay in combination with M RK 16 Myth liar detection 
of P-gp expression is the most valid method to test for P-gp dependent MI)R in 
clinical samples. This is the method used in the majority of the experiments 
performed during this research project. 
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CHAPTER 4 
MATERIALS AND METHODS 
4.1 Materials 
Peripheral blood r iononuclear cells (PBM(') were obtained 1iror» the renal 
transplant patients at Walsgravc I Iospital, Coventry, (1K and served as the main 
material for all the investigations. Blood , vas taken 
from each patient in the 
morning prior to ingestion otý the next close cif' ('y A or 1K 506. In all cases patients 
had provided prior written consent. Information and consent forms were approved 
by the local ethics committee (See Appendix 1). 
A total cif' 71 patients were entered into the study. Access toi the patients' medical 
records, either through individual case notes or from data held on the Proton 
Computer system at the renal unit at Wallgrave I lospital, Coventry was obtained. 
To ensure anonymity, patients are referred to only by serial number, with the code 
held by the author. 
The majority of these patients were on "'triple therapy'": ('y A or F K506 with 
azathioprine and prednisolone. Ages ranged fl-()nm 23 to 73 years (mean 40 years) 
with male and female. Samples were taken 1-77 months post transplant (nmean 19 
months). The characteristics cif the patients arc summarised in 'Fahle 4.1 
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Table 4.1. Patient characteristics. 
1't Age Sample Early/ Triple titcrýºicl 
Trough blood 





35 12/96 y y 
258 
8 26 8/96 Y Y 
15 
38 57 1/97 Y Y 
1-16 
1 39 10/96 1, y 220 
19 45 I. Y Y 
130 
14 34 Y y 
200 
29 39 12/96 Y Y 
I 18 
26 24 N Y 
102 
97 
20 23 1/97 1 
158 
25 ýý Y y 
200 
49 12/96 Y Y 
140 
27 37 1 /97 1. Y Y 
227 
17 51 10/96 [', y y 
125 
8 27 10/96 F: N Y 
1 tO 
23 43 10/96 E N Y 
?I `) 
34 29 2/97 Y Y 
170 
12 48 10/96 1. N N 
13O 
6 32 10/96 I. Y Y 
181 
9 40 1/97 lý. N Y 
118 
28 27 11 /96 
152 
48 8/96 1, 191 
31 51 12/96 1. N N 
1 39 
44 11 /96 1. N Y 156 
24 56 1/97 1. Y Y 
1 39 
7 25 12/96 Iý. Y Y 113 
37 51 11 /96 f: y Y 131) 
7 25 11/96 1 Y Y 439 
36 54 12/96 1. Y y 155 
30 31 1 /96 I'. N Y 80 
--------------- 3 47 10/96 Y Y 16; 
32 33 1/97 1; Y Y 170 
73 
4 61 10/96 I: lr' ---- - -- 
-- -- y II 11 
35 73 10/96 I N N 10011 
40 40 08/96 I N N I S6 
41 62 02/98 I, Y Y 116 
42 57 02/98 1, N N 1. ' 1 
- 43 43 02/98 I N N 01 
44 35 03/98 I. N N 49 
45 40 08/97 1: Y Y 122 
46 38 06/98 Y Y 107 
47 11 /96 I. N N 2164 
48 11 /96 PRI : N N 867 
49 33 12/96 1()1 
50 46 7/98 f: Y Y 202 
51 23 12/96 77 
52 29 12/96 100 
53 27 9/98 f: Y Y 19(1 
54 32 9/98 f: Y Y I? 1 
55 45 9/98 Iý, y Y 1()() 
56 58 4/98 I. Y Y 1 16 
57 34 6/99 88 
58 49 8/98 1, N N 9() 
59 44 3/99 f, N N 218 
60 31 10/98 F Y Y 170 
61 31 7/98 f., y Y 153 
62 27 6/98 f, Y Y 161 
63 34 6/99 78 
64 38 7/97 1 N N 148 
Table 4.1. Patient characteristics. Fach patient number rcl rs to an individual 
patient. The majority of' patients were receiving triple therapy with either Cy A or 
FK506 plus both prednisolone and azathioprine. 'l'he scrum creatinine level at the 
time the patient was sampled is included. 'T'hose patients referred to as `early' had 
blood samples obtained within three months of' their renal transplant. Those 
patients referred to as 1 ate" include all patients who had blood samples taken 
greater than three months after their transplant. This three month cut oft' was made 
on the basis that this is the period of `induction' anti-rejection treatment and 
subsequent treatment is `maintenance, immunosuppression. 
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Surrogate donor I'BM(' were obtained from healthy volunteers with known Ill .A 
tissue type and donor/ recipient pairing information was ohtaiined from records 
kept by the Transplant Centre at Wallgrave I lospital. The I II, A ('lass II antigens 
are listed for these patients and volunteers in 'fahle 4.2. 
Patient 
No. 
Recipient I ILA ('lass II 
antigen at I)R locus 
Donor I ILA ('lass 
antigen at DR locus 
65 13(6), 12 14(6), 7 
66 1](5), 7 17(3), 1 1(5) 
68 4.1 1 (5) 4,7 
69 17 (3), 13(6) 17(3), 13 (6) 
70 17 (3), 14(6) 17(3), 13(6) 
46 17(3), 13(6) 17 (3), 14(6) 
55 4,13(6) 4,1 3(6 ) 
54 11(5), 13(6) 11(5), 14(6) 
50 15 (2), 17(3) 15 (2 ), 17(3 ) 
60 1,14(6) 1,13(6) 
61 17(3), 8 17(3), 4 
Table 4.2 Recipient and donor HLA Class 11 antigens: Surrogate cells were 
used that were matched für the original donors' MIIC Class 11 (l)IZ) antigens. 
There are 1I combinations of' samples that conic trom the transplant recipient and 
donor. Tissue typing gives 2 alleles at DR hr each patient. 'I'hc 'broad' antigens 
that were matched are in parenthesis, while the `private' antigens may not he filly 
matched. For example, patient number 54 is matched with donor I)R 5 and () but 
the less important subtype at 6 do not match identically. 
Since the predominant stimulus in the MIR is obtained with mismatch () 
f atitIge»s 
at the Class 11 MIIC locus it was necessary to match the surrogate cells for the 
donor cells at this locus to obtain a comparable `physiologic; al' allo rCSpOl1SC. The 
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original donor spleen cells, which would have served as stimulators in these 
experiments, were not available. 
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4.2 Methods 
All operations wert carried out using standard Sterile Conditions in a lailllllufr 
how 
cabinet ((ielaire I3SB 4A, Flow Laboratories). The cabinets were routinely 
steriIiscd overnight by exposure to ultra-vicolet radial ion and then washed 
in 7O% 
alcohol prior to use. 
4.2.1 Drugs and reagents: Cy A (Novartis I'hairinaaccuticaals, Bawl, S vit/erlall(l) 
was dissolved in a 9: 1 ethanol/'I'ween (Sigma Chemicals, Poole, I1K) that was 
11 g/mi 
subsequently diluted with an equal volume cif' distilled water toi give a 10 
stock solution that was stored frozen in aliquots. An FK506 (Fu. jisawa 
Pharniaccutical Co. Ltd., Osaka, Japan) solution of O. 1 nmg/ml was prepared and 
stored in a similar manner. PSC 833 (Novartis Pharmaceuticals, Basel, 
Switzerland) was dissolved in ethanol and subsequently diluted with aIºn equal 
volume of sterile distilled water to give a 10mg/ml stock solution that was stored 
at 4°C. SI)l. RAD (Novartis Pharnmaceuticals. Rasel, Switzerlan(1) was dissolved 
in ethanol to give a1 mM and stored at -20°(' in the dark. Prior to use Sl)l 
RAD 
was diluted in RIM to reach final concentrations in cell cultures oI' U. O1, O. 1,1, 
3,10,30,80µg/1. Tissue culture medium was Roswell Park Memorial Institute 
(RPMI) 1640 (Gihco-IRL, Gaithcrshurg, MI) I JSA) supplemented with 10% 
foetal calf serum (Gihco-BRI, ). RIM was further supple mmented with 
(3-mercaptoethanol (Sigma St. Louis, MO USA) and IIFP1 S hulThr fier the Ml R. 
Lymphocyte separation medium was [ . ymphoprep (Nycomed 
('karma. Oslo. 
Norway). Round-bottomed 96 well tissue culture plates were purchaSed from 
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Costar Inc (I3adhocvcdorp, "I'he Ncthcrlands). ('can A was from Sigma Chemicals. 
, 11 thymidinc (thy) was purchased from Aºtmc'rshalll Rad o chemicals (Aº»ersham. 
UK). IZhodamine-123 (R-123) (Sigma, St. I, oouis, MO USA), a fluorescent (lye 
known to he transported by 11-gpp, was dissolved in I'Ill)ti[lhatC I hi li ered Saline 
(PBS) to give a stock solution of I mM which was stored in the dark at 4"('. 12 
well tissue culture plates were purchased from Costar Inc (13aý1hcýý"vedurn, 'I the 
Netherlands). Mitomycin C (Signa, St. Louis, Mo IJSA) was dissolved in 1113ti at 
I mg/ml and stored at 4°C'. 
4.2.2 Antibodies: Monoclonal antibodies to external epitopes ofP-gp were used. 
These were mouse anti-human 4,3-fluorescein isuthiocyanate 
conjugated, IgG2a isotypc, (Signet Labs., Inc [ IK Glasgow, I JK) and mouse anti- 
human MRK 16, IgG2a isotype, (Kamiya Biomedical Company, Seattle. WA 
USA). Mouse IgG 2a isotype control antibody was purchased from Sigma, St. 
Louis, MO USA. Goat anti-mouse Ig(J-FIT(' was used as secondary antibody 
(I. D. Labs., Inc Glasgow, UK). C'D4-phycocrythrin (PL, ) and C'I)K-PF, were use 
to characterise cell subpopulations (Becton Dickinson, San Jose, CA ( JSA). 
CD25-H ITC was used to investigate proliferation assays by flow cytonie'try 
(Becton Dickinson, San Jose, CA I )SA). 
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4.2.3 Separation and storage of 11'13M(' 
Fresh vCnOuS blood collected into F])'I'A-tubes was nii\ed with all equal volume 
of' culture medium and layered onto I , yillpllOprep and centrifuged 
fOr 30 min at 
1500 rpm. 'I-hc: interfäc; e layer was Separated, washed. and cryopres rved in 
culture medium with 10%, dimohylsulphoýxidic. 
4.2.4 PBMC culture and incorporation of 3 II thymidinc. - I'BM(' aliquots i'rc»» 
an initial 32 patients were thawed rapidly, washed twice with culture medium tu 
free them of dimethylsuiphoxide and a viable count pal'Or iied. 11' viability was 
below 90% (which was very rare) the cells were discarded. The cell concentration 
was adjusted to 10('/m1 and the suspension placed in 200pl aliquots into the wells 
of tissue culture plates. 6 wells were reserved as negative controls: toi a further 6 
positive controls was added Con A alone to a 1111a1 concentration of 5 ýLg/tlll: to 
the remaining wells, Con A plus graded concentrations of the two drugs were 
added, in triplicate. Final concentrations ui' ('y A were 1,1,1O, 30,100 and 100 
tg/1 and of FK506 were 0.1,1,3,10, and 30 µg/l. Similarly, cells from further 
patients were treated in the same way but graded doses ot'SI)! RAD either alone 
or in combination with FK506 were established. The final concentration of SI)% 
RAI) were 0.01,0.1,1,3,10,30, RO tgII. 
PE3MC from a further 14 patients were treated in the same wary except that ? µM 
PSC 933 was added along with either Cy A (11-9) or Fh506 (n 5). Controls with 
PSC 833 only were also established. After 48h culture, I j(1ii111l 'I I thymidine weis 
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added to each well, the culture contir1Ued overnight to allow incoýrrcýrýition. and 
then the cells harvested to glass fibre pads ( Mcltilex 
1 n', WAI 
,I . 
A('ýw, I urku, 
Finland), washed, and the incorporated ; II counted using a scintillation counter- 
(Wi1 I, A(1(R ). The concentration ()I' drug required to I11111hii 50'ºý0 oI 
III-lily 
incorporation (II)51 value) were established for all patients l()r both drugs by 
interpolation from graphs ofincorporation against drug co ncentratio n. 
4.2.5 Mixed Lymphocyte Reaction (MLR): 1113M(' from the surrogate 
donor/recipient combinations were thawed in the same way as described iiOr the 
proliferation experiments. PBM(' From the donor were treated with 20jtl of' 
mitomycin C (l mg/ml) and washed thoroughly prior to Co-Culturing With recipient 
PBMC. Graded doses of ' 2O tI of each of FK50 and/or SI)/ RAI) were added to 
the cell cultures. Controls were established with no drugs. The cell cultures were 
incubated fior 96 hours at 37°C in 5% CO, in air. 'II-thymidine was then added 
and left overnight to incorporate into the cells prior to coUnting. '('oo check PBM(' 
viability Con A was added to replicate control cultures at 49 hours. 
4.2.6 P-gp Expression: The percentage oftotal cells expressing surface l'-gp was 
determined by immunotluorescence techniques in those patients that were defined 
as either drug sensitive or drug resistant following the 1'UM(' cultures. UricIlY, 
cells were washed twice in ice-cold P134. Aliquots of 50µI (5 x 1Oý cells) were 
incubated with either 40µl of the undiluted 41.3-Fl T(' Mah (5µg/assay) or 5eµ1 of 
1: 10 dilution cif' MRK 16 Mab (2.5µg/assay), as per manufacturers instructions, fier 
30 minutes on ice. After incubation the cells were washed thoroughly in PUS and 
the secondary antibody (50µ) of' 1: 25 dilution cat' ( boat anti-Mouse) added in the 
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case col MRK 16, and incubated Ii)r 15 minutes on ice. Further washes in ice-cold 
PUS were hcrlortticd and the samples were retiuspetidled in I113S and kept at 4"t' in 
the dark until analysis. Control isotype antibodies at the saner concentration as the 
test antihodies were treated in the same way. 
4.2.7 Rhodamine Efflux: Aliquots containing approximatcly 
5x IW cells loaded 
with R-123 by incubating 1m 30 minutes at 37"(' with R-12) ( 611111 co ncentratioýn 
2µM). After loading the cells were washed and resuspended in c ot»plete 
RPMI-1640 in the presence or absence of'I'S(' 933 (final concentration 2pM) and 
incubated lbr a further 4 hours. At time points 0 and 4 hours a sample was taken 
for study and the cells washed and kept in ice-cold PBS in the dark until analysis. 
In some cases the samples were then incubated with anti -('O4-1'hycoerythrin (1'F) 
and CD8-PE Mab to examine which subsets OFF cells are actively humping the 
dye. Samples were analysed on a 1' ACStar flow cytometer (Becton Dickinson), 
equipped with a 488nm argon-ion laser and standard optical set-up. 1()()()() events 
were analysed with Consort 30 software (Becton Dickinson) and subsequently 
analysed with DAKO Flowmate II for Windows software. Fluorescence waS 
measured on a four-decade logarithmic scale. Manual gating via scattergram can 
Forward Scatter (cell size) versus Side Scatter (cell granularity) identified the cell 
population of interest. P-gp staining results are expressed as mean fluorescence 
intensity (MFI), and the percentage ol'cells actively el'tluxing R-123 is estimated 
from histograms obtained for each sample 
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4.2.8 Cell Line: The adriaºyciii drug-resistant hreast carcinoma cell Ii1nc 
M('1F-7/AI)[Z (originally From I-; urcoheun ('OIlectioºin OI- Animal ('cII Cultures, 
C'AMR, Porton Down, Salisbury UK), were maintained in house liar use as the 
positive controls in the rhodaiiiine cl flux and P-gp staining exIm-iments. 
4.2.9 T cell activation marker 
CI)25-I: ITC was used in flow cytometry Studies uf' "1' ccii aactivation. ('on A 
stimulated cell cultures cat' PBMC were established in 4 patients as heliorc. Graded 
doses of' SD7. RAI) and varying fixed doses of FK5U6 were added at the 
beginning of the cultures. The cells were incubated lor 48 hours prior to 
harvesting and labelling with CD25-FITC. 
4.2.10 Dual staining of R-123 loaded cells with lineage markers 
Following R-123 loading and subsequent incubation to allow efflux toi OCCUF the 
cells were harvested and then counter-stained with either ('[)4-PF or ('1)K-l1N 
monoclonal antibodies and kept on ice in the dark until analysis. 
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4.2.11 Interpretation of histogram data 
Histograms were obtained for R-123 efflux and 1'-gp expression hv: ! low 
cytometry. The data can he arranged as a histogram of cell number against 





Figure 4.1 Histogram of Rhodamine loading of PBM('. ('ells f'roni a single' patie nt 
were incubated for 30 minutes with K-123 at 2µM. "I he cells were then washed in 
ice-cold PBS and kept on ice until F=ACES analysis 
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Figure 4.2 Histogram of Rhodamine efflux. PRM(' from a single patient were 
incubated with 2µM R-123 fier 30 minutes with a subsequent 6-hour inctihjitioýii period in 
the absence of the dye. 'T'hree markers have been manually inserted toi separate the cells 
into two populations based on the level of fluorescence. 
The number cif cells per population can he estimated From the percentage ý11'cells 
gated in each group. During this experiment 62. O< <, cat' cells were in the effitixing 
group and 33.3% in the retaining group. The percentage of gated cells in ea ch1 
population can then he calculated: Total number of' cells gated and thereflorC 
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10i lOlL: lidZ& 
studied is 95.3%. Percentage of cells within et'lluxing pool is 0.65 X 
1 00 i. c. (5`%> arc in the eflluxing pool and 35"('º within retaining pool. 
These calculations were repeated for each patient sample tested. 'I'hereiiºre it was 
possible to estimate the percentage of MIS in the ef, Iluxing population tiºr all 
patients in both the high and low sensitivity groups. 
4.2.12 Drug Blood levels 
Pre-dose (trough) Cy A and FK50 levels were measured in whole blood using a 
system from Abbott (Maidenhead, IJ K). 
4.2.13 Statistical Analysis 
Tests of significance were carried out using the "Astute software package 
(University of Leeds, UK) and "Excel" (Microsoft). Spcarman Rank was used to 
test the correlation of lymphocyte sensitivity to ('y A and FK5O6. l'he Mann- 
Whitney-U test was used to examine significance of selective lymphocyte 
resistance to Cy A and FK506 depending on the drug the patient was receiving fier 
treatment. In all other cases the mean values of groups were tested fier significance 




5.1. Assessment of lymphocyte sensitivities to calcineurin inhibitors 
Introduction 
Ehe range of sensitivities of peripheral blood mononuclear cells (I'RM(') from 
renal transplant recipients to calcineurin inhibitors, ('y A and FK O6, in in rilro 
cultures were established. Patients were subsequently stratified as highly sensitive, 
moderately sensitive or of low sensitivity to both ('v A and FK 'Oc' . 
These 
experiments investigated any differences in sensitivities to either drug in 
individual patients. 
Results 
Incorporation of TI thyrnidinc into ('on A stimulated patient PBMC was 
progressively inhibited by increasing concentrations oi' both drugs. i'he inhibitory 
effects of the two drugs varied Crum patient to patient, both in the nature of. the 
response and the level of sensitivity to the drugs. Fxamplcs ofthe response ()f' ('can 
A stimulated PBMC from 4 renal transplant patients are shown in Fi , urc 
5.1. '1 WOO 
(2 and 21), representative of' the majority of the patients, showed essentially 
complete inhibition with both drugs. The other twos (3 & 4). representative O1' 5 
patients, showed a rather different response. With these, even at the highest 
concentrations cif drug used, inhibition was incomplete, only. just exceeding 5O%. 
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Figure 5.1 Representative dose response curves in 4 patients of the effects of Cy A 
and FK506 on Con A stimulated PBMC. PBM(' from each single patient were 
incubated in the presence or absence of ('y A (. ) and F' K506 (A ), as indicated, for 48 
hours prior to the addition o( ili-thymidine for a further- 16 hours. After harvesting, 
'il-thymidine incorporation was determined and the data are plotted as means of replicate 
determinations. The error bars represent standard deviation around the mean. 
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The I[)s, ti are presented 1iOr 32 patients in Table 5. I. Where there were sufficient 
PRM(' fier duplicate assays of'the same sample, l)erfi)ri»ed1 on separate occasions. 
the II);, ºs generated agreed within a 2-fold range, and the mean vat ties where 
duplicate assays were done are quoted III the gable. III the Cases OI some patients 
repeat samples were taken and the ([); () values obtained f'or these repeat samples 
are quoted separately. 
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Fable 5.1.11)511 for Cy A and FK506 following ('on A stimulation of 
PBM(' 
Patient Number II)51 for Cy A 
µg/t 
11)51 for F K506 
µ#; ßi 
Il: ºtiýº A: 1' h 
I I)ýýº, 
18.5 (2)h nd 
14 0.65 2'1.5 
(rep)el 2 
45 (? ) 0.65 (2) 69 
3 85 (2) 0.8 106 
4 100(? ) 5.5 18 
4 (rep) 30 5 6 
6 20 0.5 40 
7 3? 0.6 53 
8 16 2.3 7 
9 2 3 (2) 0.7 (2) 33 
9 (rep) 2 8 0 . 
37 76 
11 30(2) 0 .4 
(2) 75 
11 ?1 (2) 0.39 (2) 54 
13 40(2) 0.68(2) 59 
14 9 0.27 33 
17 30 0.8 38 
17 (rep) 15 5 0.6 '5 
18 6 4 1 
18 (rep) ?.? 0.17 (2) 13 
19 5 0.15 33 
20 1? 0.3 40 
21 4.6 0.6 7.7 
1.5 0.085 18 
23 17 1.4 12 
?4 30 1.5 20 
25 14 0.45 31 
?6 28 2 14 
26 (rep) 1? 0.35 3-1 
26 (rep) 13 0.55 24 
26 (rep) 11.5 (2) 0.44 26 
9 
27 15 0.2 75 
27(rep) 22.5(2) nd 
28 27.5 (2) 0.24 (2) 
--- - 
1 15 
-- -- -- - 29 9.5 0.16 59 
30 100 10 10 
30 (rep) 50 0.55 (2) 91 
31 30 0.5 60 
34 20 (2) 0.4(2) 50 
35 100 0.5 200 
36 40 1.2 33 
37 34(2) 0.5(2) 68 
38 2.5 nd 
mean 29 1.2 30 
SD 25 1.9 
median 25 0.55 
, º, S for Cy A and FK506 following Con A stimulation of 
I'I3MC Table S, I. IDr 
ID50s were obtained in proliferation assays by interpolating the dose-respeýnsc 
curves obtained following the addition of ('y A and FK506. Where there were 
sufficient PBMC for duplicate assays ofthe same sample, performed on separate 
occasions, the ID50s generated agreed within a 2-fold range, and the mean values 
where duplicate assays were done are quoted in the table. In the cases of some 
patients repeat samples were taken and the lI); () values obtained fier these repeat 
samples are quoted separately. 
'. >1 
Blood levels of ('y A and FK5O6 were taken prior to the next close from all 
patients receiving the drugs as part of' their anti-rejection regime. 'I he drug level 
obtained and the ratio oftrough blood level: 1[);, ) are shown in Table ý. 2 
Table 5.2 Trough blood levels of Cy A and F K506 and ratio of blood level AD,, 
Patient No. Cy A blood 
levelsa ng/ml 
ratio blood 
level: llc(º (('y A) a 




level: IDq) (FKI5116) 
-------- - 
N dc nd 
- 
ý I 18 9 
-- - 
2 (rep) 
d 166 3.7 
3 234 ?. x ----- 
4 170 25 
4 (rep) nd 
- 6 131 6.5 
7 200 6.3 
8 1 3.5 5. ý) 
9 17.4 25 
9 (rep) nd 
11 155 5.2 




17(rep) 11.8 19.7 
18 8.6 1. 











23 1 1.1 x 




26 (rep) 27 
26 (rep) 11.2 20 
26 (rep) 1-96 1-6 
27 179 1? 
27 (rep) 1000 e 44.4 
28 169 61 
29 nd 
30 457 9 
31 137 4.5 
34 14.1 35 
35 171 1.7 
36 131 3.3 
37 nd 
38 159 64 
mean 230 14 49 
SD 190 5 
Median 170 12 
Table 5.2 Trough blood levels of Cy A and FK506 and ratio of blood level : 11) so 
Footnotes: aPatients were treated with Cy A or FK50 : hence a blank in one 
column indicates that the patient was treated with the other drug. 
hIndicates 
mean of 2 determinations: otherwise single determinations. 
c nd -- not done 
dIndicates determination with a repeat sample (i. e. taken on a separate ocCaSi01 ) 
eminimum 
value 
The values of the II); Os for both drugs varied widely fror» patient to patient. with a' 
50-fold range. However, when the correlation between the two Sets of ll )sn values 
was analysed by the Spearman Rank method it was ! mind toi he signi l icant 
(p = 0.0001). Figure 5.2A shows the regression of the II); 1º 1or FK506 agalntit that 
91 
for (1y A. The ratio ofthe mean values 1ior the II);, tier Cy A and FK 'O6 was 24. 
this correlation conceals sonic co nsidlerahIc variation between paticºlts iºI the ratio 
of the two IUs0s, from less than 1O (e. g. patients 4,8 and 21) toi 100 ur more 
(patients 28 and 35). This indicates that individual patients arc relatively 
resistant to one or the other drug. 
To test whether this resistance was selective, i. e. patieints' PUM(' were relatively 
resistant to the drug used for treatment, the ratio of the II )cS wiiS compared for the 
patients treated with either Cy A or FK506. Figure ). 2U shows that p aticints' 
PEMC were relatively resistant to the drug used tier treatnlen1. the median value 
for the ratio of' II)5o for Cy A to l I)sO fier FK506 for patients treated with ON, A was 
47 and for patients treated with FK50 was 24: p value liar the comparison by 
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Figure 5.2A Correlation of values of 1D, ,, s for Cy A and FK506 for all patients. 
ID; 0s 
(µgll) for Cy A and FK506 were obtained for 32 patients. There is a significant 
















Current drug treatment 
Figure 5.2B Ratio of IDSps for the two drugs in patients treated with either one or 
other drug. The ratios of the ID; ()s obtained Cy A and FK506For each drug were analysed 
against the drug used for treatment. Patients treated with I'K506 were relatively more 
resistant to FK506 in these experiments. This was also the case with patients being treated 
with Cy A. 
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FK506 CyA 
Since both Cy A and FK506 have significant toxic side effects, an aim of therapy 
must he to use the minimum dose of drug consistent with preventing rejection. As 
can be seen from Table 5.2, the ratio of mean trough blood level to 11)50 was about 
30 for Cy A and about 49 for FK50 . 
Again comparing means conceals wide 
individual variations. For example, for patients treated with Cy A the ratio may he 
less than 3 (patients 3,30 & 35) or more than 60 (18,27 and 38): likewise for 
FK506,18 and 22 respectively have low and high ratios (18 had been transferred 
from FK506 to Cy A). If the optimum dose of immunosuppression were being 
given, one might expect that the sensitivity to the drug should correlate with the 
blood level: but analysis by the Spearman Rank method shows no correlation 
whatever (data not shown). Comparing ID50 for either drug between patients who 
did or did not suffer acute rejection, no difference was found. I lowever, the 
number of patients with biopsy proven or treated rejection was low (7). There was 
no correlation between sensitivities and trough blood creatinine levels. The mean 
serum creatinine level was 186.8 µmol/l (SD 154.8 range 97-1000; median 153). 
The majority of patients were receiving standard `triple' anti rejection therapy 
including either cyclosporin or FK506, azathioprine and prednisolone. There was 
no difference in sensitivities in those patients receiving steroids or not receiving 
steroids. Time since transplant was arbitrarily divided into early and late groups. 
Those patients who were within 3 months of receiving the allograft are defined as 
early. All other patients are referred to as late (See Table 4.1). Again there was no 
difference in sensitivities of lymphocytes between early and late groups. 
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Patients were allocated into three groups hased on the lE)5os obtained for the 
immunosuppressive drugs. These groups were high, medium or low sensitivity. 
Table 5.3 shows the patients allocated to the high and low sensitivity groups. The 
remainder ofthe patients were ofmedium sensitivity and were not studied further. 
High sensitivity group 
Patient No. IDS for Cy A (µg/1) 1D.  for FK506 (µg/1) 
22 1.5 0.085 
18 2.2 0.17 
38 2.5 
2l 4.6 0.6 
19 5.0 0.150 
14 9.0 0.270 
29 9.5 0.160 
26 (a) 11.5 0.440 
26 (b) 12.0 0.350 
Low sensitivity group 
Patient No. ID.; () for Cy A (µg/I) IDS for FK506 (µg/1) 
2 45.0 0.650 
3 (a) 65.0 1.0 
3 (b) 85.0 0.80 
7 100.0 10.0 
32 100.0 
30 100.0 10.0 
4 100.0 10.0 
35 100.0 0.50 
Table 5.3. Selection of patients into low and high sensitivity groups. Patients were 
stratified into groups depending on their sensitivities to Cy A and FK506 in proliferative 
assays. 
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5.2 Investigation of resistance mechanisms to immunosuppressive drugs in 
PBMC from renal transplant patients 
Introduction 
P-glycoprotein-170 (P-gp), the product cif' the multidrug resistance (MI)R 1) gene 
in man is expressed on lymphocytes from normal volunteers (Pilarski et al, 1995). 
The hypothesis that highly sensitive lymphocytes had little demonstrable P-gp 
expression or functional activity, whereas those cells that were relatively resistant 
to both drugs had high levels, leading to a reduction in the intracellular 
concentration and, therefore, the efficacy of the drug was explored. Both Cy A 
and FK506 are substrates for P-gp (Saeki el al., 1993) (see Sections 1.6.6). 
5.2.1 Demonstration of functional activity of the MDRI phenotype, 
P-glycoprotein-170, on unstimulated lymphocytes 
To investigate the functional activity of P-gp cells are loaded with a fluorescent 
P-gp substrate, in this case Rhodamine-123 (R-123 ), and then incubated in R-123- 
free medium for between 4-6 hours. Retention of R-123 within the cells is then 
analysed using flow cytometry. Those cells retaining the dye have low levels of 
P-gp functional activity and those that expel the dye having high levels of activity. 
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Results 
During preliminary experiments PI3MC from normal volunteers were used. 
Patients cells were limited resources and were studied when the experimental 
conditions were optimized. A histogram plot of cell numbers against Mean 
Fluorescent Intensity (MFI) at time 0 hour (i. e. following loading with R-123) is 
shown in Figure 5.3. The cells of interest were gated manually as described in 
Section 4.2.7. During this analysis 5000 events were collected although in most 
experiments 10000 cells were collected. The histogram demonstrates a normal 
distribution of R-123 retention within the cells. There is an approximate 10-fold 
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Figure 5.3 Histogram of R-123 loading of PBMC. Cells from a single patient were 
incubated for 30 minutes with R-123 at 2µM. The cells were then washed in ice-cold PBS 
and kept on ice until the FACS analysis. 
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Cells from a further volunteer were then loaded with R-123 and incubated in 
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Figure 5.4A Histogram of R-123 uptake at 0 hours. Cells from a single patient were 
incubated for 30 minutes with R- 123 at 2µM. The cells were then washed in ice-cold PBS 
and kept on ice until FACS analysis. Markers have been inserted manually to separate cell 
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Figure 5.4B Histogram of R-123 uptake at 6 hours. Cells from a single patient were 
loaded with 2µM R-123 for 30 minutes and subsequently incubated in R-123-free 
medium for 4 hours. Markers have been placed manually to separate cells based oil the 
level of fluorescence. 
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Two populations of cells have manifested during the incubation period. The 
histogram has two peaks. The majority of ceiis have cffluxed the R-123 
fluorochrome as evidenced from the low levels of fluorescence. The second group 
of cells have retained the dye and the MF1 for this population is as high as the 
loading sample taken at time 0 hour. For each experiment the data can be further 
analysed. This histogram serves as a model för the analyses that were performed 
for each experiment as described in section 4.2.11. As can he seen from Figure 
5.4B a marker has been introduced manually to form two gated populations. The 
histogram data includes an estimate of the Mean fluorescent Intensity (MIA) of the 
cells in each gated population. In this example the MFA tör the cells that retained 
R-123 was 239.38 and the MFI for the cells that effluxed R-123 was 16.83. The 
percentage of cells in each of the gated populations can be calculated. The 
percentage of cells that have effluxed R-123 was calculated for each patient 
tested. The results of these experiments are shown in Table 5.4. 
Patient No. I I)s for Cy A 11)s for F, K506 Percentage of cells 
(µg/t) I (pg/i) I effluxing R-123 
High Sensitivity Group 
22 1.5 0.085 49 
18 2.2 0.17 35 
38 2.5 31 
21 4.6 0.6 37 
19 5 0.15 22 
14 9 0.27 37 
29 9.5 0.16 26 
26 11.5 0.440 28 
Mean 5.7 0.28 33.1 
SD 3.79 0.19 8.4 
Table 5.4. Individual drug sensitivity and level of R-123 efflux from PBMC. The 
percentage of cells that effluxed R-123 was established in patients in high and low 
sensitivity groups. Patients were assigned these groups based on the sensitivity of PI3MC 
to Cy And FK506. The mean percentage of cells effluxed in each group was calculated. 
t-Test comparing percentage of cells effluxing in high and low resistance groups. p=0.42. 
It can be seen from Table 5.4 that in all patients drug pumping is present. 
Although the mean value for percentage of cells effluxing the dye was higher in 
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the low sensitivity group compared to the highly sensitive group (38.1: 33.1) there 
was no significant statistical difference between the two groups. 
5.2.2 Dual labelling experiments to investigate T cell subclasses responsible 
for R-123 efflux 
Introduction 
T cells can he divided into 2 major classes, so called helper "I' cells and cytotoxic 
T cells. The antigens they express on the cell surface identify the classes of 
T cells. Helper T cells are characterised by expression of CD4 whereas cytotoxic 
T cells express CD8. Subsets of cells were assessed for ability to pump R-123. 
During these experiments cells were loaded with R123 and then incubated as 
before in R-123 free medium to allow efflux to occur. Following this the cells 
were harvested and counter stained with either CD8- or CD4-PE antibodies. The 2 
colour staining was then analysed by flow cytometry. 
Results 
The results of experiments performed on 4 patient samples confirm that ('U8 
positive T cells are represented predominantly in the etfluxing group and CD4 
















Figure 5.5 Contour graph showing double staining of R-123 pumping cells (`x'- 
axis; FL1) with anti CD4 (a) or anti CD8 (b)-PE (`y'-axis; FL2). PBMC from renal 
transplant patients were loaded with 2µM R-123 for 30 minutes and subsequently 
incubated in R-123-free medium for a further 4 hours. The cells were harvested and 
counter-stained with either anti-CD4 or anti-CD8 monoclonal antibodies prior to FACS 
analysis. The areas with the greatest number of stained cells are represented by the inner 
black lines. The cell populations are subsequently less dense and scatterings of cells are 
represented in blue. 
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Note the increased density of cells in Ql in anti-('I )K compared to anti-('I )4 
stained cells. Hie contour graphs are divided Into 4 quadrants (Q 1 -4). The `y'-axis 
represents the number of culls staining fier either anti-('I)4 or ('I)X. 
Following double staining with C'[)4 and ('[)K lineage markers the majority of 
cells that appeared to he e luxing R-123 were ('I)8 positive. 
5.2.3 Investigation of P-gp inhibitors on I1-123 efflux from PBM(' from renal 
transplant patients 
Introduction 
P-gp inhibitors were introduced into the experiments to demonstrate that efflux 
was indeed mediated by P-gp and not simply a leaching process, whereby over a 
period of time the R-123 fluorochrome could exit the cells along a concentration 
gradient. There are several molecules that can modulate the effect of' I'-gp and the 
multidrug resistance phenotypes in general. As outlined in Section 1.6, the MDR 
phenotype includes a number of separate molecules. These molecules have been 
discovered following selection of cancer cell lines in various chemotherapeutic 
drug solutions. The main molecules involved include I'-gp, MRP and I. RP. The 
hypothesis that the P-gp moiety would be most relevant to the study population 
described in this thesis was investigated. The expression and functional activity of 
P-gp can he studied using specific monoclonal antibodies and R-123 cf'llux 
respectively. "There are also selective inhibitors of 11-gp available including 
the 
cyclosporin analogue, PSC 933. 
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Preliminary experiments titrating PSC 933 at varying concentrations wi're' 
performed (Sec Figure 5.6). The final concentration of PS(' 833 in the cell 
cultures ranged from 1-20 ýtM. 'I'bis experiment demonstrated that 
I'S(' 833 could 
inhibit R-123 efflux at concentrations as low as 1-2 pM. 't'herefore I'5(' 833 was 

















Figure 5.6 Effect of PSC 833 on inhibition of R-123 efflux. Fells from a single patient 
were loaded with 2µM R-123 and subsequently incubated in the absence of' K-12 liar up 
to 6 hours, in the absence (a) or presence ol'2µM PS(' 933 (b). Samples were kept on ice 
until F'ACS analysis. 
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Experimcnts to confirm this finding were performed on a further three patients 
and summarised in 'fahle 5.5. 
Pt Time point MFI for left 




MF 1 for right 




() hr 0 () 143.9 100 
A 6 firs IO 49 78 51 
6 +PSC' O U 1 12 100 
O hr 0 O 98 100 
B 6 hrs 33 53 140 47 
6+ PSC O 0 117.3 100 
0 fir 0 O 76 100 
C 6 firs 8 25 73 75 
6+PSC 0 O 99.9 100 
Table 5.5 Effect of 2 µM PSC 833 on R-123 efflux in three patients. Cells from each 
patient were loaded with 2µM R-123 and subsequently incubated in the absence of' R- 123 
for up to 6 hours, in the presence or absence cif' 2µM PSC 833. 
In each case the addition of PSC 933 rendered the cells incapable of cliluxing 
R-123. These results suggest that PSC 833 is indeed a powerful inhibitor cat' R-123 
elilux. The solvent in which 1'SC 833 is dissolved as recommended by the 
manufacturer is ethanol/Tween 90 at 9: 1 and then diluted in an equal volume Of 
sterile distilled water (SI)W). To examine any possible contaminant ellect 
from 
the solvent the experiments were repeated comparing the effect of PSC 833 with 
that of solvent alone. The results are shown in Figure 5.7. ']'his confirmed that the 
solvent could inhibit R-123 efflux sub maximally compared to PSC 833 in a dose 
dependent manner. Further control experiments were performed with ethanol 
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alone and sterile distilled water alone. Neither ofthese compounds af'kcted K-123 
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Figure 5.7 Comparison of PSC 833 and solvent on inhibition of R-123 efflux. ('ells 
were loaded with 2 µM R-123 (continuous dark line) for 30 minutes and subsequently 
incubated in the absence of' R-123 for up to 6 hours, in the presence (continuous light 
line) or absence (dotted line) of' 2µM PS(-' K33 or solvent alone (dashed line). The cell 
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Figure 5.8 Comparison of PSC 833, ethanol and SDW on inhibition of R-123 efflux. 
Cells were loaded with 2µM R-123 for 30 minutes (continuous dark line) and 
subsequently incubated in the absence of R-123 for up to 6 hours, in the presence 
(continuous light line) or absence of 2µM PSC 833 with ethanol (dotted line) or sterile 
distilled water (dashed line) alone. The cell samples were kept on ice until IAUS 
analysis. 
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Time point and 
drug 
M F1 `left' % cells effluxing 
R-123 
MH `right' '%º cells retaining 
11-123 
0 hr 0 0 170 100 
6 hr 8 37 ()8 61 
PSC 833/6 hrs 0 0 1 14 100 
Ethanol/6 hrs 6 38 92.1 62 
SDW/6 hrs 7 35 92 65 
Table 5.6 Effect of PSC 833, ethanol and SI)W on R-123 efflux. R-123 efflux is shown 
to occur in the presence of ethanol and sterile distilled water. The addition of P SU 
dissolved in ethanol: S1)W (1: 1) renders the cells incapable of'el'llux. 
Neither ethanol nor SDW have any effect on R-123 efflux. All experiments with 
PSC 833 were subsequently performed with ethanol: SI)W as solvent. 
The cell line MCF7/A[DR was tested tör R-123 efflux and inhibition by PS(' 933. 
The results are shown in Figure 5.9. 
Cell 
Number 




Figure 5.9 Effect of PSC 833 on R-123 efflux and inhibition in MCF7/Al)R cells. The 
MCF7 cells were loaded with 2ptM R-123 (continuous dark line) fier jO minutes and 
subsequently incubated in the absence of R-123 lr 90 minutes, in the (presence 
(continuous light line) or absence (dotted line) of 2iM PS(' 833. 'l'lhe cells were kept on 
ice until FACS analysis. 
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I'he M('F7/A1)R cells demonstrate a high level R-I23 et'llux that is not hilly 
inhibited by 2 j1M PSC 833. It is interesting to nute that even in the Ioadinýº 
sample, time 0 hour, there is a degree of pumping occurring that is not present 
when the cells are loaded with R-123 in the presence of 1'S(' 933. 'T'hese cells 
were used as positive control cells in R-123 pumping experiments and I-gp 
expression experinments. 
5.2.4 Expression of P-gp by PBMC from renal transplant patients 
Introduction 
The experiments described in section 5.2.3 investigated drug pumping as 
exhibited by R123 efflux and inhibition with the selective 11-gh inhibitor, I'S(' 
833. The following experiments describe the expression cif' P'-gp on PBM('. "These 
experiments require the use ol'specific; monoclonal antibodies (Mab) to I'-gp. The 
Mab to external epitopes of I'-gp, namely MRK 16 and 41-3 were used. MIZK 16 
and 4F3 are mouse anti-human P-gp monoclonal antibodies. The cell line 
MC'IF-7/AI)R served as the positive control. A mouse lg(i2a isotype-matched 
negative control antibody, diluted to the same concentration BIS the test antibody, 
was included in each experiment. 
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Control experiments 
Fach Mab was tested for binding to the positive control cell line M('1 7//11)12 and 
I'm iscýtype controls. The results are shown in Figure 5.1 U. 
Cell 
Number 
if i11{11IIIIJIIIIIf III S tip i1 j02 FLI 
Fluorescent Intensity 
1, ý. ýý 
Figure 5.10 Expression of P-gp on the cell line M(, 'F7/AI)R following binding of 
MRK16 and 4E3. MC'F7 cells were incubated with either MRK 16 (dotted line) or 41'. 3 
(dashed line) monoclonal antibodies as per manufacturers instructions. Isotype control 
antibodies (continuous lines) were established at the same concentration eil' antibody as 
with MRK 16 and 4E; 3. 
The histogram confirms high levels of' staining with 41; -FF 1'(', and MRKI6 
added at I tg and 2.5µg/assay. The isotype control antibody revealed low levels of 
background staining. These control experiments suggest that the Mab are working 
well, and can readily detect P-gp expressed can the surtace cat' individual cells. 
Expression of P-gp by PBM(' from renal transplant patients 
'I'hc positive control cell line worked well as before. I however. MRK 16 staining, 
on PBMC showed only marginal increase in MIA over isotype control. The MF 











Figure 5.11 Staining of PBMC with MRK16 Monoclonal antibody. f'RM(' 1'R )I11 a 
single patient were treated with 2.5ýtg of' MRK 16 (dotted line) and isotype control 
(continuous line) as per manufacturers instructions. 
It was clear during the running of the samples through the flow cytoýnieter that 
there was a high level of' non-specific binding of the isotype control antibody to 
the larger monocyte population cat cells. This was reduced in subsequent analYsis 
by manually gating on the lymphocyte population. Further patient samples yielded 
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similar result with negligible binding ofMRK 16 or 4F3 Mab and are presented in 
fahle 5.7. 




Intensity of Isotype 
Control Antibody 
Mean Fluorescent 
Intensity of Test 
antibody 
22 4E3 5 1 1.5 
22 MRK16 3.4 4.6 
18 MRK16 1.4 2 
21 MRK 16 1.6 1.36 
21 MRK 16 6.52 7.76 
7 MRK16 7.1 8.4 
4 MRK16 7.07 11.81 
4 4E3 8.74 9.62 
2 MRK 16 1.35 1 
7 M RK 16 3.96 9.9 
MRK 16 18.6 16.4 
14 MRK16 1.41 1.54 
MRK16 9.12 15.6 
3 MRK16 6.56 10.39 
30 MRK 16 6.79 
22 MRK 16 7 18.9 
29 MRK16 2.5 3.26 
32 MRK 16 2.06 2.43 
38 MRK 16 1.42 1.88 
19 MRK16 2.61 5.45 
26 MRK 16 4.25 8.06 
MCF-7/ADR: MRK 16 3.15 190.3 
Table 5.7 Summary of antibody staining for P-gp expression in PBMC from renal 
transplant patients. PI3MC were treated with both MRK 16 and 4F3 monoclonal 
antibodies. fach assay included an isotype matched control antibody. 'T'here is inegiigihle 
staining of the PRMC with MRK 16 and 413 above the isotype control. 'I'he positive 
control cell line stained very strongly Following treatment with MRK 16. 
Since the patients' PI3MC tested were unif'ormly negative for P-gp expression a 
number manipulations in the experimental design were investigated. For example, 
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pre-fixing the cells ire 2'%'o formaldehyde and 100"'o , rco, ýrrc; t 1w of tlrc"r ý, (- ondar\ 
antinody Conjugates Ihltycoerythriri (-I'I'; )l; use of the prin mire ýrrllihod\ rl liil'liei- 
concentration per assay and the use Of f resIh rarthe r- thhrn r` ýºIýrýýýý"r ý"ýI CAN. I Iiese 
IllM ipul, 'ltlonlti did tl()t a11'1edt the OOutCoonle and ornik the rC. "Idi. ` will i'rc-sil k i, ý()Litcd 
PBM(' wi II he presented. 
Experiments with freshly isolated cells 
Freshly isolated I'13M(' from 4 patients were tested fi)r I'-gp ex pressioon using 
41; 3-ITIV and MRK 16 Mah. 
Results 
M('1'7/ADR positive control cell line 
Isotypc control: MFI 12. I)ß 
4 F3-I- ITC; ; ý) ý7 
MRK I6 837.59 
Mean o14 patients fsoýtypc control ?. 45 0. - 
41 -. 3-I ITC ý. () + 1.4 
MRK16 5.6X +ý. 16 




These studies show that the expression of P-gp on 1'13M( ilei] 1hi isles welts not 
demonstrable. The monoclonal antibodies tested hound to the positive control 
cells well and there was little non-specific binding. this result is paradO\ical in 
view of the data obtained with R- 123. The possible reasons will he discussed in 
Section 6.2. 
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5.2.5 Effect of P-gp inhibition on the anti-proºliferaative effects of ('v ;1 and 
F'K506 
Introduction 
ýý"Iý"ý tip Since lymphocytes have drug-pumping mechanisms that are iriliihiled hy 
inhibitors of 11-gr could inhibition of drug pumping influence the sensitivit\ Of 
PBMC to immunosuppressant drugs! 'I'lse effect of the Selective I'-gp i»Ihihili r, 
PS(' 833, on II)s s 1(ßr the two drugs was determined. 
PRMC cultures were established as described in Section 4.2.4, and dose response 
curves obtained following the addition of graded lh)ses of ('ý A and Ih SO(,. 
Similar cultures were established fbliowing the addition of var` ing doses of the 
P-gp inhibitor I'SC 833. "These cultures were estahlished toi observe af\ eI'1_'o on 
cell proliferation from abrogating the ability oof' the ccIIs toº expel 
il»munosuppressant drugs from the interim. of cells toº the exteritºr IllciIlllill. 
I1 the 
ability ofthe cell to expel these drugs by MI )R I-associated i»echall iSills is ertic"i, il 
to the sensitivity o1' cells to the (Irugs then thC -seIrsitiýit\ of ccIIk to the 




Dose response curves were obtained for the effect of Cy A alone and in 
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Figure 5.12 Effect of PSC 833 on the proliferative response of Con A stimulated 
PBMC treated with Cy A. PBMC from a single patient were incubated in the presence 
or absence of PSC 833 and Cy A, as indicated, for 48 hours prior to the addition of 
3H-thymidine for a further 16 hours. After harvesting, 3H-thymidine incorporation was 
determined and the data are plotted as means of replicate determinations. 
The data points are the mean of two values. From this graph the ID50s can be 
established for Cy A alone and Cy A plus PSC 833 at varying concentrations. The 
graph demonstrates that Cy A inhibits PBMC proliferation following mitogenic 
stimulation by Con A in a dose dependent manner. The graph also shows that Cy 
A inhibits PBMC proliferation in the presence of PSC 833 at concentrations of 
0.2µM and 2µM. At a concentration of 20µM, PSC 833 obliterates any 
proliferation of PBMC after mitogenic stimulation regardless of dose of Cy A. 
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Effect of PSC 833 on the dose response curve to Cy A 
on Con A stimulated PBMC; Pt. No. 40 
"I Ill' impact cof'1'S(' 833 at the lower concentration 0.2N is negiigihle. 11(mcver, 
there appears to he a shift in the dose response Curve too the Ich \01c il I'S(' X. 1.1 k 
added at 2pM. Similarly, dose response curves were obtained in the prcwnce OI 
FK506 with or without addition of PS(' 933. Table 5.9 is a sur»marý ofthe lt ),,, s 



















I)s for F K50 
(Itg /I) plus 
'S(' x33 2EtM 
39 25 21 15.5 
40 18 20 14 
7 38 25 20 
41 23 27 28 
42 68 64 47 
----- - 43 16 15 20 
37 48 32 23 
44 58 78 
45 21 18 IS 
46 - ------ U 
. 
11-1 "1 11.114 






Mean 35 27.8 28.9 IL62 0.57 
SI) 19 15.6 21 0.77 0.67 
Table 5.8 Effect of addition of PSC 833 to 11)sfor Cy A and F K506. I )o e response 
curves were obtained fi)r each patient to Cy A or FK5O(' and compared to the cures 
obtained in the presence ofthe selective P-gp inhibitor, I'S(' 811. Paired I- Fest fier ('ý A: 
('y A/PSC 833 (2µM) p-O. 24: Paired t-'l'est tir- l'K 06 :I I`5()6/P (' 831 I) (). -15. 
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The results in 'f'ahle 5.8 demonstrate that P SC 833 did mt significantly affect the 
IDs,,, in either Cy A or FK506 treated cells. the m earn II), (, t , ()I. ('v, A alone was 1'S 
ýtý/1 (SU 19 rangt 16-68) and the mean II), n I 'or ('v A plus PS(' X13 at 21LM "gis 
28.9 
. tg/1 
(SI) 20.9 range 15-79). This was not statistically signllIlcun11 as tested by 
the paired t-Test (p 0.24). The mean IDs(, fier FK 50lß alone was 0.62 pg/I (tiI ) 
'vas 0.57 pg'I 0.77 range 0.044-1.75) and the mean [[); () fier FK506 plus PS(' 81 
(SI) 0.67 range 0.04-1.4: p =0.45). The concentration of I'S(' 833 used (2 LM) is 
equivalent to the concentration used to inhihit IZ-I23 efflux. This c<ýnceni nitioºn iii 
molar terms is approximately 8 foolcl higher than the highest dose of ('v A used. 
Similarly, the addition of 0.2pM FS(' 833 causes a reduction in the mean 11);,, 
compared to Cy A alone but again this does not reach statistical sigill lieaiice when 
subjected to a paired t-test (p=O. 12 ). 
Experiments to assess any direct anti-proliferative effect of PS(' 833 
Since PSC 833 is a cyclosporin analogue alny direct cIThet On the pproolilerativ'e 
response of PRMC was examined. Titration experiments of P SC Wi at closes of 
0.2,2 and 20 µM were performed in the absence of ('v A. The results or these 






























. 1/1'S(' ' 
833 
24) tM 
7 38 64124 61717.5 S66; 1. ý 1108. 
41 23 28678.7 27696.7 29081. -1 . 101. x, 
42 68 46904.85 45536.4 56772.2 
43 16 37009.85 38170.7 337,18.5 1-3957.9 
37 a 48 16286.9 17832.6 19089.3 2352 
44 58 
46 21 26339 24968 34174.6 23161.2 
- 51 63215.7 66556.3 65818.1 61996.1 7.176.7 
52 84139.9 93230.5 79253.; 82238A 19002 2 
- 37 h 31242.6 31136.5 29136.2 25555 j 5291.6 
Mean 44215.3 45205 45427.5 42018.0 
SD 22135.4 24361.4 22025.8 22140 
Table 5.9 Effect of PSC 833 on Con A stimulated PBMC. ('ell cultures %%cre 
established following stimulation with 5µg /ml ('on A. The effect of I'S(' 833 on MI 
proliferation was explored, and the counts per mm ule (chill) recorded. 
Paired t-Test comparing no I'SC 83 3: 0.2 tM PS(' 833: p 0.42 
Paired t-Test comparing no PSS' 833: (). 6µM PS(' 833: p 0.4 
Paired t-Test comparing no PSC 833:?. OtM PS(' 833: p 0.27 
It can he seen from the "fahl' 5.9 that there is an anti-pro! ilcrati\c L'li ct of I'S(' 
833 at the high concentrations of 6 and 2O tM. At 2pM there is variation in 
response with some samples showing a direct anti-proliferative ct'tcct (7,41.44h) 
and the other samples demonstrating no appreciable et'fect. This is reflected in the 
means öl'the 2 groups and overall no statistical effect. 
PSC 933 exhibited an effect on ('can A stimulated cells at a ccýnc; entration oI'6pM. 
At 2µM a direct effect was variable and not significant. This is important since it 
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dcnionstratcs that the P gp inhibitor is not toxic at this (1o)se. Ili' InIc"re"rrce". ilie 
ell' c; t of I'S(' 833 on R-123 cliff ix indicates that the retentiOin oI 
d`le 1,011( miiq', 
addition cif' PSC 833 was not simply cell toxicity, but a 1111,11-nr, rcolupºiC. tI effect of 
the drug. 
Summary of Sections 5.1-5.2.5 
There is a dose dependent inhibition of lymphocyte proliferation fi01lm%'il)g the 
addition of the immunosuppressive drugs Cy A and FK 5Oh. There is ai wide 
variation in sensitivity to the drugs. The hypothesis that Mt)R I-associated 
mechanisms may be responsible for this variation remains unproved. I luwever, it 
has been demonstrated that drug pumping occurs i» all the patient salllpic's as 
assessed by R-123 efflux and inhibition with PS(' 933. This suggests that the 
pumping is due to 11-gp functional activity. It has not heen possihie to denionstrate 
P-gp expression on the patients' samples of' PRM(' although the a11tiho (lies 
worked well with the positive control cell lire MCI-7/AI)R. 'I'Ihe majority ooFcells 
pumping R-123 are C t) positive T cells. PS(' 933 (lid not significantly affect the 
II)5o, in either Cy A or FK50 ß treated PBM(' when Stimulated h`' ('can A. 
Conclusion 
The data demonstrate that 1'-gp dependent mechanisnms are not responsible iior the 
variation in sensitivity of PBMC to the immuno suppressant drugs ('y A and 
1"K506. 
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5.3 Investigation of the interaction of immunosuppressant drugs on 1'I; M( 
from renal transplant patients 
Introduction 
As discussed in Section 1.5 the idea behind the work described in this thesis ýti, is 
to develop a means of studying in vitro patient lymphocyte responses to 
immunosuppressant drugs in order to understand their mode of action, 
mechanisms of resistance, and interactions between the'nl. Another . apprc)ilrl1 toi 
optimising immunosuppressant drug regimes IS to use multiple drug coýiuhin ati0 ns 
at lower than conventional individual doses. Drug ccýnmhinatioýns that (Icnioºnstrate 
synergy may improve efficacy and side etlect proýlile. Recently, ralpamyclll has 
been introduced into clinical transplantation. Rapamycin and a synthetic analogue. 
SI)Z RAD, have a different mechanism of action to FK506 but share the same 
intracellular binding site (see Section 1.3.4-1.3.6). The interaction of 1 K506 with 
SI)Z RAD was explored in PLM(' from renal transplant patients. 
Lymphocyte cultures were established in twos systems, namely ('on A stimulated 
lymphocyte cultures and Mixed Lymphocyte Reactions (MI. R). 'Ilhe MI. Il 'gas 
employed fior the reasons outlined in Section 3.1.3. These cultures were herfiornmcd 
with graded doses of SD/, RAU alone and with SI)% RAI) in combination vVith 
low close FK506 (less than the mean Il);,, in the previous work in Section 5. l ). 
Lymphocyte proliferation was assessed in two ways. Firstlý, following 
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incorporation of 3H-thymidine (3H-thy) and secondly by expression of'('I)25 on 
the cell surface using flow cytometry. 
5.3.1 Con A data 
To assess the interactions between the drugs the effects of the drugs on a maximal 
stimulus provided by Con A were investigated. The experimental method has been 
described in Section 4.2.4. The results are divided into preliminary dose response 
curves for SDZ RAD and the effects of combining SDZ RAD with FK506. 
(Patient characteristics are presented in Table 4.1). 
5.3.1.1 SDZ RAD dose response curves 
The results are presented graphically to illustrate the dose response curves 
obtained with SDZ RAD (see Figure 5.13). The ID50s obtained in the presence of 
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Effect of SDZ RAD on Con A stimulated PBMC; 
Pt. No. 53 
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Figure 5.13A-C. The effect of SDZ RAD on Con A stimulated 1'13MC from renal 
transplant patients. Each graph demonstrates proliferation of PBMC from a single 
patient in the presence of graded doses of SDZ RAD, as indicated, for 48 hours prior to 
the addition of 3H-thymidine for a further 16 hours. After harvesting, iH-thymidine 
incorporation was determined and the data are plotted as the means of replicate 
determinations. The error bars refer to the standard deviation around the mean value. The 
ID50 for SDZ RAD are obtained by interpolation from the graph. 
124 
I'hc majority of the experiments, illustrated by graphs (A) and (11). shoý a aº. ýºýºýI 
response to tit) RAI) with inhibition of proliterati'ºii iii responn'ýe to Vrlidcd (1(º"e' 
of the drug. Further studies, illustrated by graph ((') revealed a relativeI\ poor 
response to the drug and also evidence of increased pruliicralion eil lo do', '.. 'ý. I the 
range of' sensitivities of' patients PBM(' to SD/ RAD was e stahl isle d by 
estimating the II); (), for each individual. 'I'lhe I I)ºs arc presented in I . ihIc 5.1(). 
Patent No. II). S[» RAI) (ig/h 
53 A 20.0 
54 U 0. OUt) 
55C 5.1 
-- ----- y 56 [) - ý 16.0 
57F, 0.14 
5F 0.2 
63 G ýº. 25 
59 11 0.06 
0.06 
60 74. (º 
61 46.0 
64 . 80. (º 
62 '90.0 
Mean 24.9 
Table 5.10 ll) )s for SI)Z KAI). II),.,, \tiere estahli hcd týºr tiI)/ i1-11) III Coll 
stimulated PBMC cultures. 13 patients ýkere investigatcdl. 
The mean for the whole group is 24.8 ýtg/l (SI) 3.1.0 rang (1. (1110-Kll. l)1. Shgrmmp 
analysis of the 9 patients A-1 confirms as m eaan II),,, I'm- tlhese t) patients oof 4.7p I 
(S[) 7.8 range 0.009-20). From the data presented in Section 5.1, the n can II ),,, 
flor ['K506 was 1.2 tg/I (S[) 1.9 range (). U-5.5 ). I'Iie ratio of the mean II); ý Iiºr 
the drugs SI)! KAI) and FK50 is 3.9. 'I'hc other suhlet OI' patients behaves 
12S 
differently. The mean I I)5, º fier this subset is 70 1tg/I (ýI) 16. ' raný'e -11i X(1) 
Further cxpcrimc»ts were pe'rlormcd toi characterise the eI'Icet OI' Ih S1)(º Ull the 
dose-response curve to SD/ RAD. 
5.3.1.2 SI)Z RAI) & FK506 
Fixed doses of FK506 at either O. 1 tigl) or I .Oi 
/I were added 1oß the Con A 
stimulated 1113MC cultures in the presence of graded doses of SD/ RAD. Hic 
ct'fccts cif S[)Z RAI) in combination with FK 506 are presented in Figure 5.14A-1 I. 
Fach patient is represented by two graphs. (he first dIchirts the ýIcttlitl lc v levels of 
cell proliferation as measured by incorporation OI' 'I I-thymidine. HIC second is 
normalised for the response obtained to ('on A in the ahkence oof', SI )/ RAD ('No 
Drug" Control). 
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Effect of SDZ RAD alone and in combination with 
















Figure 5.14A Effect of SI)Z RAI) alone and in combination with F K506 on ('on A 
stimulated PBMC. PBMC from a single patient were incubated in the presence or 
absence of SDZ RAD and FK506, as indicated, for 48 hours prior to the addition of 
; H-thymidine for a further 16 hours. After harvesting, '11-thymidine incorporation was 
determined and the data are plotted as means of replicate determinations. The error bars 
refer to the standard deviation around the mean value. 1[),. s were obtained for Sl)Z RAD 
alone, and for SDZ RAD in combination with FK506 by interpolation of the graphs. 
Effect of SDZ RAD alone and In combination with 
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Figure 5.14B Effect of SDZ RAD alone and in combination with F K. %% on ('on A 
stimulated PBMC; Pt. 53 Normalised for'No Drug' control. l hr data were normalised 
by assigning '100%' to the level of' proliferation obtained in the absence of any drug and 
calculating the percentage of inhibition achieved with respect to the 100% level of 
proliferation for both SDZ RAD alone and SDZ RAI) in combination with I: K506. 
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Figure 5.14C Effect of SDZ RAD alone and in combination with FK506 on Con A 
stimulated PBMC. PBMC from a single patient were incubated in the presence or 
absence of SDZ RAD and FK506, as indicated, for 48 hours prior to the addition of 
3H-thymidine for a further 16 hours. After harvesting, iH-thymidine incorporation was 
determined and the data are plotted as means of replicate determinations. 1135s were 
obtained for SDZ RAD alone, and for SDZ RAD in combination with FK506 by 
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Effect of SDZ RAD alone and in combination with 
FK506 on Con A stimulated PBMC; 57: Normalised for 
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Figure 5.14D Effect of SDZ RAD alone and in combination with FK506 on Con A 
stimulated PBMC; normalised for 'No Drug' control. The data were normalised by 
assigning '100%' to the level of proliferation obtained in the absence of any drug and 
calculating the percentage of inhibition achieved with respect to the 100% level of 
proliferation for both SDZ RAD alone and SDZ RAD in combination with I`K506. 
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Figure 5.14E Effect of SDZ RAD alone and in combination with FK506 on Con A 
stimulated PBMC; Pt. 56. PBMC from a single patient were incubated in the presence 
or absence of SDZ RAD and FK506, as indicated, for 48 hours prior to the addition of 
; H-thymidine for a further 16 hours. After harvesting, 3H-thymidine incorporation was 
determined and the data are plotted as means of replicate determinations. ID50s were 
obtained for SDZ RAD alone, and for SDZ RAD in combination with F K506 by 
interpolation of the graphs. 
Effect of SDZ RAD alone and in combination with 
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Figure 5.14F Effect of SDZ RAD alone and in combination with FK506 on Con A 
stimulated PBMC; Pt. 56: Normalised for 'No Drug' control. The data were 
normalised by assigning '100%' to the level of proliferation obtained in the absence of 
any drug and calculating the percentage of inhibition achieved with respect to the 100% 
level of proliferation for both SDZ RAD alone and SDZ RAD in combination with 
FK506. 
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Figure 5.14G Effect of SDZ RAD alone and in combination with F K506 on Con A 
stimulated PBMC. PBMC from a single patient were incubated in the presence or 
absence of SDZ RAD and FK506, as indicated, for 48 hours prior to the addition of 
3H-thymidine for a further 16 hours. After harvesting, 3H-thymidine incorporation was 
determined and the data are plotted as means of replicate determinations. 
Effect of SDZ RAD alone and in combination with 
FK506 on Con A stimulated PBMC; Pt. 62: Normalised 
for 'No Drug' Control 














Figure 5.14H Effect of SDZ RAD alone and in combination with FK506 on Con A 
stimulated PBMC; Pt. 62 Normalised for'No Drug' control. The data were normalised 
by assigning '100%' to the level of proliferation obtained in the absence of any drug and 
calculating the percentage of inhibition achieved with respect to the 100% level of 
proliferation for both SDZ RAD alone and SDZ RAD in combination with F K506. 
130 
0 0.01 0.1 1 10 50 80 
S DZ RAD (µ g/L) 
0 0.01 0.1 1 10 50 80 
SDZ RAD (µgIL) 
'I'hc dose response curves fier S1)/ RAI) and SD/ RAD in combination mth 
FK506 are similar. For cxaniple, Ffigure 5.14A-11, dci>>o, n,, 1raitc,, iiicrc, iýcd 
anti-proliferative d iedt of SI)l RAI) in the presence of(). I pg/I FK 506.1 here k 
no c1'fcct at the cquimolar close range. A variable cu ert is scen in Figure S. 14('-I ). 
Again there is no cllec: t of combining the drugs at the eyuir>>uIaºr dose range, 
although at high closes of SI)% RAI) there is less eI'Iect ýýith the , ic1ý1i1iýºn , ºI 
F K506. Patient 62 is resistant to S1)Z Ri\) alone and in combination w itlh FK SO( 
(14igure 5.14(1-11). The results are summarised in Fable 5.1 1. 
Patient No. II)% SI)Z RAI) (µg/1) 11)5, º SI)Z 1kAl) &F K506 
53 20.0 10.5 
56 16.0 4.5 
57 0.34 -KO 
58 0.2 1.5 
63 0.2 5 9.0 
59 0.06 4.4 
9 0.06 03 
64 "180.0 -80 
62 >80.0 -80 
50 >80 19 
41 0.1 . 1O 
Mean 25.2* 27.1 * 
SI) 35.9 ; 4.3 
Table 5.11 11)s, ºs for S1)Z RAI) alone and till, KAI) in combination with FK506. 
UMs were established Con A stimulated P11M(' cultures ti)r tiI )t RAI) lind SD/ RAI) in 
combination with FK50 . 
Footnote to "fahle 5.11. Paired 2 tail t best Iý g( ýrrl) Ip (). 
It''=>80' then '80' entered into equations; i1-' -10' then I I. I(1' entered irito equation 
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The mean II)5u for SI)/ RAI) alone is 25.2Irg/I (tit) 35.9 range . 
06-90). 'I Ise mean 
IU; o 1cor SI)Z RAI) used in combination with 1'K 506 is 27.1'tg/I (ti)) . 
14.. E range 
0.3-8O). There is no statistical difference between the two groups. I Ioowever, there 
appears to be 2 anomalous results that may he skewing the results (patients 50 and 
57). If these results are withheld from the analysis the respective mean II);,, s are 
21.9Ltg/1 (S[) 33.8) and 22.? Ltg/l (, SI) 32.9). (p 0.87). Despite the lack (& effect 
across the group this hides some marked dilicrences between the patients. 
In 3 
patients the addition of FK506 rendered the cells more sensitise toi the e f'frcts iºf' 
SDZ RAD. In 2 patients there was no overall demonstrahlc cf'icct. although these 
patients were resistant to the effects cif' SD/, RAD. In the remaining 6 patients the 
cells became less sensitive to the effects cri' S1)! RAI) fiollowing the addition Oi 
I= K506. 
Conclusion 





The MLR was performed by co-culturing recipient PBM(' with l UM(' from 
surrogate donors matched at the UR locus as discussed in Sections : x. 1.3 and 4.2.5. 
The MIA offers the opportunity to study the response of' I'RM(' from renal 
transplant patients with a physiological stimulus. '! 'he level of proliferation 
obtained is low in comparison to the broad stimulus provided by mito gern. 
During these experiments one of the two populations of }113M(* were rendered 
incapable of proliferation following pre-treatment with mitomycin C. 'llhcsc 
treated cells are termed `stimulators, (S). The untreated cells remain capable of 
proliferation and serve as `responders' (R). The responder cells were renal 
transplant recipients and the stimulator cells were matched fier the original kidney 
donor at the DR locus. The recipient characteristics including lll, n typing are 
included in "Fable 4.2. 
5.3.2.1 Preliminary experiment to investigate duration of culture and 
optimum cell number in 1-way MLR 
Al -way MLR was established with varying duration cal' cultures (108-15( hours) 
and comparing the response of Ix 10 Y coils/culture to 0.5 x 1O-ý cells/culture. "l he 
MLR containing Ix IO cells from both `donor and recipient did very poorly and 
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did not survive (data not shown). When 0.5 x 105 cells from both (S) and (R) were 
established in the MLR there was a time dependent effect with no response at the 
longest duration. The best response was seen at 108 hours (Figure 5.15). 













Duration of MLR 
 108hrs 
  132 hrs 
Q 156 hrs 
156 hrs 
Figure 5.15 Bar Chart of 3H-thymidime incorporation against duration of MLR 
Pt. No. 68 ]-way MLR were established in cell cultures for 108,132 and 156 hours with 
the addition of 'H-thymidine 16 hours before the end of the culture. After harvesting, 
; H-thymidime incorporation was determined and the data are presented as means of 
replicate determinations. 
Footnote: (S)/(R) refers to stimulator and responder combination in MLR. The responder 
only (R) results have been deducted. 
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5.3.2.2. Quantifying the proliferative response 
Thc surrogate donor/rec; ipicnt combinations tested were c)mraeterkcd as to the 
degree of'prc)liferative response obtained during the MI. R (See fahle S. 12). 
Experiment No. (S)/(It) pairs Stimulation Index 
- A1 46: 65 1 
A? 78: 66 1.1 
A3 39: 67 1.6 
A4 79: 68 35&;. 5 
AS 90: 69 2.2 & 2.35 
A6 80: 7O 1 
A7 81-: 54 
AS 80: 46 111.5 
--- A9 81: 55 16 
AIO 82: 54 1. I 
All 84: 69 7.1 
X11? 70: 21 6.2 
A1_3 65: 28 3.6 
Al4 55: 60 6.9 
A15 83: 69 7& 18.7 
A 16 85: 54 17.5 
A17 64: 59 
A18 85: 61 H. 6 
Table 5.12 Summary of the stimulation index (SI) for each stint ulator/responder 
(S)/(R) pair. 'I'hc SI weis calculated from each pair h\ dig idiing the ý aIluc obtained %ý ill, 
the stim Maiur/responder pair by that o1' tlhe responder cells alone. i. e. (S)(R)/(R ). 
I'he (S)/(R) pairs from AI -A9 show relatively Ioow stimiiulatioýn, except fier A8. On 
3 occasions in this series the MIR were repeated and consistent results stiere 
obtained. 
H5 
Following the use ofthe supplemented medium A I0-A 19 the levels of stimulation 
increased to maximum stimulation index of 19.5. It is possih(c th t the tnelhlllll 
initially used was not fully sustaining I 'Or these Ml. R experiments. It is interesting 
to note, however, that despite this the cells responded v e11 toi ('on A ý%he» , iddcd 
attcr 72 hours of culture. 
5.3.2.3 Investigation of effect of FK506 on MLR 
FK506 was added in graded doses from 0.01-5JJg/I to the Ml. R and the cultures 
were maintained as described previously (see Section 4.2.5). The data fier patient 
65 are presented in "fahle 5.13 
(S) 
Only 
(R) Only Con A (ti)/(R) F K506 (pIg/1) 
-- - -_ ---- U 0.01 11. I 0.3 1 5 
62 1565 8969 1553 48 28 6 lº 2, 
48 1588 9335 982 633 90 50 36 168 
819 455 16 lb 28 11.1 
Mean cpm 
3H-thy 
1577 9152 1118 378.7 44.7 24 101.3 
S1) 385.4 299.9 39.7 73.8 
Table 5.13 Effect of FK506 on MI. R: pt. 65 1-way MIR was established in the 
presence of graded doses of' FK506 (0.0 1-5 tg/I ). Profi f *crtt ion \\ as assessed hý 
incorporation of IEl-thyiidine. I(S) refers to stimulator cells; (R) relcrs toi responder cell, 
from patient 651 
The mitomycin treated cells (S) do not proliferate at all, and this is a consistent 
finding throughout the experiments. The response to ('on A stimulated controls is 
maintained, and this is consistent throughout the experinments. 
I 36 
Data from a further patient (number 66) is presented graphically as in I figure ý. I (ý. 
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Figure 5.16 Effect of FK506 on proliferative response during; the M I. K. I -ý<a MIR 
were established in the presence or absence of IX506, as in(icated, fier 9)2 hhOurN I)riOr to 
the addition of 31-1-thymidine for a further 16 hours. After harvesting. '11-thy mid ne 
incorporation was determined and the data are plotted as means of replicate 
determinations. The error bars represent the standard deviation around a mean OI' I 
values. 
A dose response curve is obtained during the Mt R in response toi FK5(Th. 1Imwver, there 
is a significant amount cif background stimulation seen in the Responder (R) onl` control 
cells. The stimulator (S) cells however, do not proliferate since they have been Eire-treated 
with the anti-mitotic agent full myciii 
5.3.2.4 Investigation of the effect of SI)% RAI) on M I. R 
1-way MIA were established in the presence of graded doses OI* SI)/. RAI) 
hrý ýý"ntý"ý1 (0.01-5tig/l) as discussed in Section 4.2.5. Data from Irrt ie rats Ls 
graphically in Figurc 5.17A-t'. 
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Data from a further patient (number 66) is presented graphically as in Figure 5.16. 
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Figure 5.16 Effect of FK506 on proliferative response during the MLR. 1-way MLR 
were established in the presence or absence of FK506, as indicated, für 92 hours prior to 
the addition of 3H-thymidine for a further 16 hours. After harvesting, 3H-thymidine 
incorporation was determined and the data are plotted as means of' replicate 
determinations. The error bars represent the standard deviation around a mean of 3 
values. 
A dose response curve is obtained during the MLR in response to FK506. However, there 
is a significant amount of background stimulation seen in the Responder (R) only control 
cells. The stimulator (S) cells however, do not proliferate since they have been pre-treated 
with the anti-mitotic agent mitomycin C. 
5.3.2.4 Investigation of the effect of SDZ RAI) on MLR 
1-way MLR were established in the presence of' graded doses of SDZ RAI) 
(0.01-5µg/1) as discussed in Section 4.2.5. Data from 3 patients is presented 
graphically in Figure 5.17A-C. 
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Figure 5.17A-C Effect of SDZ RAD on MLR. I-way MLR were established in the 
presence or absence of SDZ RAD, as indicated, for 92 hours prior to the addition of 
H-thymidine for a further 16 hours. After harvesting, 3H-thymidine incorporation was 
determined and the data are plotted as means of replicate determinations. The error bars 
represent the standard deviation around a mean of 3 values. 
Dose-Response curves were obtained in these 3 patients. However, a number of 
further experiments yielded unsatisfactory results with low levels of proliferative 
response to the stimulator cells and accompanying this a lack of demonstrable 
inhibition with the 2 drugs. 
Discussion 
There was evidence of a poor proliferative response in a number of MLR. The 
poor responses obtained during the MLR made it more difficult to interpret the 
inhibitory effects of the drugs and may have accounted for the lack of 
pharmacological effect of combining the two drugs in in vitro lymphocyte 
cultures. There are a number of possible explanations for the observed poor 
responses. 
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Immune recognition 
The plain stimulus i'Or the MI. R is a mismatch at the Class II MI I(' locus. 'I the 
MLR is an in vitro model of allograll recognition and is clear that allugralis 
mismatched 1'()r class 11 antigens (those in the I)R region of the MI I(') are rejected 
most strongly by the host immune response. Low proliferative responses were 
obtained during the MLR experiments possibly becaaus \Nc i»: atc: hed the 
stimulator cells used in the experiments with the donor DR antigens. The majority 
of transplant recipients in the experiments are matched at this locus (See Zahle 
4.2). The MI, R performed when there is matching I'm Class II MI I(' alleles do not 
react or proliferate briskly. 
Technical 
(a) Despite repeated washes the iiiitomyciii (' treated cells may 
have led toi 
contamination of the MI, R, which abrogated a proliferative rCS OýnSC in the 
responder cells. 
(h) The medium used for the experiments may not 
have been sustaining the cc, I 
cultures. The medium used I 'or the early experiments did not contain I IFI'I': ti 
buffer or 1i-mercaptoethanol (I3-M l -. ) that serves as an anti-oxidant. 'Hic later 
experiments were Characterised by improv'ed proliferative rCs[)OIi'es and the 
medium at this stage contained both 11FPFS and 1ý-MF. However, at all stages 
; ýý1 when the cells were tested fier prýýlifcrýýtive response to ('cýii A at day 
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culture, there was always a brisk prcýlilerativc response, suggesting, that the 
media used during the experiments were sustaining, even during the ýýrýýlýºiýýº. ý"ýi 
culture duration associated with the Ml , R. 
(c) The cells, although in general were able to respond toi ('on A (ifllo ing 
freezing and thawing, may have lost the ability to respond to a more specific 
stimulus. Again there is the anomaly of MIS responding po orly toi the spec iI is 
allogeneic stimulus during the MLR, but continuing to respond well when ('on 
A is introduced into the cultures alter 3 days. 
5.3.2.5 Effect of SI)Z RAI) and FK506 used in combination on M I. R 
The effect ofý combining the two drugs on the close response Curves ohlaiiicd 
during the MLR was assessed (section 4.2.3). The MLR were established with 
SDZ RAD added to the cultures in graded closes, either alone, or with a1 fixed 
amount of FK506 (between 0.01-1.0 pg/1). Data from these experiments are 
presented graphically in Figure 5.18. It can he seen from F igurc 5.1 KA that the 
curves are similar. However, they start from different values of 'l1-thvnnidine 
incorporation. The graphs are normalised by nominating the amount Ol 
proliferation seen with neither drug present ('No Drug' Control) als 100%. Any 
change in proliferation above or below this level is Compared to this level. Roth 
curves now begin from the same point of I O0%. Figure 5.1911 is a graph of the 
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Figure 5.18A Effect of SDZ RAD alone and in combination with FK506.1-way MLR 
were established in the presence or absence of SDZ RAD and FK506, as indicated, for 92 
hours prior to the addition of ; H-thymidine for a further 16 hours. After harvesting, 
3H-thymidine incorporation was determined and the data are plotted as means of replicate 
determinations. The error bars represent the standard deviation around a mean of 3 













Effect of SDZ RAD alone and in combination with 
FK506 on MLR: Pt. No. 61 
Effect of SDZ RAD alone and in combination with 
FK506 on MLR; Pt. No. 61 (normalised for 'No Drug 
Control') 
Figure 5.18B Normalisation curve of effect of SDZ RAD alone and in combination 
with FK506 on MLR: (Normalised for 'No Drug' control). 1-way MIR were 
established in the presence or absence of SDZ RAD and FK506, as indicated, for 92 
hours prior to the addition of ; H-thymidine for a further 16 hours. After harvesting, 
3H-thymidine incorporation was determined. The data are normalised such that the 2 
curves commence from '100%'. This is the level of proliferation obtained when neither 
SDZ RAD nor FK506 are present in the cell cultures. ID so, can be estimated by 
interpolation of the graphs. 
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The curves obtained are similar to each other, with inhibition of proliferation of' 
the MLR occurring with both SDZ RAD alone and SDZ RAD used in 
combination with FK506 at 1.0 µg/1. There is some effect of FK506 at the lowest 
concentrations of SDZ RAD. This effect is lost at doses of SDZ RAD above 10 
µg/1. At equimolar concentrations there is some apparent enhanced effect of 
FK506 on the MLR, although the error bars seen in Figure 5.18A may render this 
observation non-significant. The ID 50s can be interpolated from the graphs (II)sO 
for SDZ RAD alone is 0.062 µg/l and for SDZ RAD in combination with FK506 
is 0.042 µg/1). Normalised data from 2 further patients are presented in Figures 
5.19 and 20. 
Effect of SDZ RAD alone and in combination with 
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Figure 5.19 Effect of SDZ RAD alone and in combination with FK506: (Normalised 
for'No Drug' control). 1-way MLR were established in the presence or absence of SDZ 
RAD and FK506, as indicated, for 92 hours prior to the addition of ; H-thymidine for a 
further 16 hours. After harvesting, ; H-thymidine incorporation was determined. The data 
are normalised such that the 2 curves commence from '100%'. This is the level of 
proliferation obtained when neither SDZ RAD nor FK506 are present in the cell cultures. 
ID 50s can be estimated by interpolation of the graphs. 
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At equimolar doses (0.1 and 1.0 µg/1) the curves for SI)Z RAI) alone and SI)Z 
RAD in combination with FK506 come together. The greatest effect on inhibition 
(greater than 80%) occurs at the highest doses of each drug used in combination 
(SDZ RAD 10 µg/1 and FK506 1.0 µg/1). When SDZ RAD is used alone the curve 
does not reach the 50% of inhibition level and therefore an ID5o cannot be 
estimated. Data from patient 86 is presented in Figure 5.20. 
Effect of SDZ RAD alone and in combination with 























Figure 5.20 Effect of SDZ RAD alone and in combination with FK506: Pt. No. 86: 
(Normalised for 'No Drug' control). 1-way MLR were established in the presence or 
absence of SDZ RAD and FK506, as indicated, for 92 hours prior to the addition of 
3H-thymidine for a further 16 hours. The data are normalised such that the 2 curves 
commence from `100%'. This is the level of proliferation obtained when neither SDZ 
RAD nor FK506 are present in the cell cultures. 
A dose response curve is obtained for both SDZ RAD alone and in combination 
with FK506. At low doses of SDZ RAD there is an increase in proliferation of 
cells as measured by the percentage inhibition being greater than 100%. The cffect 
of the drug combination appears to be less than that when SI)Z RAD is used 
alone. The overall level of inhibition is sub maximal and although a dose response 
is seen from 0.01 µg/1 with SDZ RAD alone, and 0.1 µg/1 when used in 
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combination with FK 0 ß, doses of SI )/, KAI) greater than 10 'it,, %I vwiitd Iia 
been necessary liar maximal inhibitory effect. 
Summary 
I'hcrc are no COnsiStCnt effects cif Ct1I11hining St)/. RAI) mth I-'KS1)6 on the Ml R 
from renal transplant recipients. OI' particular nagte there is nc evidence ()f 
interaction at cqui»>ular drug levels since the two curves tend to coin\ ergo at tlhes e 
levels. 
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5.3.3 (11)25 expression 
Cell proliferation can he assessed by I illowing incorporation OI* . 
1I I-thvnridlinh" a 
demonstrated in the data presented in the preceding Sections. I he 
immunosuppressant drugs studied inhibit I ccII , Ictiv*altiuln in rý"ýýýýºIýýý" lo 
alloantigens. ('1)25 la-chain cif' the lnterleukin-2 Receptor (11. -2101 is it marker OI 
T cell activation that is specifically upregulated during I ccli ach i\ atio ll (sec 
Section 3.1.5). (11)25 expression was assessed by flow cytonieir` fiºIIowinqº Con A 
stimulation in the presence of graded closes of Si)! RAJ ) ait ne and SD/ RAI ) in 
combination with FK506. 
The data obtained for patient 
55 is shown in I Ahle 5.14 and Figure 5.21. 
Test cells 
I. Jnstimulated Cells/Isotype control 
Stimulated ('ells/Isotype control 
Unstimulated Cells/('D25 stained 
Stimulated Cells/C'U'-15 stained 
Stimulated Cells/ C'D25 stained 
Stimulated Cells/ C'D25 stained 
, 
Stimulated Cells/ ('1)25 Stained 
Stimulated ('ells/ ('[)25 stained 
Stimulated ('ells/ ('1)25 stained 







'%, Of evils staining 
for ('1)25 
%-. 
Table 5.14 Effect of SI)Z RAI) on expression of ('1)25 following ('on A stimulation 
of PBMC from a renal transplant patient. PI3M(' were stimulated with SIpg/rnºI ('on A 
for 60 hours in the presence of grade(1 do es of SI )l RAI) 10.1) I -50pg; 'I ). I he cells \ý c rc 
harvested and stained with anti-('O25 nmonoctonal antibod\. An kot`pe control antihod\ 
was used in the experinment. The cells %ticrc examined liar ('1)2S c. \pres, io n h", tloo\ý 
cytometry lind the percentage of positive eel Is was obtained. 
146 
Effect of SDZ RAD on CD25 Expression following Con 














Figure 5.21 Effect of SDZ RAD on expression levels of CD25 following Con A 
stimulation of PBMC from a renal transplant patient. PBMC from a single patient 
were stimulated with 5µg/ml Con A for 60 hours in the presence or absence of SDZ RAD 
as indicated. The cells were harvested and stained with anti-CD25 monoclonal antibody 
and isotype control antibody. The cells were examined for CD25 expression by flow 
cytometry and the percentage of positive cells obtained. 
The percentage of cells expressing CD25 is progressively reduced following the 
addition of SDZ RAD up to a dose of l µg/l. The level of CD25 expression in non- 
stimulated cells is almost zero. CD25 expression on stimulated PBMC in the 
presence of SDZ RAD and FK506 was also examined in 2 further patients 
(Figures 22 and 23). There is no evidence of inhibition of CI)25 in patient 58 
following the addition of SDZ RAD alone or in combination with FK506 (Figure 
5.22). It is therefore not possible to assess any interaction between the two drugs. 
Patient 57 is similarly resistant to SDZ RAD and FK506 as assessed by CD25 
expression. The expression of CD25 is not inhibited by SDI. RAD alone or in 
combination with FK506 except when FK506 is added at high concentration 
(Figure 23). 
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Figure 5.22 Effect of SDZ RAD alone and in combination with FK506 on expression 
levels of CD25 following Con A stimulation of PBMC. PBMC' from a single patient 
were stimulated with 5µg/ml Con A for 60 hours in the presence or absence of SD7. RAD 
as indicated. The cells were harvested and stained with anti-CD25 monoclonal antibody 
and isotype control antibody. The cells were examined for CD25 expression by flow 
cytometry and the percentage of positive cells obtained. 
Effect of SDZ RAD and FK506, alone and in 
combination, on CD25 expression by Con A stimulated 
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Figure 5.23 Effect of SDZ RAD alone and in combination with F'K506 on CD25 
expression by Con A stimulated PBMC. (Normalised for maximum expression). 
PBMC from a single patient were stimulated with 5p. g/ml Con A for 60 hours in the 
presence or absence of SDZ RAD as indicated. The cells were harvested and stained with 
anti-CD25 monoclonal antibody and isotype control antibody. The cells were examined 
for CD25 expression by flow cytometry and the percentage of positive cells obtained. The 
data are normalised for the maximum expression obtained with no drug present in the 
culture. 
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In all cases the negative controls are very `clean' with very Iuuwk IeveR OI' ('I ). '' 
detectable. 
Conclusion 
There is no overall deiiionstrahle significant effect of coºi>>I-liiºiiºp, tlºc IVsO druiý, 




6.1 Lymphocyte sensitivity to ('y A and F K506 
To investigate the range of'variation oflymphocyte sensitivity to ('ý A , iinl FK ý11h 
assays were performed using ulitOgen stinuulatioºn I?? v! IrO riºtºrlonticICar cell 
cultures from patients who had received .t renal trainspla till. I he data coinliriim ,i 
wide variation in the response of' peripheral hluuoo(. 1 muýnoýnnclear cells (I'I IM(') to 
Cy /\ and FK50 both quantitatively and LillaiitativeIv sectitºri S. 11. I here ýý, rý .r 
correlation between Cy A and FK506 sensitivities between hatiet ls. 1 his i111plies 
that in general it' the cclIs are sensitive toi ('v A Own the will he 'en itiw t(º 
FK506. The data, however, also concealed some considerable variation het%%een 
patients in terms of' the ratio of' sensitivities toi either chug. I his %%<« timid to he 
dependent on the drug used in the patient's treatment protocol and is sti gcstivc of 
the development of selective resistance to the drug received h\ the ind1\1(fil al 
patient. The two independent associations described suggest that more than one 
mechanism may determine drug sensitivity at the cellular le\ cl. I he inter-paticnt 
correlation of' IDsos for the two drugs implies that there nw he common 
mechanisms to account for drug sensitivities since hoch (It-tips act via calcinettrin 
inhibition. Ilowcver, the development of selective resistance toi either drug 
suggests other mechanisms may he important. I Ill' Stated h\ potlhesis CXI)I()red1 
during this thesis that the intracellular drug concentration is modulated h` 
multidrug resistance mechanisms will he discussed in section 
o. 
-I.. 
The initial impetus tier this study was the observation that r uieints rejecting their 
kidney transplants with apparently therapeutic le,,, is of ('v A could Im \c gait 
function salvaged by conversion from ('y A toi another ('akiticurin irnhibitor, 
I sl 
Bali eIy, i"K506 cartacrolimus (. Jordan el cal., 1994 and 1997º. The C\pIan itiuii lot 
this cflcct is not clear but would appear to he im iltificturial. Faclu , likek I() he 
important in explaining this phenomenon have been explored (luring'. this thesis. 
To begin a discussion 01' the putative factors expIaiininp this ohser%aitiun it is 
necessary to describe the basic pharmacological principles relating to the use OI 
the drugs ('y a and FK50 . 
I'hc pharmacological effects of a given drug are defined by the pharmaceutical. 
pharmacokinctic and pharmacodynaniic prop sties Of the drug. (3rietl\ - the 
pharmaceutical properties of' a drug are thcºsc associated with the 1i0rnni1 rtion (d 
the drug for administration and the route of administration. Hic pImrnmcokinetic 
properties of' a drug relate to absorption of the drug 1Ollwwing administration, 
whether given orally or by another route (ibr example transiknual, huecal, or by 
inhalation etc) and the Subsequent metabolism, distribution and elimi»atiom from 
the body. Alter oral administration the amount of drug that reacIie,, the sv,, tcrriic 
circulation depends on its absorption and the extent to %-%hich it escapes 
metabolism in the gastrointestinal tract and liver and this is its s steº>>ic" 
availability or hioavailahility. The pharmacodynamic properties of the drug are 
the effects that the drug has on individual cells that lead toi the plarni. icoIogical 
effects cif the drug. The pharmacodynatmc eticcts of a drug are deterimned hý thL 
ability of' the drug to interlere with target 'receptors' WW ithiii the cell or on the cell 
membrane. The drug-receptor interaction can he stimulatorv or inhihitur`. All (d 
these factors are relevant when considering the ohserv, ºtioýn ()I'('\ , -1 't'ºilure' in 
allogratt rejection. Firstly, as discussed in section I. 4.2 plharmucoýkiiietic Iproýliliing. 
ofI ('y A has evolved from the introduction o ('ý A in the 1 ýýX(k to the present 
iýý 
day. During the studies reported by Jordan vi ci1 Ire I')O. 1 and 1997 the ItºimukitItn 
OI' ('v /A administered toi patients was conventional ('v . -1 or 1, .I 
hiti 
Comm Iation is an inconlpICte emulsification of('`' A tlhat prod tice, ý ýýi(Ie" %. -; I ri; itit)rr. 
in hicýaavailahility. Since ('v A hals a narrow therapeutic mnd(m it iý ii>>ýýýºý t, ýýýt týº 
perform therapeutic drug level monitoring in blood salllple'ý taken t'roi>> ýý, rtiý"rit. ý. 
The widely practiced method of ttmo nito ring has been ti-ml h or pre-dtº"c Ie\cI 
monitoring I lowever, it has been demonstrated that trough leek do not 
predict clinical outcomes in teriiis of acute rejection cpimºddes , it1O olic-\ ear grillt 
survival (Kahan el u!., 1996). 't'his observation may give a pharmaco kinetic 
explanation fier the apparent ('y A fitilure seal with coºmeiltioii il ('` A iii rcnid 
transplant recipients despite apparently adequate therapeutic drag Iýý ý"lý. I he 
subsequent formulation. Neoral(R) was introduced which is a nmicrocinuklon \' ith 
improved absorption characteristics compared toi conventional C\ A. I )at a fi't in 
Canadian Investigators has recently shown that trough blood Ieý cls o1' ('ý \% lhenn 
the Neoral(R) formulation is administered cloy not predict those patients in whom 
acute rejection occurs although high trough levels are associated ' ith increased 
nephrotoxicity (Mahalati o at, 1o)9o)). ('cýnvý"rýýlý, the absorption pr(ºhIi' (A 
FK506 den onstrates a wide variahil its but mill a Iow 
association of' trough blood levels with clinical e ernts (Kerslhncr and 
Fitzsimmons, 1996). 'I'hcsc täctcýrs relating toi the plh. LrIuaeoýkinetic OI the drum', 
oiler one explanation fier the improved e f'i icacy of * 1-'K 5O( over con %e ntiooimýml ( '\ A 
seen in the `salvaging' trials reported by Jordan. 
[loth ('y A and FK50 are potent inhibitors of I' eeII activation in to aann 
immunological stimulus via the inhibition oi, the phospli aase ell/\111e, calciineeuiriii. 
lt 
Both drugs mediate their el'thc'ts on calcinetirin fiºIIo iiýýý, hinýliriýý. týº tlicit 
respective intracellular receptors, cy'clophilin and FK. l)O hi»diiný,, pu1tcm (I K Iil' ) 
Both ofthese molecules, known collectively as Illllllllllophillllti, are present at Ilil. '. ll 
levels within cells. The I cell response tu these drup. is central to tlheit 
pharmacological effects and this led to the hyruthesik that variation ire rý"ýýýýýrý. ýý" of 
T cells from renal transplant recipients to ('y A and F K506 ma\ C\ist. It as not 
clear whether the individual responses to the two drugs wk-mild he the , amc ur 
independent. FxtrapoIating these questions tot the 'salvatiilp data' the iýý lýýºtlýý"ýiý 
that individual patients cells were either resistant, or had resistance, to 
the effects of Cy A. 'l'he data irescnted iii this thesis data ýýilýlýýºrt tlhiý as ,i 
potential mechanism. 
In vitro inhibition cif mitogen induced lymphocyte hrolit`ration h\ hotte ('ý ;1 '111d 
FK506 has been reported on cells from healthy volunteers and ur. renmic dialysis 
patients (Ilibbins et ul., 1993). These studies confirmed th. i FF'K506 is cfIedtiye in 
concentrations approximately 30-100 times lower that o1' ('y A and that there is 
wide inter-individual variability. The data presented in this thesis is an exteiisioin 
of the above, having been performed on renal transplant patients' cells, and 
confirms the wide variability in sensitivity. Meastireill ißt of Iý i»IýIýýºý tý 
sensitivity may define drug failure (i. e. rejection occurring despite therapeutic 
blood levels) more scientifically. I'hc current ý. tiidespread clinical rr,, e oI ký(ºlº 
f'or "('y f1 failure" has no scientific validity. Patients with trough ('> A blood 
levels ofabout 200 pg/I are converted to FK. O6 at startinp IL-\eis ()I ahmit I5 p«]. 
which means that if FK50 is about 30 time,, more potent that ('v A, the same 
immunosuppressive result might have been achieved hy irýýrcýrýirýsý the ('ý A lc cl 
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to 450 [tg/I. "['he advantage of I" K506 could there liºrc suºIcly he clue tu its reI, ºt i' e 
dose, and perhaps a better therapeutic index (ralio ()I' desired ý"t ccl h) ad cP-c 
e11ccIs). 
Comparison cif the II),, ºS and scrum Concentration. ', suprests that ; illllmlý'lh in nw, - t 
cases there is a reasonable excess, sonic patients may he uneierclýºsýýý1 i. e. trýºrr}_i 
blood concentration may he close to the 11); oº and other., nmv, he overdowd i. e. the 
blood concentration may he many times the II),,,. The question arises as toº 
whether this is of' clinical signif cannce. C Indcrdosing implies poteintiýall` 
inadequate immunosuppression: whilst overdosing would exacerbate 'dde etiects,. 
One difficulty in assessing the data is that the trough blood levels do not repre,, ei1t 
the peak drug level or area under the curve (Al f (' ). Comparing II) ,,, tier either- 
drug between patients who did or did not suffer acute re. jectio n, nog Ali fig reihe ýý ýiý 
found. However, the number cif patients rejecting was very low (seven). I . 
ikewise, 
there was no correlation between sensitivities and blood cr<alinin lc\ cls. nature 
of therapy (triple therapy with prednisolone against therapy without prednisolonc ) 
or time since transplant. Since the study was not set 111) to exanmiine these ppaartictilat 
aspects then the sample size of patients may have been to() tu 'ice a 
correlation with clinical parameters. 
The observation of selective resistance developing to the drug used tiºr treatment 
is novel and interesting. Longitudinal studies mcasurnig of I'I; N1(' 
from renal transplant patients may elucidate the time aller a transplant that 
resistance develops. This would be important clinically since it'resiktancc could he 
predicted the patients could he switched toi alternative treatment. It is ho ssilhle that 
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a new approach to anti-rejection protocols could he established hased on tlhe 
observation of' selective resistance that would . ºIItº % týºilýºriiýýý ýºI trý. iti>>ý"iýt t(º. 
individual patients. Should resistance develop to each drug used 1 , or 
treitrnnernt them 
protocols that utilise rotating ininiunosuppressant would he 
6.2 1)o multidrug resistance (MI)R) mechanisms account for the variation in 
sensitivity to Cy A and FK506? 
The stated hypothesis that the development of scle tive drug resistance occurs 
through the intracellular drug concentration being modulated h\ ii , 11111,11-11V 
resistance mechanisms has not been proven, although there are a number of 
reasons for it to he an attractive model. As discussed in section 1.6.6, hotli ('' ,\ 
and FK506 are substrates for at least one of the mechanisms implicated in 
multidrug resistance to cancer chemotherapy. This is the I1-g1vct+prtºtein ernc(ºk1ed 
by the MDR I locus (Saeki el (rl., 1992), a membrane protein that pumps 
hydrophobic substances out of' cells 0 Jeda o al.. 1097). ,l hi", is expressed hk 
subsets of lymphocytes (Klimecki cal a!., 1994) and ('on A-stitimlated mows 
spleen cells have been shown to become more sLnsitiv to Flo wi-tihicin in 111C 
presence cif i'-gp inhibitors (I'ourtier-Mani, anedo cl a/., 19())). 
Despite a report in the literature ( Pilarski e/ cal., 1995) that I'-gip is readiI' detected 
can the surface cif' normal lymphocytes none of' the patients tested in this studs had 
even moderate levels of' P-gp detectable on the surface t 1'their IN mpli c\ res %% 1111 
the monoclonal antibodies 4(, 3 and MRKI0. Fliese antihýýý1i« ýNcrc ý"Iýosen sincc 
they recognise external epitopes coil the eel I surface and can he applied to ýiiý Ii ýý"ýi 
fi() 
cells in suspension. The lack of MRK16 staining in this study may reflect 
insufficient sensitivity to detect P-gp rather than non-expression. Another group 
found little expression of P-gp on peripheral lymphocytes despite attempting to 
increase sensitivity by using biotinylated MRK16 (Takeshita et al., 1995). 
Similarly it has been shown that P-gp mRNA can be detected despite the absence 
of immunological expression of P-gp (Ludescher et al., 1992). A factor that may 
influence antibody binding in this experimental system includes distortion of the 
external epitope. The possibility that unfixed cells may have distorted the target 
epitope or internalised the epitope was investigated. Experiments were performed 
on cells fixed with formaldehyde/acetone. By fixing the cells it was hypothesised 
that the epitope would be fixed on the external surface of the cell and would not 
be subject to post antibody binding modification. However, the results of these 
experiments confirmed that antibody binding to the cells could not be 
demonstrated. Whether the process of cryoprecipitation and thawing of cells was 
disrupting the epitope sites was explored by repeating the experiments using fresh 
cells. There was no evidence of P"gp expression during these experiments. Further 
experiments with higher concentrations of the primary monoclonal antibody and 
different secondary conjugates similarly yielded no significant binding to PBMC. 
Clearly, the positive control cell line MCF7 exhibited high levels of P"gp 
expression confirming the antibodies were working. However, this breast cancer 
cell line has been selected for high levels of P-gp expression by culture in medium 
containing adriamycin and may not bear any resemblance to PBMC from renal 
transplant patients. 
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Despite the lack of detectable P-gp expression, all the patients tested in this study 
exhibited P-gp functional activity as demonstrated by R-123 dye efflux. R-123 is a 
fluorescent dye that diffuses into the cell and if not actively transported by an 
efflux pump is trapped in the cell and accumulates within mitochondria. 
Approximately 42% of total normal adult PBMC export the dye and this decreases 
with age (Pilarski et al., 1995). The dye efflux is secondary to P"gp activity since 
specific inhibitors such as the cyclosporin analogue, PSC 833, readily inhibit it. 
All patients exhibited similar levels of cells actively pumping and there was no 
difference in pumping activity in those patients where the Con A stimulated 
lymphocytes were sensitive to Cy A and FK506 compared to those where the cells 
were resistant to the drugs. This indicates that there is no gross difference between 
the drug sensitive and drug insensitive PBMC in P-gp function. However, the 
majority of the experiments were performed on bulk cell populations rather than 
subsets of cells. In those experiments where subsets of cells were analysed it was 
demonstrated that CD8 positive cells more actively pumped than CD4 positive 
cells and this is consistent with an earlier report (Pilarski et al., 1995). One could 
speculate that the responsive cells in the PBMC cultures stimulated with Con A 
are primarily CD4 positive and therefore it was unlikely that a vast difference in 
pumping activity between high and low sensitivity groups would be observed 
since the background level of pumping is relatively low. 
The observation of P-gp functional activity in PBMC from renal transplant 
patients raises the possibility of P-gp activity affecting the proliferation of cells in 
response to Cy A and FK506. In these experiments with PBMC from renal 
transplant patients there was no demonstrable effect on sensitivity to Cy A or 
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FK506 following the addition of selective P-gp inhibitor, PSC 833. The patients 
had received treatment with either drug as part of their immunosuppressivc regime 
and it may be that MDR1 gene expression and P-gp function is down-regulated 
following prolonged treatment with the drugs, perhaps in a similar fashion that 
P-gp expression can be induced with rifampicin (Greiner et al., 1999). Indeed, it 
has been shown previously that no patients who had transplants for more than 40 
months expressed the MDR1 gene in their lymphocytes (Gotzl et al., 1995). 
Characterisation of the MDR1 gene has intensified recently with the findings of 
functional polymorphisms and the correlation of one allele with P-glycoprotein 
expression and activity (Hoffmeyer et al., 2000). Analysis of the MDRI sequence 
in 21 volunteers was performed. P-gp expression and functional activity in 
intestinal mucosa had also been determined. There was a significant correlation of 
a polymorphism in exon 26 (C3435T) of the MDRI gene with expression levels 
and function of the MDR1 phenotype. The homozygous `T'-allele is associated 
with more than two fold lower MDR1 expression levels compared with 
homozygous CC samples. This finding was consistent when the function of P-gp 
was assessed. 
Could variation in the frequency of this polymorphism have an effect on P-gp 
expression and function in cells from lymphoid lineages? A report has suggested 
that the C3434T mutation in the MDRI gene may alter the functional 
characteristics of P-gp in CD56+ natural killer cells, as assessed by rhodamine 
123 efflux (Hitzl et al., 2001). Although, clearly, the patients in this present study 
have not been examined for MDR1 polymorphisms it would be an interesting area 
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for future study. A population-based survey has been performed to analyse the 
frequency of the C3435T polymorphism of the MDR1 gene in different ethnic 
groups (Schaeffeler et al., 2001). The results reveal that 83% of West Africans 
compared to 26% of Caucasians are homozygous for the C allele. It is proposed 
by these investigators that the consequences of higher intestinal P-gp expression 
due to the increased frequency of the CC genotype in Africans could be that 
bioavailability of drug substrates of P-gp could be reduced. This has been 
confirmed for Cy A (Min et al., 2000). The population studied in this thesis was 
predominantly of Caucasian origin and this may explain the low levels of 
expression and function of P-gp observed. 
The calcineurin inhibitors are highly lipophilic and therefore can readily enter 
cells. Since the intracellular receptors for the drugs are abundant within a cell, for 
example, FKBP proteins constituting between 0.3-0.5% of cellular proteins 
(Siekierka et al., 1989) then complexes of drug/immunophilin will be formed 
readily. In addition to this, experiments utilising an FK506-derived radioactive 
ligand confirm that half maximal T cell suppression occurs following occupancy 
of FKBP12 of only 3-5% of the available pool (Dumont et al., 1994). For P-gp to 
modulate the intracellular concentration of Cy A and FK506 to such an extent as 
to affect their anti-proliferative effects in these circumstances would require the 
molecule to be very highly expressed and functionally active. Experiments to test 
the hypothesis that increased expression of P"gp confers protection against Cy A 
dependent inhibition of calcineurin (CN) phosphatase activity have been 
performed on selected cell lines expressing varying levels of P"gp (Fakata cl al., 
1998). The study group utilised cells of the human epidermal carcinoma cell line 
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KB-V that were grown in media supplemented with varying strengths of 
vinblastine. Dose response curves were then obtained for CN phosphatase activity 
against Cy A concentration. KB-V cells grown in high dose vinblastinc shifted the 
dose response curve to the right some 70-fold compared to the parent KB cells. 
Verapamil, a P-gp inhibitor, completely extinguished the protection afforded by 
P-gp expression. The cell line reported by this group was highly selected in 
vinblastine and although this offers a model of how P-gp may affect sensitivity to 
Cy A, the cells used are not directly comparable to the patients' cells examined in 
this thesis. Alternative mechanisms to explain variations in lymphocyte sensitivity 
need to be considered. Both drugs act by binding to intracellular receptors of the 
immunophilin type (Bierer, 1994). The differences in drug response could be 
accounted for in differences in the amounts of these proteins in cells from 
different donors. Downregulation of cyclophilin levels in T lymphocytes from 
Cy A-treated patients, and likewise of FKBP in FK506-treated patients, is one 
possible explanation for the selective drug resistance observed. There is some 
evidence that both cyclophilins and FKBP proteins are regulated genes, for 
example varying in their expression with differentiation status (Chatellard"Gruaz 
et al., 1994 and Lyons et al., 1995), biit as yet no evidence that this may influence 
the response of cells to Cy A or FK506. Due to time and resource constraints there 
was no opportunity to undertake this area of study. 
Non P-gp phenotypes of MDR, namely, MRP and LRP have been described. The 
detection of MRP mRNA in normal haemopoietic cells from peripheral blood and 
bone marrow has been demonstrated as well as MRP protein expression 
determined with specific monoclonal antibodies (Logrand et al., 1996). Functional 
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assays of MRP have been explored (Den Boer et al., 1997). The clinical data 
regarding MRP is sparse and difficult to interpret since the methods used to 
characterise the expression and functional activity arc not standardised. The data 
pertaining to LRP suggest that LRP is not detectable on normal lymphocytes 
(Michieli et al., 1997). This data led to the conclusion that the most relevant 
system to study was P-gp dependent mechanisms of MDR. Nevertheless, further 
investigation of MRP in normal lymphocytes and lymphocytes from renal 
transplant recipients may be warranted. In summary P-gp dependent mechanisms 
do not appear to explain variations in lymphocyte sensitivities to the 
immunosuppressant drugs Cy A and FK506 and the data indicate that several 
mechanisms may be of importance in this area. 
As outlined in the Preface to this thesis, the idea behind this work was to develop 
a means of studying in vitro patient lymphocyte responses to immunosuppressive 
drugs in order to understand their mode of action, mechanisms of resistance, and 
interactions between them. Such an understanding may allow for future 
prescribing of rational, patient-specific immunosuppressive drug protocols. 
Having described their mode of action, and the investigation of mechanisms of 
resistance, the data relating to the interactions between the macrolide FK506 and 
the rapamycin analogue SDZ RAD is considered. FK506 and SDZ RAD share the 
same intracellular binding sites but have different anti"prolifcrative targets within 
the cell. The early studies on rapamycin confirmed mutual antagonism with 
FK506 and led to the theory of a shared intracellular binding site (Dumont ei al., 
1990a). However, a study in a rat cardiac transplantation model did not 
demonstrate antagonism but an enhanced immunosuppressant effect of combining 
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rapamycin with FK506 (Vu et al., 1997). This polarisation of of ect raised the 
question of how would the drugs interact in in vitro cultures of lymphocytes from 
renal transplant patients. This is a worthwhile area of study since the potential of 
using two drugs with predictable pharmacokinetic profiles in a synergistic way 
may lead to safer and more efficacious anti rejection protocols. 
6.3 Interaction of FK506 and SDZ RAD in in vitro lymphocyte cultures from 
renal transplant patients. 
Lymphocyte cultures were established in both Con A driven systems and by 
Mixed Lymphocyte Reaction (MLR). Lymphocyte proliferation in response to 
Con A was inhibited in a dose dependent manner following the addition of either 
FK506 or SDZ RAD in the majority of cases. Considering the data with SDZ 
RAD alone there was a wide range of sensitivity with values of IDSO from 0.009- 
80 pg/I. However, subgroup analysis of 9 patients confirms a mean IDso of 4.7µg11 
with a range of values from 0.009-20µg/l. This figure for SDZ RAD is 
approximately three fold higher than that obtained with FK506 in the previous 
experiments, and is also in the same order of magnitude as that reported with in 
vitro data comparing SDZ RAD and rapamycin (Schuler et al., 1997). The reasons 
for the wide variation in sensitivities to SDZ RAD are unclear. It is possible that 
certain cell samples from individual patients are inherently less sensitive, 
however, since the sample size is small it is not possible to draw any formal 
conclusions. The assays were performed in either duplicate or triplicate dependent 
entirely by the number of available cells harvested. It was not possible, however, 
to repeat experiments with further samples due to limited availability. Following 
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the addition of FK506 to the SDZ RAD inhibition assays there was no consistent 
effect obtained, although in individual cases the ID50s were altered. For example 
patient sample 53 there was no change in the nature of the dose response curve to 
SDZ RAD following the addition of FK506 at 0.1 µg/l to the cultures but there was 
a slight additive effect at high doses of SDZ RAD. The data obtained for patient 
57 revealed less inhibition of proliferation following the addition of FK506 at 
equimolar and at high doses of SDZ RAD. This would be consistent with previous 
reports investigating rapamycin and FK506 in molar excess (Dumont et al., 1990 
and 1994). Although the ID5os were altered following the addition of FK506 there 
was no significant change across the group of patients tested with the mean ID5o 
for SDZ RAD alone of 25.2 µg/I and the mean ID50 for SDZ RAD and FK506 of 
27.1 µg/l. 
The relatively small number of patients studied makes it difficult to formulate firm 
conclusions from this data. The variation of effect among individual samples 
within the group could imply that the mean ID5os are similar simply as a 
mathematical quirk rather than a firm scientific observation. However, this is the 
data obtained using Con A stimulation of PBMC. It is not clear therefore whether 
the variation in the individual experiments indicates inter-experiment variation or 
genuine variation between individual patients. To answer this question would 
require repeating multiple experiments from the same donors. Unfortunately, this 
was not undertaken due to resource constraints. 
Con A stimulated assays have been utilised throughout the experimental work 
described during this thesis. Although mitogen stimulation of cells is not a 
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physiological or specific stimulus of lymphocyte activation, it is a 
well-established technique to investigate the pharmacological effects of drugs on 
cells. By obtaining a maximal response from PBMC to mitogen stimulation any 
differences in the sensitivity of cells to the drugs could be detected. However, in 
an attempt to develop an experimental system that is more `physiological' 
experiments using the MLR were performed. The potential advantage is that the 
MLR relies on the specific response of recipient and donor cells that differ in their 
histocompatibility and is therefore an in vitro model of the immune response to an 
allograft. However it is clear from the data that brisk alloresponses measured 
during the MLR were not always obtained. This makes the interpretation of the 
effects of drugs such as FK506 and SDZ RAD very difficult. The low responses 
seen during the MLR may have been due to the fact that the majority of donor: 
recipient combinations are well matched, particularly at the DR locus, which is the 
main drive for the MLR. This matching is obtained when selecting a patient to 
receive a transplant from a donor since the long-term outcome of the graft will be 
improved by HLA matching. During the experiments described here a surrogate 
donor was used as the stimulator cells during the MLR. This is not the ideal but 
the original donor cells were not available. Therefore, I matched surrogate donor 
cells to the original donor DR locus. These cells may well have behaved 
differently to the original donor cells had they been available but since they were 
matched at the DR locus then any difference would be expected to be minimal. 
The levels of cell stimulation obtained during the MLR experiments improved 
following modification of the culture medium. However, it is noted that even 
during the earlier experiments that the cell cultures responded well to Con A when 
added at 48 hours to control cultures. This suggests the cells remain viable and 
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capable of proliferation. Nevertheless, there are some examples where the MLR is 
brisk and a dose response curve is obtained to SDZ RAD and to FK506 as in 
patient 69 and patient 66 respectively. The effect of combining the two drugs 
during the MLR was variable and in particular there was no evidence of an 
interaction at drug levels that are equimolar. It is interesting to note that in many 
cases the level of cell proliferation as measured by incorporation of 3li-thymidine 
actually initially increased following the addition of either drug at the very low 
doses. This phenomenon may in part be explained by the possibility of the drugs 
selectively inhibiting anti-proliferative cells within the cultures. 
The experimental systems used to test whether there are interactions between SDZ 
and FK506 in lymphocytes from renal transplant recipients included both mitogen 
stimulation and MLR. The effects of the drugs in each experimental system tend 
to be the same. The data, however, do not support a consistent interaction between 
SDZ RAD and FK506 in in vitro lymphocyte cultures. This in itself does not 
mean that there would not be an effect in vivo. The reasons for the difficulties 
obtaining consistent data are not clear. I feel that one explanation for the variable 
effects seen in the experimental systems is that the cell samples on which the 
experiments are performed come from a heterogeneous population. By this I mean 
the samples were taken from patients of different ethnic backgrounds, varying 
levels of renal function and who had variably been exposed to powerful anti- 
rejection drugs. These factors may have led to a degree of background `noise' 
within the experimental system. However, despite the variance the conclusions 
drawn from these studies are solid. 
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Conversely, a number of the previous reports that I have cited in this thesis have 
utilised either samples from healthy volunteers or from animal models. Laboratory 
animals can be bred to a degree of uniformity that will allow for the collection of 
`clean' data. However, one is then left with the very real difficulty regarding the 
relevance of extrapolating the data from `mouse to man'. Despite the limitations 
of these in vitro techniques, the pharmacodynamic assessment of individuals' 
lymphocyte responses to immunosuppressive drugs have been reported previously 
in an attempt to develop a strategy for tailoring treatment protocols. For example, 
the MLR in pre-operative samples from potential renal transplant patients was 
obtained to assess recipient sensitivities to anti-rejection drugs (Francis el al., 
1988). The resistant group had a higher rate of graft loss from acute rejection, 
more episodes of graft rejection and higher levels of serum creatinine. Sensitivity 
experiments performed on PBMC from subjects with renal disease including 
patients who had received a renal transplant report large individual variations in 
ID50 values for Cy A (Hirano et al., 1997). The incidence of graft loss in those 
patients in the low sensitivity group compared to the highly sensitive group was 
significantly higher and there was an association with higher serum creatinine in 
the low sensitivity group. Although this is an interesting observation the numbers 
in each of the groups were small. 
These studies attempted to predict clinical response to anti rejection drugs based 
on an in vitro test of lymphocyte sensitivity. The experiments described in this 
thesis utilised the in vitro methods of lymphocyte stimulation to test for variation 
in lymphocyte sensitivity to immunosuppressive drugs, for development of 
resistance to these drugs, and for exploring potential drug interactions between 
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FK506 and the structurally related novel compound, SDZ RAD. It would be 
valuable if an in vitro test of lymphocyte responsiveness could predict patients 
where for example the drug doses could be safely reduced. This type of work may 
lead to the possibility of allowing the clinician to tailor immunosuppression for 
individual patients. 
Further experiments were performed to develop alternative assays for cell 
activation. Flow cytometry analyses of CD25 expression on lymphocytes from 
renal transplant patients and normal volunteers were performed following 
stimulation with Con A. Following mitogen stimulation the percentage of cells 
expressing CD25 was high (up to 90%) and in one patient (number 55) a dose 
response curve following the addition of graded doses of SDZ RAD was obtained. 
At the highest dose of SDZ RAD used the percentage of cells expressing CD25 
fell from 90% to around 40%. In other samples the effect of SDZ RAD on 
expression of CD25 was less marked. There was no additional effect of combining 
the drug with FK506 except at high concentrations of FK506 (l Opg/L) when it 
was most likely to be an effect of FK506 only. With the small number of 
experiments performed firm conclusions regarding the interaction of FK506 with 
SDZ RAD on expression of CD25 in lymphocyte cultures cannot be reached. 
From consideration of all the data relating to SDZ RAD and FK506, it is clear that 
they are not antagonistic when used in lymphocyte cultures from renal transplant 
patients. 
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In summary, the experiments described during this thesis have revealed some 
interesting and novel observations. Firstly, there is a wide range of sensitivities of 
PBMC from renal transplant patients to the immunosuppressant drugs, Cy A and 
FK506. Resistance of PBMC from renal transplant patient cells to either drug is 
correlated. The development of selective resistance to the drug used for treatment 
has potential clinical implications. If patients that are developing resistance can be 
predicted from similar in vitro studies to those reported here, then pre-emptive 
treatment changes could be introduced. 
P-gp dependent mechanisms do not explain the variation of sensitivity to Cy A 
and FK506 in cell cultures from renal transplant patients. However, PBMC from 
all patients exhibited R-123 drug pumping and inhibition of pumping following 
exposure to the selective P-gp inhibitor, PSC 833. This implies that P-gp 
dependent drug pumping occurs in PBMC from renal transplant patients. 
The combination of FK506 and the rapamycin analogue, SDZ RAD did not show 
any antagonism in in vitro PBMC cultures. Immunosuppressant protocols 
continue to be refined and future protocols may contain SDZ RAD in combination 
with FK506. 
Lastly, I have derived much pleasure from investigating and presenting these 
fascinating areas of research that combine medicine and science. 
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APPENDIX 1 
Information and Consent Form 
Title of project 
Characterisation of Multidrug-Resistance Phenotypes in T-lymphocytes from 
Renal Transplant Patients. 
Description 
We would like you to help us with some research. We would like to take some 
extra blood at the time of routine blood-taking. White blood cells (the type that 
cause rejection) will be extracted and studied for their responses to anti-rejection 
drugs. The additional amount of blood required is a maximum of 20mis. And we 
may ask you to help us more than once with this. 
The aim of the study is to see if we can identify resistance to anti-rejection drugs 
and explore potential resistance mechanisms. If this were to be the case , we could 
plan anti-rejection treatment in the future to try and avoid transplant rejection, 
rather than just treat it when it occurs. 
The research is at an early stage, and we cannot use these results to plan your drug 
treatment. Therefore your drug treatment will not be affected by this study. 
You are free to spend some free time thinking about this study, and to discuss it 
with either Dr Higgins or Dr Delaney. Even if you agree to take part, you are quite 
free to change your mind at any time without giving a reason. Taking part in the 
study will not affect your treatment in any way. 
Thank you for your attention. 
Potential risks of research: those of taking a slightly larger blood sample from 
you. 
Potential benefit of the research: improving future anti-rejection drug treatment. 
Name of Investigators: Dr. Mike Delaney and Dr. Rob Higgins 
Name of research volunteer: 
I have read the description of the research project given above and the investigator 
has explained it to me to my satisfaction. I am aware that there may be some risk 
attached, and that my should I suffer injury as a consequence of the research the 
University of Warwick will pay compensation. The level of the compensation will 
be determined by reference to damages awarded by courts for similar injuries at 
the time the injury was suffered. 
I understand that I may withdraw from the project at any time for any reason and 
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